

THE HPV AND ANAL CANCER FOUNDATION LIMITED

England & Wales · Charity number 1147457

Details

Status	Registered
Legal form	Charitable company
Company number	07955451
Registered	2012-05-25
Register	View on the Charity Commission register

Contact

Address	128 City Road London EC1V 2NX
Phone	02034886567
Email	info@analcancerfoundation.org
Website	http://www.analcancerfoundation.org/

Activities

Objects: 6. THE OBJECTS OF THE CHARITY ARE TO PRESERVE AND PROTECT THE HEALTH OF THE PUBLIC AND IN PARTICULAR TO: 6.1 PROMOTE AND SUPPORT RESEARCH INTO THE NATURE, CAUSES, DIAGNOSIS, PREVENTION, TREATMENT AND CARE OF ANAL CANCER AND ILLNESS CAUSED BY OR ASSOCIATED WITH HUMAN PAPILLOMAVIRUS (HPV); 6.2 PROMOTE AND PROVIDE THE PROVISION OF CARE, SUPPORT AND OTHER RESOURCES FOR THOSE WITH ANAL CANCER OR ILLNESS CAUSED BY OR ASSOCIATED WITH HPV AND FOR THEIR CARERS; AND 6.3 PROVIDE INFORMATION AND RAISE PUBLIC AWARENESS OF ANAL CANCER AND OTHER ILLNESS CAUSED BY OR ASSOCIATED WITH HPV

Activities: The HPV and Anal Cancer Foundation is dedicated to empowering anal cancer patients and accelerating prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Classification

- **How:** Makes Grants To Organisations, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research, Acts As An Umbrella Or Resource Body
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

Geography

- United States

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£63,948	£168,988	-	-
2023-12-31	£579,781	£342,973	£294,755	1
2022-12-31	£154,892	£173,009	-	-
2021-12-31	£204,749	£255,874	-	-
2020-12-31	£90,186	£129,268	-	-

Trustees

Name	Role	Appointed
TRISTAN ALMADA	Chair	2012-05-01
CAMILLE ALMADA		2012-05-01
CHRISTIAN CLIVE LEVETT		2012-05-01
JUSTINE ALMADA		2012-05-01

THE HPV AND ANAL CANCER FOUNDATION LIMITED

England & Wales - Charity number 1147457

Accounts

THE HPV AND ANAL CANCER FOUNDATION LIMITED

TRUSTEES REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31st DECEMBER 2024

REGISTERED COMPANY NO: 07955451 (England and Wales)

REGISTERED CHARITY NO: 1147457

THE HPV AND ANAL CANCER FOUNDATION LIMITED

TRUSTEES REPORT

AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

CONTENTS

	<u>Page</u>
Reference and Administrative Details	1
Report of the Trustees	2-14
Independent Examiners' report	15
Statement of Financial Activities	16
Balance Sheet	17
Statement of Cash Flow	18
Notes to the Financial Statements	19-26

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024

Reference and Administrative Details For the Year ended 31 December 2024

LEGAL AND ADMINISTRATIVE INFORMATION

TRUSTEES	C Almada J Almada T Almada C Levett
REGISTERED OFFICE	128 City Road London EC1V 2NX
REGISTERED COMPANY NUMBER	07955451 (England and Wales)
REGISTERED CHARITY NUMBER	1147457
INDEPENDENT EXAMINER	Richard Billinghamurst Knox Cropper LLP 65 Leadenhall Street London EC3A 2AD
SOLICITORS	Stone King 16 St John's Lane London EC1M 4BS
BANKERS	HSBC 16 King Street Covent Garden London WC2E 8JF

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024

STRUCTURE, GOVERNANCE AND MANAGEMENT

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20th February 2012 and registered as a charity on the 25th May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The directors are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 30. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the UK CEO is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given an overview of the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws, and policies.

Risk Management

The trustees of the Foundation hold the responsibility of safeguarding the charity's assets and are satisfied that systems are in place to mitigate those risks which the charity may face.

FINANCIAL REVIEW

It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organisation. The revenue for the charity is dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundation in 2024 was £63,948 and expenditure was £168,988.

Total free reserves at the year end amounted to £176,615.

Reserves Policy

The Trustees have reviewed the amount of reserves it regards as a minimum prudent requirement. They have concluded that provision for three months operating reserves that enable the organisation to meet its financial commitments including grants, contracts and staff salaries is sufficient. This would allow time to manage cost reductions or generate funds as required whilst minimising the impact on service provision. At 31 December 2024 this amounted to £32,421.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

OBJECTIVES, ACTIVITIES AND ACHIEVEMENTS

Public Benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

History

The Foundation was first established in the USA in 2010 by three siblings who lost their mother, aged 53, to stage IV HPV-related anal cancer. Frustrated by the limited therapeutic and community support available to her, they created the organisation to fill the void caused by scant public, scientific and medical focus on this disease and its cause, the human papillomavirus (HPV). HPV causes anal cancer and at least five other cancers, amounting to 5% of cancers worldwide. These cancers are preventable. In 2012, the organization expanded to the UK with 2013 as its first full operational year.

Mission

The HPV and Anal Cancer Foundation empowers anal cancer patients and accelerates prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Objectives

- Highlight the relevance of human papillomavirus (HPV) in contracting cancer;
- Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender-neutral vaccination;
- Accelerate a cure for the 5% of all cancers that are caused by HPV, with a focus on anal cancer; and
- Provide support for survivors, caregivers, scientists and providers connected to anal cancer.

The Need

A fundamental objective of the Foundation's work is to reduce the incidence of anal cancer and other HPV-related cancers. HPV is a very common skin virus that nearly every sexually active person will get at some point in their lives. HPV affects both men and women and is responsible for 5% of the world's cancer burden. HPV causes cancers of the anus, cervix, head and neck, penis, vagina, and vulva.

Protection against HPV through universal HPV vaccination is a critical public health goal. With HPV identified as a cause of six different types of cancer, and 5% of cancer cases worldwide, it is imperative that we protect the entire population against it. The most effective method to reduce cancers related to HPV is to prevent initial infection of the virus through immunisation. The Foundation achieves this important aim through its efforts to advance equal access to HPV protection for both boys and girls through gender-neutral vaccination (GNV) against the virus. At the introduction of the vaccine in most countries, only girls were able to receive this life-saving intervention while boys were generally excluded. The Foundation created and led the coalitions in the US and UK to ensure all children have equal access to protection against these cancers. The US achieved the milestone of recommending HPV protection to all children in 2011. Following the Foundation's five-year advocacy campaign in the UK, school-based HPV vaccination for boys began in September 2019. Our focus is on securing the same protection for boys as well as girls across Europe, and beyond.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

While we work to prevent future cases, it is also fundamental that scientific and medical disparities are addressed for the population that will continue to be diagnosed with HPV-related cancers like anal cancer. Treatment options have barely progressed since the 1970s and minimal research has been undertaken in new therapies. The medical and scientific communities need better research tools and investment in novel ideas to develop a cure.

The stigma surrounding anal cancer remains one of the central challenges to improving outcomes for anal cancer patients. Unfortunately, many medical centres provide only limited information specific to the experience of anal cancer. Many patients feel isolated and lack the support and educational resources that significantly improve quality of life during and after treatment.

Strategies to Achieve Our Goals

We achieve our mission in the UK and US through collaboration with scientists, clinicians, survivors, organisations, and government agencies; education of stakeholders and the general public; survivor support; and investment in the medical and scientific community to end HPV and the cancers it causes. Specifically, we take action to destigmatize and raise awareness about HPV, HPV-related cancers, and anal cancer; increase access to the HPV vaccine; improve screening protocols and preventative care; empower anal cancer thrivers; and accelerate a cure for anal cancer and other HPV-related illnesses.

Key achievements in 2024

NOMAN is an Island: Race to End HPV

The NOMAN Campaign raises awareness about the HPV-related cancer epidemic in men and women and educates about the importance of universal HPV vaccination, while challenging participants to extreme endurance races across the world. It is through such extreme feats of athleticism that NOMAN honour the struggle and isolation that many cancer patients feel.

NOMAN has been an incredibly successful campaign. Since its inaugural event in 2013 with the Barcelona – Ibiza: Row to End HPV, over 200 individuals – and their hundreds of supporters – have embraced the cause and our values. These NOMAN have raised awareness about HPV cancers on a local, national and international scale, as well as funds to support out programmes.

2024 was a year of remarkable progress toward our vision of a world free from HPV cancers, with new milestones bringing us closer to this goal. Seventy-six countries around the world now undertake gender-neutral HPV vaccination, protecting both their daughters and their sons against the devastation caused by this preventable virus. In 2024 we fostered new coalitions with key stakeholders in HPV advocacy and policy, created innovative resources and expanded support for communities, and engaged even more people in the fight against HPV-related cancers.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

HPV Action Europe Network

In 2018 and 2019 the Foundation was involved in discussions to establish an advocacy campaign in Europe to introduce gender-neutral vaccination (GNV) across the region and completely eliminate HPV-related diseases. NOMAN has partnered with the European Cancer Organisation (ECO) to achieve this mission. ECO works to reduce the burden of cancer and improve outcomes and the quality of care for patients through multidisciplinary initiatives. As the European not-for-profit federation of member organisations working in cancer, they convene oncology professional and patients to agree on policy, advocate for positive change, and be the united voice of the European cancer community.

Together with ECO, the Foundation looks forward to continuing to work with European policy makers to end the suffering caused by HPV cancers. In 2021, we achieved a major milestone by securing for the first time, a commitment to eliminate HPV cancers in Europe's Beating Cancer Plan. The HPV Action Network has built on this major success with the following achievements in 2024, including supporting advocacy work in countries that are falling behind.

The EPF/ECO HPV Prevention Policy Atlas launched in 2023 serves as a powerful advocacy tool to engage politicians and policy makers by providing information on the inequalities that exist in HPV prevention, along with recommendations for legislators to tackle HPV cancers. In 2024, we expanded from this foundation by convening organisations and individuals with direct experience of advocacy campaigns on HPV cancer elimination from a variety of countries, in order to share with each other experiences and learnings about effective advocacy campaigns on HPV. The key takeaways were distilled into a written report '[Advocating for Action on HPV: Lessons and Legacies](#)' detailing eight essential ingredients for advocacy success. This will serve as a useful resource for organisations who are beginning, or are indeed in the midst of their own campaigns to advocate for better HPV prevention policy.

In 2023, the HPV Action Network began supporting advocacy campaigns on HPV elimination in Romania, Croatia and Bulgaria to see more young people vaccinated against HPV, in line with the recommendations of Europe's Beating Cancer Plan, and cervical screening programmes established in each country. Eastern European countries fall behind many other European countries in their efforts to eliminate HPV cancers, with low levels of HPV immunisation and cervical screening. Each month, the HPV Action network organises video conferences bringing together physicians, scientists, public health experts, and representatives of mothers and young people from all over the respective countries in order to address and identify opportunities for improvement.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

In 2024, [HPV Action Now](#) campaigns in Bulgaria, Croatia and Romania continue to unite national organisations and institutions to mobilise action on HPV vaccination, screening and public awareness. In Bulgaria, during the national “Time to Accelerate: Together Against Cancer” event in March, the landmark announcement was made that boys will be included in the national HPV vaccination programme. This received widespread media coverage, including on broadcast TV. The third National Conference on vaccine-preventable diseases for the first time featured a dedicated HPV panel, including presentations from various specialists from the HPV Coalition. In Croatia, HPV Action Croatia has expanded to over 17 stakeholders, strengthened by the inclusion of the national Pilot Cervical Cancer Screening Program coordinator, and gained high-level political engagement through the Zagreb Declaration, and meetings with the Director of the Croatian Institute of Public Health, and with the President, Mr. Zoran Milanović who opened “The Voice of Oncology Patient” conference on 6-7 September. The initiative also presented at the 37th IUSTI congress and finalised national recommendations on HPV prevention and screening improvement. In Romania, political commitment was reinforced at the World Cancer Day event in Parliament, while a football stadium awareness campaign reached thousands of fans with messages on HPV risks. Work is progressing on the “Action Direction in HPV Vaccination” white paper, developed through stakeholder consultations and informed by the European context.

In June, the [Council of the European Union adapted a groundbreaking set of recommendations to increase vaccination rates](#) against both the human papillomavirus (HPV) and hepatitis B virus (Hep B) and to combat cancers caused by these two viruses. This includes ensuring that vaccination against HPV and HBV is free of charge and easily accessible, improving communication about vaccination among parents and young people, combating misinformation and integrating immunisation against vaccine-preventable cancers into their national cancer plans. Whilst these recommendations are a welcome addition and show clear commitment to expanding access to prevention methods there is still opportunity for improvement such as the establishment of a target for HPV immunisation coverage in boys.

The work of the HPV Action network continues to draw insights from, and contribute valuable knowledge to [PROTECT-EUROPE](#), an EU4Health Project that champions gender-neutral vaccination programmes in EU Member States to provide protection for everyone against cancers caused by HPV. In particular, the project provides EU Member States with guidance on communication on HPV vaccination between clinicians and young people and their parents/caregivers, developing effective public health messaging on HPV vaccination aimed at young people and their parents/caregivers and proposing innovations that improve uptake (e.g. bundling adolescent vaccines).

In 2019, GNV was a novel concept. Today, all EU member states have now begun or committed to immunising both girls and boys against HPV. In 2025 we will make the case for change in the Europe, beyond the borders of the European Union.

[Learn more about the HPV and Hep B Action Network](#)

Leading the charge for global gender-neutral HPV vaccination

In 2023, a record number of countries added boys into their HPV vaccination programmes, alongside girls. But gender-neutral HPV immunisation programmes, the most effective means we have to prevent HPV cancers, are still only utilised in the minority of programmes globally.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

In the past year we have seen increased vaccine supplies made available, new studies highlighting the effectiveness of gender-neutral immunisation, increased calls for inclusion on vaccine equity and gender-equality grounds, and the opportunity to speed up progress towards the elimination of cervical cancer, and in turn all HPV cancers.

Making the case for global gender-neutral HPV vaccination

In Autumn 2023 we announced a new partnership between NOMAN is an Island: Race to End HPV Campaign and Global Action on Men's Health (GAMH), an organisation dedicated to promoting health and well-being on a global scale. Together, we are embarking on a mission to ensure global universal access to gender-neutral HPV vaccination, a vital step towards a healthier future for all.

Why is this partnership crucial? HPV-related diseases affect millions worldwide, irrespective of gender. HPV can cause a range of cancers - cervical, anal, penile, vaginal, vulvar, head and neck - as well as genital warts and recurrent respiratory papillomatosis (RRP). Yet gender-neutral HPV vaccination, despite now being a 'flagship' cancer prevention policy in the European Union (as detailed in Europe's Beating Cancer Plan, 2021), is still only the gold standard of protection in less than 50% of HPV vaccination programmes. In most countries with an HPV vaccination programme, only girls are vaccinated. Gender-neutral vaccination remains a controversial policy, especially for lower-income countries with very high rates of cervical cancer, and is not yet fully recommended by the World Health Organisation (WHO) or supported by GAVI.

By focusing only on the vaccination of girls to prevent cervical cancer, girls-only programmes fail to protect males sufficiently from the cancers caused by HPV. They also fail to protect unvaccinated women from infection by men, a particular problem in countries with low vaccination rates in girls. Girls-only programmes also mean that they unfairly shoulder the responsibility for prevention. With vaccine supply increasing, single-dose programmes changing cost-effectiveness calculations and evidence showing that 21% of males have a high-risk (cancer-causing) HPV infection we believe it is time to make the case for gender-neutral vaccination on a global basis.

By advocating gender-neutral HPV vaccination, we are not only safeguarding the health of current generations, male and female, but also paving the way for a future where HPV-related cancers and diseases are relics of the past.

Working in collaboration, GAMH and NOMAN's partnership in 2024 entailed the following:

Publication of Boys, Men and HPV: A global call for gender-neutral HPV vaccination

Traditionally, HPV prevention programs have focused on vaccinating girls, as the majority of HPV cancer cases affect females, particularly cervical cancer. However, evidence is growing regarding the burden of HPV disease in males. To succeed in our global health efforts to eliminate cervical cancer in line with the World Health Organisation (WHO) objective, protecting males is the pragmatic solution, enabling us to accelerate elimination efforts, in addition to removing barriers to immunisation

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

In May we headed to Geneva for the 77th World Health Assembly where we participated in several symposiums and seminars focusing on HPV elimination. As part of the week's events NOMAN hosted a side-event roundtable co-chaired by our CEO, David Winterflood, in partnership with GAMH, bringing together public health leaders and policymakers to discuss advancing GNV. During the event, we highlighted our roadmap to ending HPV cancers, discussed avenues for collaboration, and identified the key barriers to and opportunities for achieving worldwide GNV.

Capturing the evidence and knowledge from this roundtable, in September we launched our new report '[Boys, Men and HPV: A global call for gender-neutral HPV vaccination](#)' at the Union for International Cancer Control (UICC) World Cancer Congress. Calling for a more ambitious and ethical approach to HPV vaccination at the global level, our goal is clear: by 2030, all countries without an HPV vaccination programme should have introduced HPV vaccination on a gender-neutral basis, while countries currently with a girls-only programme should have transitioned to GNV.

Our 6 recommendations for global and national stakeholders are:

1. HPV must be understood, and responded to, as a threat to the health of all sexes and genders.
2. GNV should be viewed from the perspective of its potential to eliminate high-risk, oncogenic HPV types, thereby accelerating the elimination of not only cervical cancer but also all the cancers caused by HPV.
3. By 2028, global policymakers should have reviewed the issue of GNV with a view to recommending its implementation. The WHO should make boys a primary target for HPV vaccination.
4. By 2030, all countries currently without an HPV vaccination programme should have introduced HPV vaccination on a gender-neutral basis while countries currently with a girls-only programme should have transitioned to GNV.
5. Health partnerships between countries with established GNV programmes and lower-income countries should be established along with capacity-building initiatives to support the wider implementation of GNV.
6. A greater focus is needed on increasing vaccine uptake to at least 90% for all, a target most likely to be achieved through school-based vaccination programmes.

GNV is no longer a novel concept. Updating WHO policy to recognise the importance of protecting both boys and girls would act as a catalyst to strengthen and accelerate progress towards the elimination of all HPV cancers. Already endorsed by over 30 organisations from around the world, this call to action is already serving as a centerpiece for our advocacy work, in order to safeguard the health of current generations, male and female, but also to pave the way for a future where HPV-related cancers and diseases are relics of the past.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

Shaping the global conversation around HPV prevention

We continue to inform the discussion around HPV and its connection to cancers in males as well as females, and why protecting everyone is vital if we are to eliminate all HPV cancers. Throughout 2024, NOMAN presented and participated at forums across the globe including:

- The [Cervical Cancer Elimination Initiative](#) (CCEI) third partners meeting at WHO in the Palais des Nations, Geneva. Discussions focused on policy and advocacy, innovation and implementation, and general engagement strategies with global stakeholders.
- '[Co-creating priorities for cancer 2030 with people affected by cancer and emergent leaders](#)' at the WHO, discussing opportunities to ensure that we eliminate barriers to cancer care for cancer patients and ensure that no one is left behind.
- The first ever 'Males and HPV' session, and 'Harnessing the Power of Cross-sectoral and Country-based Partners for Cervical Cancer Elimination' at the [International Papillomavirus Conference \(IPVC\) in Edinburgh](#), sharing our story of how NOMAN's mission was inspired by personal tragedy, and our achievements during the last 14 years, in addition to providing reflections on 10 years of the Barcelona - Ibiza: Row to End HPV as a vehicle to engage the public and policymakers alike in our mission to end all HPV cancers.
- 'Going Global - Eliminating HPV and Hep B in Europe and beyond' at the [European Cancer Summit](#) in Brussels, reflecting on 5 years of achievement of the HPV Action network in Europe, and sharing our new global call to action report.
- Co-chairing the roundtable 'Men and Cancer: Improving Outcomes, Saving Lives' at [ESMO-Asia in Singapore](#), bringing together prominent figures in the HPV, cancer, and public health domains from across Asia who are concerned about men's cancer incidence and mortality, and the role gender-neutral HPV vaccination can play in improving outcomes.

Anal Cancer Foundation

Anal cancer is one of the fastest growing cancers in the United States, and steadily increasing in the United Kingdom. We continue to work tirelessly to make life better for families facing anal cancer through our programs to raise awareness, accelerate early detection, improve quality of life, and advance a cure. This year, we made incredible progress raising awareness about the need to reform how anal cancer thrivers are diagnosed and treated.

Peer to Peer Support Programme and Thriver Education

In the UK, about 1,600 people, and in the US, about 10,500 are diagnosed with anal cancer annually. Anal cancer incidence is increasing and affects more people across the world every year. The social stigma that anal cancer carries prevents fair and equitable conversation, awareness, and funding to support research and care for people with the disease.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

Support and information is limited for anal cancer thrivers (our word for survivors) and many thrivers never meet another anal cancer patient. The Foundation provides educational forums and a peer mentoring program to support thrivers to close this gap. The Peer to Peer Support Program is a free service provided by the Foundation in the UK and USA to connect patients and caregivers facing the challenges brought on by anal cancer with a peer who has undertaken the same journey.

Connections are available for anyone at any cancer stage from newly diagnosed to years after treatment. Volunteers listen and help thrivers through their cancer journey by sharing their own experiences on treatment, stigma and social experiences relating to an anal cancer diagnosis. The programme's goals are to improve the lives of those affected by anal cancer and give survivors a voice and a community. The program also matches caregivers together. At the end of 2024, the HPVACF's Peer to Peer Support Program included 1,300 thrivers, caregivers, and peer mentors.

Our online educational events continue to provide hope and resources for thrivers. Our 'Taking Care of You: Managing Side Effects From Treatment For Anal Cancer' event, featuring expert clinicians who treat people living with anal cancer as well as a panel of thrivers has been viewed by over 6,500 people by the end of 2024. 'Living and Thriving After Treatment for Anal Cancer: Addressing Long Term Side Effects', was viewed 12,500 times by the end of the year.

International Anal Neoplasia Society (IANS)

IANS, the International Anal Neoplasia Medical Society, creates medical guidelines and supports research essential to preventing and treating anal cancer. IANS was created with a seed grant from the Foundation.

IANS mission is to provide a forum for individuals with a broad spectrum of background, viewpoints and geographic origin, an exchange of ideas and dissemination of knowledge regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

In support of this mission IANS:

- Develops position papers regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Represents the consensus opinion of IANS regarding the above topics to other professional societies, public organizations, regulatory authorities and governmental bodies.
- Encourages the development of a robust research agenda on the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Develops educational materials and conduct training courses that encourage the entry of a broad spectrum of clinicians into the field of anal neoplasia, and that furthers the development and depth of skills of clinicians needed to optimally diagnose, treat and prevent anal neoplasia.
- Develop educational materials for patients with anal neoplasia.

UK CEO David Winterflood has been invited to present at the upcoming 2025 symposium as part of a panel on anal cancer screening, and will highlight the importance of DAREs by HCPs for patients presenting symptoms.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

Information and Connection

The Foundation's anal cancer program website features a wealth of resources and is a source of information, support, and inspiration for patients and families affected by anal cancer.

Our focus is ensuring patients get the information and support they need during their anal cancer journey. Our *Living with Anal Cancer* section features information for patients at all stages of the anal cancer journey from newly diagnosed to post-treatment resources, such as how physical therapy can help with anal cancer treatment recovery. The site is the most comprehensive source of information on side effects and side effect mitigation during and after anal cancer treatment. This digital hub is populated with personal thriver stories (patients' stories of their experiences), information about helpful medical resources, and professional medical bodies, as well as connections to other patients and caregivers through our Peer-to-Peer Support Program.

Our goal in 2024 continued to be ensuring that more anal cancer thrivers have access to the information they need to face their cancer journey through targeted outreach based on our existing supporter base and a newsletter series for patients and caregivers, focused on our expert and popular resources. Our communications strategy continues to focus on consistency and providing useful information, with content covering treatment and research updates, stories from community members, and explainers of our services and how we support the anal cancer community.

The continued investment into our digital resources is continuing to pay dividends. Organic and direct traffic to the website has increased by 13% and 3% respectively vs the previous year. The significant increases in both of these metrics, indicate that despite the threats and challenges posed by AI to internet search, users still value authoritative and trustworthy resources when it comes to their health. We will continue to refine our online content to ensure that our information and content is of the highest quality.

In 2024, we also undertook several webinars. On Anal Cancer Awareness Day, fellow anal cancer thrivers shared their personal experiences advocating for themselves during their anal cancer journeys. Whether it be how the patient negotiated for a different treatment, demanded a second opinion, requested a referral for supportive services, or simply shared their story for the world to hear, these provided moments of inspiration and vulnerability to connect our community. We also undertook the latest instalments of our expert hour series in the autumn. Dr. Van Morris from MD Anderson talked us through the role of circulating tumor DNA (ctDNA), a blood-based test which is changing how we manage and monitor cancers like colorectal and anal. This technology could help us detect which patients are at higher risk for recurrence, providing a new edge in the fight to cure more patients. Dr Morris' team measured HPV ctDNA before, during, and after treatment in patients with anal cancer, and HPV ctDNA presence three months after chemoradiation was associated with an increased risk of cancer recurrence. We also hosted a webinar exploring fertility preservation options during anal cancer treatment. Led by reproductive endocrinologist Dr Alexander Kotlyar and urologist Dr Jacob Khurgin who led an important discussion about the impacts of anal cancer treatment on fertility for both men and women, featuring an engaged Q&A session. Several hundred attendees attended the sessions and for those unable to join live, the session are published on our YouTube channel and have been viewed over 1,000 times in the short period following their publication.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

ACF's 2024 direct impact includes:

- 185 new anal cancer thrivers and caregivers signing up to be matched through the Peer-to-Peer Support Program.
- 230 anal cancer thrivers and caregivers helped by the 1:1 Patient Navigation Service.
- 14 thrivers sharing their story publicly with our community through our Share Your Story Initiative.
- 650+ people participating in our informational forums.

Overall, in 2024, ACF directly served over 1,000 anal cancer patients through our best-in-class patient programs, at no cost to them. Going forward, we will continue working to provide all the support the anal cancer community needs.

Looking Ahead: 2025

As we look ahead, the HPV and Anal Cancer Foundation continues to seek the most effective methods to prevent HPV and cure the cancers it causes.

The Foundation will continue to work tirelessly to eliminate all HPV-related cancers by furthering public policy and scientific debate, eliciting further professional and expert support, encouraging the development of regional initiatives on vaccinating boys, and demonstrating why it is important to protect all children against HPV at the recommended age.

Our advocacy efforts in Europe with the European Cancer Organisation and HPV Action Network to attain gender neutral HPV vaccination across the continent, continue apace. With the EU Beating Cancer Plan specifically including actions on HPV cancers within its remit, we have a mandate to gain support and empower stakeholders within member states to eliminate HPV cancers. With over 40% of cancers in the region preventable, the extension of HPV vaccination programmes to protect boys as well as girls provides a recognised and effective means to tackle cancer. By continuing to build our evidence base, seeking and identifying barriers to uptake in EC member countries, harnessing the possibilities presented by Europe's Beating Cancer Plan and launching advocacy groups in member states, we are confident that more countries will sign up to gender neutral protection initiatives. An early commitment for 2025 is making the case for change in Europe beyond the borders of the European Union. '[A Shared Vision for South East Europe: Eliminating HPV Cancers Together](#)' will be hosted in the Bulgarian parliament in January and provide a forum to discuss challenges and opportunities in combating HPV cancers across countries in the region including Albania, Bosnia & Herzegovina, Montenegro and Serbia.

Additionally, we will build on these national and regional endeavours, by furthering our global campaign work in 2025 with Global Action on Men's Health. In the year ahead we will continue to develop our evidence-based case for global GNV including launching a joint statement supported by over 100 distinguished global health experts advocating for cancer prevention in males, conducting side events at pre-eminent health gathering such as the World Health Assembly and IPVC, hosting a series of policy webinars exploring cancer prevention in males, and organising meetings with relevant multilateral and civil society organisation to foster dialogue and collaboration.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

Through the NOMAN is an Island Campaign, collaborations with advocates and legislators, media attention and athletic event participation, a broader audience is understanding the importance of protecting all children against HPV. With the NOMAN Campaign leading our HPV-advocacy initiatives, our platform is growing from which to broadcast our message. 2025 will also see the return of our flagship Barcelona – Ibiza: Row to End HPV event, serving as an opportunity to galvanise both long-standing and new supporters and furthering the reach of our message to prevent 5% of cancer.

We will continue to push for legislative, research and policy changes to end anal cancer and improve the lives of those affected by it. We are excited by the response to our Patient Summit and "Ask the Expert" sessions and look forward to providing more touchpoints for our community in 2025. Our Peer-to-Peer support program retains its importance in supporting and empowering anal cancer survivors and caregivers.

Utilising digital and live platforms, we will reach a wider proportion of the anal cancer community, enabling patients to gain answers to the concerns they have and to connect to other anal cancer patient experiences. This will be underpinned by continued investment into our digital platforms, ensuring that we provide best-in-class information for anal cancer thrivers, and their loved ones as they face an anal cancer diagnosis.

2025 will also see the return of our patient summit, bringing together anal cancer thrivers, caretakers, and advocates with medical experts to discuss the latest in anal cancer treatment and prevention research. The intention is to learn from one another, and join in solidarity to empower all those impacted by anal cancer to thrive.

We thank all of our donors and look forward to continuing the mission to empower anal cancer patients and accelerate prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees (who are also the directors of The HPV and Anal Cancer Foundation Limited) for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently
- observe the methods and principles in the Charity SORP
- make judgements and estimates that are reasonable and prudent
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:


- there is no relevant information of which the charitable company's examiners are unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the examiners are aware of that information.

The independent examiner, Knox Cropper LLP, will be proposed for re-appointment at the forthcoming Annual General Meeting.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

APPROVAL

This report was approved by the Board of Directors and Trustees on 22 September 2025 and signed on their behalf by:


.....
T Almada - Trustee

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF THE HPV AND ANAL CANCER FOUNDATION LIMITED

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2024.

Responsibilities and basis of report

As the trustees of the charitable company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act'). You are satisfied that the accounts of the Company are not required by charity or company law to be audited and have chosen instead to have an independent examination.

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Company's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view which is not a matter considered as part of an independent examination; or

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Richard Billinghamurst
Knox Cropper LLP
Chartered Accountants
65-68 Leadenhall Street, London, EC3A 2AD

Date: 23/09/2025

THE HPV AND ANAL CANCER FOUNDATION LIMITED
STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2024

	Notes	Unrestricted Funds	Restricted Funds	2024 Total Funds	2023 Total Funds
		£	£	£	£
INCOME AND ENDOWMENTS FROM					
Donations and Legacies	2	10,711	-	10,711	122,220
Other Trading Activities	3	51,705	-	51,705	457,311
Investment Income		1,532	-	1,532	250
Total		63,948	-	63,948	579,781
EXPENDITURE ON					
Raising Funds	4	13,796	-	13,796	95,515
CHARITABLE ACTIVITIES					
Care and Support	5	40,707	-	40,707	47,757
Awareness Raising & Education		108,026	-	108,026	192,337
Research for a Cure		6,459	-	6,459	7,364
TOTAL		168,988	-	168,988	342,973
NET INCOME/(EXPENDITURE)		(105,040)	-	(105,040)	236,808
RECONCILIATION OF FUNDS					
Total Funds Brought Forward		281,655	13,100	294,755	57,947
TOTAL FUNDS CARRIED FORWARD		£176,615	£13,100	£189,715	£294,755

THE HPV AND ANAL CANCER FOUNDATION LIMITED
(REGISTERED COMPANY NUMBER: 07955451)

BALANCE SHEET

AS AT 31st DECEMBER 2024

	Notes	2024 £	2023 £
FIXED ASSETS	12	-	-
CURRENT ASSETS	13		
Debtors		-	1,791
Cash at Bank and in hand		194,936	301,944
		<u>194,936</u>	<u>303,735</u>
CREDITORS: Amounts falling due within one year	14	(5,221)	(8,980)
NET CURRENT ASSETS		<u>189,715</u>	<u>294,755</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		189,715	294,755
NET ASSETS		<u>£189,715</u>	<u>£294,755</u>
FUNDS	16		
Unrestricted Funds		176,615	281,655
Restricted Funds		13,100	13,100
TOTAL FUNDS		<u>£189,715</u>	<u>£294,755</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.


The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 22 September 2025 and were signed on its behalf by:

.....

T Almada – Trustee

THE HPV AND ANAL CANCER FOUNDATION LIMITED

STATEMENT OF CASH FLOW
FOR THE YEAR ENDED 31 DECEMBER 2024

	2024	2023
	£	£
OPERATING ACTIVITIES		
Net income/(expenditure) for the reporting period	(105,040)	236,808
Depreciation charge	-	-
Interest payable	-	-
Investment income	(1,532)	(250)
(Increase)/decrease in debtors	1,791	(960)
Increase/(decrease) in creditors	(3,759)	(1,683)
	<hr/>	<hr/>
Net cash provided by/(used in) operating activities	(108,540)	233,915
INVESTING ACTIVITIES		
Investment income	1,532	250
Purchase of equipment	-	-
	<hr/>	<hr/>
Net cash provided by/(used in) investing activities	1,532	250
FINANCING ACTIVITIES		
Repayment of borrowing		-
Cash inflows from new borrowing		-
	<hr/>	<hr/>
Cash flows from financing activities	-	-
	<hr/>	<hr/>
Change in cash and cash equivalents in the reporting period	301,944	234,165
Cash and cash equivalents at the beginning of the reporting period	(107,008)	67,779
	<hr/>	<hr/>
Cash and cash equivalents at the end of the reporting period	194,936	301,944
	<hr/>	<hr/>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31st DECEMBER 2024

1. ACCOUNTING POLICIES

Basis of Preparation of Accounts

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

Financial Reporting Standard 102 – reduced disclosure exemptions

The Charitable company has taken advantage of the following disclosure exemptions in preparing these Financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

- The requirements of Section 7 Statement of Cash Flows.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible Fixed Assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Ocean rowing boat and accessories – over 3 years.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund Accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purpose within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2024

1. ACCOUNTING POLICIES - continued

Fund Accounting

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension Costs and Other Post-Retirement Benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Judgements and Key Sources of Estimation Uncertainty.

No judgement (apart from those involving estimates) have been made in the process of applying the above accounting policies that have significant effect on amounts recognised in the financial statements.

2. GRANTS AND DONATIONS

	2024	2023
	£	£
Grants	-	10,000
Donations and gift aid	10,711	112,220
	<u>10,711</u>	<u>122,220</u>

3. OTHER TRADING ACTIVITIES

	2024	2023
	£	£
Fundraising Events	51,705	457,311

4. RAISING FUNDS

Raising Donations and Legacies

	2024	2023
	£	£
Staff Costs	9,236	6,990
Development Expenses	32	32
Donor Software Subscription	3,375	3,246
Event Expenses	-	83,139
Support Costs	1,153	2,108
	<u>13,796</u>	<u>95,515</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2024

4. CHARITABLE ACTIVITIES COSTS

	Direct Costs	Grant Funding of Activities (see note 6)	Support Costs (see note 7)	2024 Totals
	£	£	£	£
Care and Support	37,306	-	3,401	40,707
Awareness Raising & Education	71,466	27,533	9,027	108,026
Research for a Cure	5,919	-	540	6,459
	<u>114,691</u>	<u>27,533</u>	<u>12,968</u>	<u>155,192</u>
	Direct Costs	Grant Funding of Activities (see note 6)	Support Costs (see note 7)	2023 Totals
	£	£	£	£
Care and Support	40,826	-	6,931	47,757
Awareness Raising & Education	158,820	22,934	10,583	192,337
Research for a Cure	3,828	-	3,536	7,364
	<u>203,474</u>	<u>22,934</u>	<u>21,050</u>	<u>247,458</u>

6. GRANTS PAYABLE

	2024	2023
	£	£
Awareness Raising & Education	<u>27,533</u>	<u>22,934</u>

The total grants paid to institutions during the year was as follows

	2024	2023
	£	£
European Cancer Organisation	17,533	17,934
Global Action on Men's Health	10,000	5,000
	<u>27,533</u>	<u>22,934</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2024

7. SUPPORT COSTS

	2024	2023
	£	£
Bank charges	313	301
Pensions	-	-
Rent and rates	4,427	7,212
Insurance	277	306
Fees and subscriptions	1,331	828
Office costs	935	741
Sundries	-	400
Travel and meetings	1,018	7,658
Staff training	-	-
Consultancy fees	-	-
Conference expenses	-	-
Independent examination fee	5,820	4,980
Accountancy and legal fees	-	732
	<hr/> <hr/>	<hr/> <hr/>
	14,121	23,158

8. NET INCOME (EXPENDITURE)

	2024	2023
	£	£
Net Income/(Expenditure) is stated after charging/(Crediting):		
Independent Examiner's Fee	<hr/> <hr/>	<hr/> <hr/>
	5,220	4,980

9. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2024 nor for the year ended 31 December 2023.

Trustees' Expenses

There were no trustees' expenses paid for the year ended 31 December 2024 nor for the year ended 31 December 2023.

10. STAFF COSTS

	2024	2023
	£	£
Wages and Salaries	53,009	40,295
Social Security Costs	6,728	4,955
Other Pension Costs	1,500	1,350
	<hr/> <hr/>	<hr/> <hr/>
	61,237	46,600

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2024

10. STAFF COSTS – continued

The average monthly number of employees during the year was as follows:

	2024	2023
Average monthly employees	1	1

No employees received emoluments in excess of £60,000.

The key management personnel of the charity are those persons having authority and responsibility for planning, directing and controlling the activities of the charity, directly or indirectly, including any trustee of the charity and, in the case of the charity, includes the Director of UK Operations. Total employee benefits paid to key management personnel in the period amounted to £45,250 (2022: £47,523).

11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted Funds	Restricted Funds	Total Funds 2023
INCOME AND ENDOWMENTS FROM	£	£	£
Donations and Legacies	122,220	-	122,220
Other Trading Activities	457,311	-	457,311
Investment Income	250	-	250
Total	579,781	-	579,781
EXPENDITURE ON			
Raising Funds	95,515	-	95,515
Charitable Activities			
Care and Support	47,757	-	47,757
Awareness Raising & Education	192,337	-	192,337
Research for a Cure	7,364	-	7,364
Total	342,973	-	342,973
NET INCOME/(EXPENDITURE)	236,808	-	236,808
RECONCILIATION OF FUNDS			
Total Funds Brought Forward	44,847	13,100	57,947
TOTAL FUNDS CARRIED FORWARD	£281,655	£13,100	£294,755

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2024

12. TANGIBLE FIXED ASSETS

	Plant and Machinery
	£
COST	
At 1 January 2024 and 31 December 2024	<u>47,250</u>
DEPRECIATION	
At 1 January 2024 and 31 December 2024	<u>47,250</u>
NET BOOK VALUE	
At 31 December 2024	<u>-</u>
At 31 December 2023	<u>-</u>

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Gift Aid Recoverable	<u>-</u>	<u>1,791</u>

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2024	2023
	£	£
Deferred Income	-	4,000
Accrued Expenses	<u>5,220</u>	<u>4,980</u>
	<u>5,220</u>	<u>8,980</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2024

15. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted Funds	Restricted Funds	2024	2023
	£	£	£	£
Current Assets	181,836	13,100	194,936	303,735
Current Liabilities	(5,221)	-	(5,221)	(8,980)
	<u>176,615</u>	<u>13,100</u>	<u>189,715</u>	<u>294,755</u>

COMPARATIVE

	Unrestricted Funds	Restricted Funds	2023	2022
	£	£	£	£
Current Assets	290,635	13,100	303,735	68,610
Current Liabilities	(8,980)	-	(8,980)	(10,663)
	<u>281,655</u>	<u>13,100</u>	<u>294,755</u>	<u>57,947</u>

16. MOVEMENT IN FUNDS

	Brought forward	Income	Expenditure	At 31.12.24
	£	£	£	£
Unrestricted Funds				
General Fund	281,655	63,948	(168,988)	176,615
Restricted Funds				
Research for a Cure	13,100	-	-	13,100
TOTAL FUNDS	<u>294,755</u>	<u>63,948</u>	<u>(168,988)</u>	<u>189,715</u>

Net Movement in Funds, included in the above are as follows:

COMPARATIVE	Brought forward	Income	Expenditure	At 31.12.23
	£	£	£	£
Unrestricted Funds				
General Fund	44,847	579,781	(342,973)	281,655
Restricted Funds				
Research for a Cure	13,100	-	-	13,100
TOTAL FUNDS	<u>57,947</u>	<u>579,781</u>	<u>(342,973)</u>	<u>294,755</u>

Capital Fund

The HPV and Anal Cancer Foundation Limited has shareholder capital equal to £1 and is owned by HPV and Anal Cancer Foundation, a registered charity in the United States of America, EIN 27-3217520.

Research for a Cure Fund

The Fund was set up to award grants to research which will advance development of effective treatments for anal and all HPV-related cancers.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2024

17. RELATED PARTY DISCLOSURES

No remuneration was paid to the trustees in the year (2023: £NIL).

The trustees made no donations to the Charity during the year (2023: £35,400 there were no conditions attached to those donations).

18. GOING CONCERN

The Trustees have considered the effect of the current economic climate on the Charity's activities. The Charity currently holds a comfortable level of reserves, and its fixed costs are not significant. It has the ability to align its activities to the level of reserves available. The Trustees are optimistic about the fundraising outlook for the next twelve months.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

England & Wales - Charity number 1147457

Accounts

THE HPV AND ANAL CANCER FOUNDATION LIMITED

TRUSTEES REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31st DECEMBER 2023

REGISTERED COMPANY NO: 07955451 (England and Wales)

REGISTERED CHARITY NO: 1147457

THE HPV AND ANAL CANCER FOUNDATION LIMITED

TRUSTEES REPORT

AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

CONTENTS

	<u>Page</u>
Reference and Administrative Details	1
Report of the Trustees	2-17
Independent Examiners' report	18
Statement of Financial Activities	19
Balance Sheet	20
Statement of Cash Flow	21
Notes to the Financial Statements	22-29

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023

Reference and Administrative Details For the Year ended 31 December 2023

LEGAL AND ADMINISTRATIVE INFORMATION

TRUSTEES	C Almada J Almada T Almada C Levett
REGISTERED OFFICE	128 City Road London EC1V 2NX
REGISTERED COMPANY NUMBER	07955451 (England and Wales)
REGISTERED CHARITY NUMBER	1147457
INDEPENDENT EXAMINER	Knox Cropper LLP 65 Leadenhall Street London EC3A 2AD
SOLICITORS	Stone King 16 St John's Lane London EC1M 4BS
BANKERS	HSBC 16 King Street Covent Garden London WC2E 8JF

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023

STRUCTURE, GOVERNANCE AND MANAGEMENT

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20th February 2012 and registered as a charity on the 25th May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The directors are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 28. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given an overview of the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws, and policies.

Risk Management

The trustees of the Foundation hold the responsibility of safeguarding the charity's assets and are satisfied that systems are in place to mitigate those risks which the charity may face.

FINANCIAL REVIEW

It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organisation. The revenue for the charity is dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundation in 2023 was £579,781 and expenditure was £342,973.

Total free reserves at the year end amounted to £281,655.

Reserves Policy

The Trustees have reviewed the amount of reserves it regards as a minimum prudent requirement. They have concluded that provision for three months operating reserves that enable the organisation to meet its financial commitments including grants, contracts and staff salaries is sufficient. This would allow time to manage cost reductions or generate funds as required whilst minimising the impact on service provision. At 31 December 2023 this amounted to £21,478. This indicates a healthy surplus of free reserves of £260,177, which will be allocated for use in 2024 and 2025 to support our initiatives to empower anal cancer patients, and accelerate prevention and research methods that eliminate human papillomavirus, and anal cancer.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

OBJECTIVES, ACTIVITIES AND ACHIEVEMENTS

Public Benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

History

The Foundation was first established in the USA in 2010 by three siblings who lost their mother, aged 53, to stage IV HPV-related anal cancer. Frustrated by the limited therapeutic and community support available to her, they created the organisation to fill the void caused by scant public, scientific and medical focus on this disease and its cause, the human papillomavirus (HPV). HPV causes anal cancer and at least five other cancers, amounting to 5% of cancers worldwide. These cancers are preventable. In 2012, the organization expanded to the UK with 2013 as its first full operational year.

Mission

The HPV and Anal Cancer Foundation empowers anal cancer patients and accelerates prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Objectives

- Highlight the relevance of human papillomavirus (HPV) in contracting cancer;
- Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender-neutral vaccination;
- Accelerate a cure for the 5% of all cancers that are caused by HPV, with a focus on anal cancer; and
- Provide support for survivors, caregivers, scientists and providers connected to anal cancer.

The Need

A fundamental objective of the Foundation's work is to reduce the incidence of anal cancer and other HPV-related cancers. HPV is a very common skin virus that nearly every sexually active person will get at some point in their lives. HPV affects both men and women and is responsible for 5% of the world's cancer burden. HPV causes cancers of the anus, cervix, head and neck, penis, vagina, and vulva.

Protection against HPV through universal HPV vaccination is a critical public health goal. With HPV identified as a cause of six different types of cancer, and 5% of cancer cases worldwide, it is imperative that we protect the entire population against it. The most effective method to reduce cancers related to HPV is to prevent initial infection of the virus through immunisation. The Foundation achieves this important aim through its efforts to advance equal access to HPV protection for both boys and girls through gender-neutral vaccination against the virus. At the introduction of the vaccine in most countries, only girls were able to receive this life-saving intervention while boys were generally excluded. The Foundation created and led the coalitions in the US and UK to ensure all children have equal access to protection against these cancers. The US achieved the milestone of recommending HPV protection to all children in 2011. Following the Foundation's five-year advocacy campaign in the UK, school-based HPV vaccination for boys began in September 2019. Our focus is on securing the same protection for boys as well as girls across Europe, and beyond.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

While we work to prevent future cases, it is also fundamental that scientific and medical disparities are addressed for the population that will continue to be diagnosed with HPV-related cancers like anal cancer. Treatment options have barely progressed since the 1970s and minimal research has been undertaken in new therapies. The medical and scientific communities need better research tools and investment in novel ideas to develop a cure.

The stigma surrounding anal cancer remains one of the central challenges to improving outcomes for anal cancer patients. Unfortunately, many medical centres provide only limited information specific to the experience of anal cancer. Many patients feel isolated and lack the support and educational resources that significantly improve quality of life during and after treatment.

Strategies to Achieve Our Goals

We achieve our mission in the UK and US through collaboration with scientists, clinicians, survivors, organisations, and government agencies; education of stakeholders and the general public; survivor support; and investment in the medical and scientific community to end HPV and the cancers it causes. Specifically, we take action to destigmatize and raise awareness about HPV, HPV-related cancers, and anal cancer; increase access to the HPV vaccine; improve screening protocols and preventative care; empower anal cancer thrivers; and accelerate a cure for anal cancer and other HPV-related illnesses.

Key achievements in 2023

NOMAN is an Island: Race to End HPV

The NOMAN Campaign raises awareness about the HPV-related cancer epidemic in men and women and educates about the importance of universal HPV vaccination, while challenging participants to extreme endurance races across the world. It is through such extreme feats of athleticism that NOMAN honour the struggle and isolation that many cancer patients feel.

NOMAN has been an incredibly successful campaign. Since its inaugural event in 2013 with the Barcelona – Ibiza: Row to End HPV, over 200 individuals – and their hundreds of supporters – have embraced the cause and our values. These NOMAN have raised awareness about HPV cancers on a local, national and international scale, as well as funds to support our programmes.

2023 was a special year for the foundation as the 10th anniversary of the NOMAN campaign. Book-ending our event calendar, NOMAN riders took on the Haute Route events at Crans-Montana and Ventoux. The Haute Route is the world's most prestigious cycling event for amateur cyclists. The races provided unparalleled experiences with 3-,5-and 7- day professional road cycling events in the most iconic cycling destinations worldwide. During the 3-day events, riders take on some 300km and 8000m+ of vertical ascent, testing themselves against the most infamous climbs in the world, all in the name of raising awareness of HPV-related cancers. Additionally, at each event all participants, (nearly 3000 participants in total) are given our END HPV socks to light up the climbs and generate conversation about our work to eliminate HPV cancers. NOMAN co-founder Tristan Almada also spoke about our mission to eliminate HPV cancers at the pre-stage briefing.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

July saw the 10th anniversary edition of the Barcelona-Ibiza: Row to End HPV, our flagship event. NOMAN's ocean rowing race pits teams of amateur rowers against each other in a three-day sprint across the Mediterranean. Rowing across an ocean is like no other sport: it is as much about the crews' ability to cope mentally as it is about technique and physical strength. The race has seen great interest among adventure seekers, and rowers range from people with no prior experience to more seasoned rowers looking to attempt an ocean row before committing to a longer challenge such as the Pacific or Atlantic Oceans.

2023 saw great interest from our community, and the return of participants from previous editions looking to be part of this special anniversary race, alongside new supporters of our work. They were joined on the water by Olympic gold medallist, Will Satch MBE as our NOMAN ambassador whose participation generated increased interest and support for our cause.

We are grateful for the generosity of the Trafigura Foundation for their tremendous support of our campaign and the Foundation's work in 2023 in the form of a matching contribution of \$150,000.

We look forward to building on these initiatives in the coming years.

HPV Action Europe Network

In 2018 and 2019 the Foundation was involved in discussions to establish an advocacy campaign in Europe to introduce gender-neutral vaccination across the region and completely eliminate HPV-related diseases.

NOMAN has partnered with the European Cancer Organisation (ECO) to achieve this mission. ECO works to reduce the burden of cancer and improve outcomes and the quality of care for patients through multidisciplinary initiatives. As the European not-for-profit federation of member organisations working in cancer, they convene oncology professional and patients to agree on policy, advocate for positive change, and be the united voice of the European cancer community.

Together with ECO, the Foundation looks forward to working with European policy makers to end the suffering caused by HPV cancers. In 2021, we achieved a major milestone by securing for the first time, a commitment to eliminate HPV cancers in Europe's Beating Cancer Plan. The HPV Action Network has built on this major success with the following achievements in 2023, including supporting advocacy work in countries that are falling behind.

Publication of the 2nd edition of the HPV Policy Prevention Atlas

On 22 June, 2023, the HPV Prevention Policy Atlas was launched at the Romanian Parliament. This latest update of the Atlas, initially published in 2020, led by the European Parliamentary Forum for Sexual and Reproductive Rights (EPF) scores 48 European governments on their approach to HPV prevention – primary prevention (vaccination), secondary prevention (screening), and online information. The tool aims at providing up-to-date publicly available information across all countries of WHO European region in line with WHO cervical cancer elimination strategy and Europe's Beating Cancer Plan. The 2nd edition highlights the geographical disparities which exist in HPV prevention policies across the WHO European region, as highlighted by the visible East-West divide in EPF's scores across the continent.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

The Atlas serves as a powerful call to action; underlining the need for action to tackle HPV, in particular via policies related to HPV immunisation, cervical screening and online information, and underlines the importance of implementing the goals of Europe's Beating Cancer Plan.

Out of 48 countries in geographical Europe:

39 countries (83%) offer a national routine vaccination programme.

30 countries (64%) provide gender-neutral vaccination.

23 countries (49%) maintain an HPV vaccination registry.

25 countries (53%) offer easy-to-find, government-hosted websites with good or excellent information on HPV prevention.

In 2023, Denmark, Sweden, Finland, the UK, and Ireland are the top-performing countries in HPV prevention. These nations have implemented best-practice policies, including national routine HPV vaccination programs that are gender-neutral and freely available, resulting in high vaccination rates supported by robust immunisation data systems. They also offer free HPV screening for adults and maintain public websites with clear, factual information provided by authorities. Conversely, countries like Kosovo and Azerbaijan are at the bottom of the list, marked by a lack of primary and secondary prevention policies and an absence of reliable, evidence-based information on HPV prevention.

The Atlas has been presented at several high-level events throughout the year including the Serbian Parliament, and in a presentation to senior politicians and policymakers in Poland in October 2023.

The Atlas is available: <https://www.epfweb.org/node/552>

Launch of HPV Action Croatia and Romania and support for HPV Coalition, Bulgaria

In 2023, the HPV Action Network began supporting advocacy campaigns on HPV elimination in Romania, Croatia and Bulgaria to see more young people vaccinated against HPV, in line with the recommendations of Europe's Beating Cancer Plan, and cervical screening programmes established in each country.

Eastern European countries fall behind many other European countries in their efforts to eliminate HPV cancers, with low levels of HPV immunisation and cervical screening. Each month, the HPV Action network organises video conferences bringing together physicians, scientists, public health experts, and representatives of mothers and young people from all over the respective countries in order to address and identify opportunities for improvement. In country coordinators have been appointed in 2023 to support the coalitions and identify areas of need and opportunity. At the ECO Summit in November 2023, work in Romania, Bulgaria and Croatia was discussed at a well-attended satellite meeting, including by the Deputy Health Minister of Bulgaria.

Specific achievements for each of the countries in 2023 are detailed below.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

Romania

HPV Action Romania – (Acțiunea HPV România) is helping national organisations and institutions to mobilise and join forces to implement policies aimed at increasing HPV vaccination, screening and information coverage. A wide range of organisations have come together as part of this new campaign, whose call to action is focused on three points:

- Routine gender-neutral HPV vaccination for all 11-18-year-olds with 90% uptake by 2030.
- A national population-wide cervical cancer screening programme, based on HPV testing and including self-sampling as an option for hard-to-reach groups and others, with 70% of women screened by the age of 35 and again by age 45, to be achieved by 2030.
- A sustained public education campaign promoting HPV awareness, vaccination and screening.

In 2023:

- In the context of World Cancer Day (4th February) a debate was held with parliamentarians focusing on the theme of "Women's Cancers – Directions for Improving Prevention, Early Diagnosis, and Early Access to Treatment to Reduce Incidence and Improve Survival Rates", in order to identify public health opportunities to decrease cancer incidence and improve survival rates. HPV immunisation and screening are key tools in the public health toolkit to address these issues.
- In May, a public awareness campaign was launched in Romanian football stadiums, reaching thousands of fans with our critical message about the dangers of HPV and its link to at least six different types of cancer. The objective of this campaign is to heighten awareness and encourage vaccination, in particular through encouraging parents to protect their children by asking their doctors about the immunisation.
- HPV Action Romania was officially launched, and an in-country coordinator appointed, on 31 October at the HPV Action Now event in the Romanian Parliament in Bucharest. At the event, Romania's health minister, Alexandru Rafila, announced that by the end of 2023, HPV immunisation would be fully reimbursable by the state for all boys and girls 11 to 18 years old. Although there are still barriers such as delivery and distribution, as well as combating public misunderstanding and misinformation, this commitment is a significant step forward.

Croatia

Croatia introduced GNV in 2016, but immunisation coverage is well below WHO elimination targets of 90%. In 2023:

- Croatian policymakers were invited to an event in early October with the coalition of national supporters of HPV prevention, highlighting the means by which national and local organisations can support advocacy efforts to encourage uptake of vaccination in order to prevent HPV cancers. On 20 October, the group participated in the '**Stakeholder Forum "Better Health for All: EU Global Health Strategy"**', overviewing the upcoming plans for the Coalition and presenting the aims of the upcoming cervical cancer screening programs in Croatia.
- Throughout 2023, the coalition was represented in interviews on 'Good Morning Croatia', which have emphasised the preventability of HPV cancers through immunisation, and have highlighted the underutilisation of HPV vaccines among young people, to a national audience.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

HPV Action Croatia was officially launched on 6 December at the Croatian parliament hosted by Ivan Čelić, MP, and virtually via YouTube. Bringing together experts from epidemiologists, researchers, patients, civil society groups the aim is to create a united approach to improve preventive policies in HPV.

Bulgaria

In Bulgaria, the HPV Action Now project aims at bringing together, uniting and supporting organisations and institutions that work towards HPV vaccination and cervical cancer screening.

This campaign will be coordinated with the Bulgarian HPV Coalition, a national expert non-governmental coalition actively supported by the World Health Organization. It's objectives are:

- Raising public awareness around the risk of contracting the virus;
- Encouraging regular screening;
- Achieving a high level of vaccination, in accordance with WHO recommendations.

In 2023:

- On 19 September, representatives of the HPV Action Network and Bulgarian HPV Coalition had a fruitful meeting in Sofia at the Bulgarian Parliament where local MPs were encouraged to continue efforts towards HPV prevention through vaccination.
- Held on 10-12th November, HPV Action Network representatives spoke at the second Bulgarian national conference on vaccine-preventable diseases, the largest event ever held in the country dedicated to these topics. Organised by the Bulgarian HPV Coalition and Astra Forum Foundation, leading specialist in vaccination and prevention convened to discuss progress and challenges within Bulgaria.

Protect Europe

The EU4Health programme was adopted as a response to the COVID-19 pandemic and to reinforce crisis preparedness in the EU. The pandemic highlighted the fragility of national health systems. The EU4Health programme will bring a contribution to the long-term health challenges by building stronger, more resilient and more accessible health systems, through financial support from the European Union.

Through this funding, the PROTECT-EUROPE project will champion gender-neutral HPV vaccination in the EU to protect everyone against HPV cancers, by providing information and guidance to EU Member States on:

- How healthcare professionals can better communicate directly with young people and their parents or caregivers.
- How public health messaging on HPV can be tailored to better resonate with young people and their parents or caregivers.
- How other innovative approaches, such as bundling various adolescent vaccines, could improve HPV vaccine uptake.

A key element of the project is ensuring that boys as well girls are offered the vaccine. Gender-neutral HPV vaccination is one of the flagship commitments of Europe's Beating Cancer Plan. Findings from this project will contribute to the HPV Action network as they become available.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

Response to European Commission call for evidence on action to promote vaccination against cancer causing viruses.

The HPV Action network supported a response to the European Commission Call for Evidence on cancer prevention – action to promote vaccination against cancer-causing viruses. The consultation invited public feedback on future initiatives to increase the uptake of vaccination against the Hepatitis B virus and Human Papillomavirus.

The call for evidence will support the drafting of the European Commission proposal for a Council Recommendation on vaccine-preventable cancers, which will be published by the end of 2023. The HPV Action Network emphasised the following points for inclusion in the upcoming Recommendation:

1. Accelerating the achievement of HPV cancer elimination through gender-neutral vaccination.
2. Increasing coverage of HBV vaccination including for new-borns, children and risk-groups.
3. Ensuring an inequalities focus throughout the recommendation.
4. Actively tracking and monitoring progress towards the achievement of HPV and HBV cancers elimination goals.
5. Enhancing EU level action against misinformation and disinformation about vaccination on social media.
6. Supporting a stable supply environment for HPV and HBV vaccines across Europe.
7. Creating synergies between the European Commission and the World Health Organization in implementing policies and strategies for the elimination of all cancers and diseases caused by HPV and HBV.
8. Urging Member States to adopt public health strategies that include multi-stakeholders educational campaigns.
9. Committing Member States to further facilitate access to vaccination and to implement coordinated vaccination catch-up programmes among the population.
10. Securing long-term commitment by the European Union to the funding of vaccine-preventable cancers research.

Future plans

In 2024 and beyond, the HPV Action Network will:

- Complete the PROTECT-EUROPE project and utilise the outputs wherever possible for Action Now.
- Continue to support the national campaigns in Bulgaria, Croatia and Romania and actively consider expanding the approach into Poland and other countries where possible.
- Hold an Advocacy Symposium on 25 January and publish a follow-up report. We will learn the lessons from the symposium for our own advocacy work and encourage others to utilise the outputs for their own campaigns on HPV policy.
- Respond to the forthcoming EC proposal for an EU Council Recommendation on vaccine-preventable cancers.
- Continue to disseminate and use as an advocacy tool the EPF/ECO HPV Prevention Policy Atlas.
- Use ECO's Time to Accelerate Manifesto and the Men and Cancer Roadmap to raise HPV issues during the European Parliament elections.
- Continue to participate in the Mission Board on vaccination chaired by Prof Walter Ricciardi.
- Participate in International HPV Awareness Day and European Immunisation Week.
- Explore other opportunities to maximise our impact.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

HPV Coalition UK

In October 2022, the NOMAN Campaign were proud to join forces with Jo's Cervical Cancer Trust to launch and co-chair the HPV Coalition in the United Kingdom. The Coalition was officially launched in the Palace of Westminster in an event hosted by long standing HPV advocate, Jess Phillips MP, and supported by politicians from both sides of the aisle, as well as community stakeholders such as HPV cancer thrivers.

The HPV Coalition is an expert advisory group of leading patient groups, professional groups, clinicians, and expert individuals who have come together to inform and advance the UK's journey towards elimination of HPV-related cancers – cancers which account for 5% of all cancers globally, and which we now, for the first time in history, have the opportunity to eliminate as a public health threat.

Despite the scale of the opportunity, the UK has yet to take the step of other countries, such as Australia and Canada, in developing an action plan for cervical cancer elimination. The UK also lags behind the European Union which, through the Beating Cancer Plan, has gone one step further, in committing to eliminate all HPV cancers. The HPV Coalition is therefore eager to see the UK put in place a concrete plan for elimination as a matter of priority, targeted at the whole range of HPV-related cancers and supporting access to preventative interventions for all parts of the population.

The Coalition will stand at the forefront of UK policymaking and will bring together a membership of patient organisations, professional groups, clinicians, and expert individuals to build and demonstrate broad stakeholder consensus around the significant – and as yet unharnessed – opportunity to pursue elimination in the UK. The membership will advocate for commitment and action from all UK governments to pursue elimination of the whole range of HPV-related cancers, in both men and women.

Publication of the 'Roadmap towards making the elimination of all HPV-related cancers a reality across the UK'

In May 2023, the Coalition published a Roadmap towards making the elimination of all HPV-related cancers a reality across the UK. This sets out ambitious, yet realistic goals, mapping out key areas of action, including milestones, markers of success, and research recommendations for areas which require further understanding.

The Roadmap serves as a call to Governments across the four nations of the UK to take action, while providing the blueprint of how elimination can be delivered. The goal is simple: Make the elimination of all HPV-related cancers a reality across the UK. We have many of the tools available to us now to make this a reality, and we must ensure it is grasped without delay.

To achieve this, we must ensure foundations of HPV prevention are strengthened. The Roadmap is therefore made up of a number of building blocks – with associated actions – that plot a course to elimination:

1. National and regional leadership and accountability
2. Improving education on HPV to tackle stigma and drive access to prevention
3. Making sure everyone has equitable access to screening and early diagnosis
4. Restoring and boosting immunisation uptake, including catch-up programmes
5. Enhancing the data, digital and workforce infrastructure
6. Embracing future innovations

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

It is critical that UK governments set out a concrete strategy for the elimination of all HPV-related cancers, widening the scope of our ambition beyond cervical cancer elimination. Along with our fellow members of the HPV Coalition, we stand ready to support the implementation of recommendations and take meaningful steps to prevent HPV-related cancers from affecting the lives of so many women and men.

Upon its publication, the Roadmap received national media coverage at launch, including an OpEd authored by the Foundation's CEO David Winterflood in The Times. It has also enabled the Coalition to engage with policy and parliamentary stakeholders to facilitate wider consensus around the roadmap and the ultimate goal of elimination. This included securing a Westminster Hall debate on HPV vaccination attended by MPs, and meetings with UK Health Security Agency (UKHSA) the government agency responsible for England-wide public health protection and infectious disease capability, NHS England, and an invitation to 10 Downing Street to brief the Prime Minister's Health Adviser.

In November 2023, NHS chief executive Amanda Pritchard pledged to eliminate cervical cancer by 2040, a key step in the journey to the elimination of all HPV cancers. In December, NHS England's first ever Vaccination Strategy was published containing a positive focus on improving HPV vaccination coverage rates.

In 2024, the Coalition will engage with NHS England as a partner in the implementation of the elimination ambition, to ensure that HPV prevention stays at the top of the agenda should there be a change of government. We will work with local systems to improve HPV prevention, and to advocate for similar commitments towards elimination in the devolved nations.

You can read the roadmap here: <https://www.nomancampaign.org/post/hpv-coalition-roadmap-to-elimination>

Leading the charge for global gender-neutral HPV vaccination

In 2023, a record number of countries added boys into their HPV vaccination programmes, alongside girls. But gender-neutral HPV immunisation programmes, the most effective means we have to prevent HPV cancers, are still only utilised in the minority of programmes globally. If this year is anything to go by, it won't be the case for long.

In the past year we have seen increased vaccine supplies made available, new studies highlighting the effectiveness of gender-neutral immunisation, increased calls for inclusion on vaccine equity and gender-equality grounds, and the opportunity to speed up progress towards the elimination of cervical cancer, and in turn all HPV cancers. Yet there is still work to be done. NOMAN continues to lead global advocacy efforts for the inclusion of boys into countries' HPV immunisation programmes. In 2023, we joined the Global HPV Consortium's launch in Kuala Lumpur to scope out the framework to take global action on HPV cancers, spoke at a panel discussion in Belgium: Elimination of HPV Cancers: Dream or Reality? (REALITY!), in addition to partnering with Global Action on Men's Health (GAMH), as discussed below.

Making the case for global gender-neutral HPV vaccination

In 2023 we announced a new partnership between NOMAN is an Island: Race to End HPV Campaign and Global Action on Men's Health (GAMH), an organisation dedicated to promoting health and well-being on a global scale. Together, we are embarking on a mission to ensure global universal access to gender-neutral HPV vaccination, a vital step towards a healthier future for all.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

Why is this partnership crucial? HPV-related diseases affect millions worldwide, irrespective of gender. HPV can cause a range of cancers - cervical, anal, penile, vaginal, vulvar, head and neck - as well as genital warts and recurrent respiratory papillomatosis (RRP). Yet gender-neutral HPV vaccination, despite now being a 'flagship' cancer prevention policy in the European Union (as detailed in Europe's Beating Cancer Plan, 2021), is still only the gold standard of protection in a minority of HPV vaccination programmes. In most countries with an HPV vaccination programme, only girls are vaccinated. Gender-neutral vaccination remains a controversial policy, especially for lower-income countries with very high rates of cervical cancer, and is not yet fully recommended by the World Health Organisation or supported by GAVI.

By focusing only on the vaccination of girls to prevent cervical cancer, girls-only programmes fail to protect males sufficiently from the cancers caused by HPV. They also fail to protect unvaccinated women from infection by men, a particular problem in countries with low vaccination rates in girls. Girls-only programmes also mean that they unfairly shoulder the responsibility for prevention. With vaccine supply increasing, single-dose programmes changing cost-effectiveness calculations and new evidence showing that 21% of males have a high-risk (cancer-causing) HPV infection (Buni L. et al, 2023), we believe it is time to make the case for gender-neutral vaccination on a global basis.

By advocating gender-neutral HPV vaccination, we are not only safeguarding the health of current generations, male and female, but also paving the way for a future where HPV-related cancers and diseases are relics of the past.

Working in collaboration, GAMH and NOMAN's partnership in 2023/2024 will entail:

- Developing an evidence-based case for gender-neutral HPV vaccination globally.
- Identifying the key stakeholders for partnership and advocacy in each WHO region with a focus on those regions with fewest countries offering gender-neutral vaccinations.
- Building an international alliance for action on gender-neutral HPV vaccination.

Anal Cancer Foundation

Anal cancer is one of the fastest growing cancers in the United States, and steadily increasing in the United Kingdom. We continue to work tirelessly to make life better for families facing anal cancer through our programs to raise awareness, accelerate early detection, improve quality of life, and advance a cure. This year, we made incredible progress raising awareness about the need to reform how anal cancer thrivers are diagnosed and treated.

Peer to Peer Support Programme and Thriver Education

In the UK, about 1,500 people, and in the US, about 10,500 are diagnosed with anal cancer annually. Anal cancer incidence is increasing and affects more people across the world every year. The social stigma that anal cancer carries prevents fair and equitable conversation, awareness, and funding to support research and care for people with the disease.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

Support and information is limited for anal cancer thrivers (our word for survivors) and many thrivers never meet another anal cancer patient. The Foundation provides educational forums and a peer mentoring program to support thrivers to close this gap. The Peer to Peer Support Program is a free service provided by the Foundation in the UK and USA to connect patients and caregivers facing the challenges brought on by anal cancer with a peer who has undertaken the same journey.

Connections are available for anyone at any cancer stage from newly diagnosed to years after treatment. Volunteers listen and help thrivers through their cancer journey by sharing their own experiences on treatment, stigma and social experiences relating to an anal cancer diagnosis. The programme's goals are to improve the lives of those affected by anal cancer and give survivors a voice and a community. The program also matches caregivers together. At the end of 2023, the HPVACF's Peer to Peer Support Program included 1199 thrivers, caregivers, and peer mentors. Our online educational events continue to provide hope and resources for thrivers. Our 'Taking Care of You: Managing Side Effects From Treatment For Anal Cancer' event, featuring expert clinicians who treat people living with anal cancer as well as a panel of thrivers has been viewed by over 5,900 people by the end of 2023. 'Living and Thriving After Treatment for Anal Cancer: Addressing Long Term Side Effects', was viewed 11,000 times by the end of the year.

Anal Cancer Patient Conference

On October 21st, 2023, the Anal Cancer Foundation held the second Anal Cancer Patient Summit.

Medical professionals spoke about anal cancer causes, treatments, and how to mitigate the various side effects of chemoradiation. We also heard from advocates who taught us, through sharing their own stories, how to use our personal experiences to advance the fight against anal cancer. Finally, thrivers were able to network both in groups and within one-on-one sessions which, for many people, was the first time they were meeting a fellow thriver.

The conference was created to provide an annual opportunity for anal cancer patients and caregivers to learn from medical professionals, connect with experts and each other, and take action to empower themselves and this community.

Over 449 people registered for the conference from 22 countries around the world.

Anal Cancer Foundation Co-Founder Justine Almada facilitated the day's events. Experts including Kevin Du, Cathy Eng, and Paul Romesser spoke about anal cancer causes, treatments, emerging therapies, and quality of life after treatment. Thrivers were given the opportunity to ask questions live, as well as to connect with one another.

We would like to make sure every family facing anal cancer has access to the same information as their doctors. Recordings of the day's events are now available on YouTube and has 1500 views since their publication.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

International Anal Neoplasia Society (IANS)

IANS, the International Anal Neoplasia Medical Society, creates medical guidelines and supports research essential to preventing and treating anal cancer. IANS was created with a seed grant from the Foundation.

IANS mission is to provide a forum for individuals with a broad spectrum of background, viewpoints and geographic origin, an exchange of ideas and dissemination of knowledge regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

In support of this mission IANS:

- Develops position papers regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Represents the consensus opinion of IANS regarding the above topics to other professional societies, public organizations, regulatory authorities and governmental bodies.
- Encourages the development of a robust research agenda on the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Develops educational materials and conduct training courses that encourage the entry of a broad spectrum of clinicians into the field of anal neoplasia, and that furthers the development and depth of skills of clinicians needed to optimally diagnose, treat and prevent anal neoplasia.
- Develop educational materials for patients with anal neoplasia.

Information and Connection

The Foundation's anal cancer program website features a wealth of resources and is a source of information, support, and inspiration for patients and families affected by anal cancer.

Our focus is ensuring patients get the information and support they need during their anal cancer journey. Our *Living with Anal Cancer* section features information for patients at all stages of the anal cancer journey from newly diagnosed to post-treatment resources, such as how physical therapy can help with anal cancer treatment recovery. The site is the most comprehensive source of information on side effects and side effect mitigation during and after anal cancer treatment. This digital hub is populated with personal thriver stories (patients' stories of their experiences), information about helpful medical resources, and professional medical bodies, as well as connections to other patients and caregivers through our Peer to Peer Support Program.

Our goal in 2023 continued to be ensuring that more anal cancer thrivers have access to the information they need to face their cancer journey through targeted outreach based on our existing supporter base and a newsletter series for patients and caregivers, focused on our expert and popular resources. Our communications strategy continues to focus on consistency and providing "useful" information, with content covering treatment and research updates, stories from community members, and explainers of our services and how we support the anal cancer community.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

ACF's 2023 direct impact includes:

- 185 new anal cancer thrivers and caregivers signing up to be matched through the Peer-to-Peer Support Program.
- 330 anal cancer thrivers and caregivers helped by the 1:1 Patient Navigation Service. Peer to Peer Support signups in 2023 are up 49% on 2020 figures.
- 7 thrivers sharing their story publicly with our community through our Share Your Story Initiative.
- 650+ people participating in our informational forums.

Overall, in 2023, ACF directly served over 1,100 anal cancer patients through our best-in-class patient programs, at no cost to them.

Going forward, we will continue working to provide all the support the anal cancer community needs.

Looking Ahead: 2024

As we look ahead, the HPV and Anal Cancer Foundation continues to seek the most effective methods to prevent HPV and cure the cancers it causes.

The Foundation will continue to work tirelessly to eliminate all HPV-related cancers by furthering public policy and scientific debate, eliciting further professional and expert support, encouraging the development of regional initiatives on vaccinating boys, and demonstrating why it is important to protect all children against HPV at the recommended age.

The UK began vaccinating boys against HPV in September 2019 and we will continue to work with stakeholders in the HPV-related disease space to ensure that uptake for this cancer-preventing intervention among 12–13-year-old boys is as high as possible, rebounding from the disruption to immunisation programmes caused by the pandemic, by using the collective knowledge of the HPV Coalition's membership to ensure that the opportunity to eliminate HPV cancers in the UK

Our advocacy efforts in Europe with the European Cancer Organisation and HPV Action Network to attain gender neutral HPV vaccination across the continent, continue apace. With the EU Beating Cancer Plan specifically including actions on HPV cancers within its remit, we have a mandate to gain support and empower stakeholders within member states to eliminate HPV cancers. With over 40% of cancers in the region preventable, the extension of HPV vaccination programmes to protect boys as well as girls provides a recognised and effective means to tackle cancer. By continuing to build our evidence base, seeking and identifying barriers to uptake in EC member countries, harnessing the possibilities presented by Europe's Beating Cancer Plan and launching advocacy groups in member states, we are confident that more countries will sign up to gender neutral protection initiatives. Additionally, we will build on these national and regional endeavours, by taking our campaign global in 2024, working with Global Action on Men's Health will develop an evidence-based case for global gender-neutral HPV vaccination, and utilising high-level symposiums such as World Health Assembly week and the World Cancer Congress to build recognition, and an international alliance for gender-neutral HPV vaccination.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

Through the NOMAN is an Island Campaign, collaborations with advocates and legislators, media attention and athletic event participation, a broader audience is understanding the importance of protecting all children against HPV. With the NOMAN side of the organisation leading on HPV-related activities, our platform is growing from which to broadcast our message.

We will continue to push for legislative, research and policy changes to end anal cancer and improve the lives of those affected by it. We are excited by the response to our Patient Summit and "Ask the Expert" sessions and look forward to providing more touchpoints for our community in 2024. Our Peer-to-Peer support program retains its importance in supporting and empowering anal cancer survivors and caregivers. Utilizing digital and live platforms, we will reach a wider proportion of the anal cancer community, enabling patients to gain answers to the concerns they have and to connect to other anal cancer patient experiences.

We thank all of our donors and look forward to continuing the mission to empower anal cancer patients and accelerate prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

THE HPV AND ANAL CANCER FOUNDATION LIMITED
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2023 (continued)

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees (who are also the directors of The HPV and Anal Cancer Foundation Limited) for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently
- observe the methods and principles in the Charity SORP
- make judgements and estimates that are reasonable and prudent
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant information of which the charitable company's examiners are unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the examiners are aware of that information.

The independent examiner, Knox Cropper LLP, will be proposed for re-appointment at the forthcoming Annual General Meeting.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

APPROVAL

This report was approved by the Board of Directors and Trustees on 26 September 2024 and signed on their behalf by:



.....
T Almada - Trustee

INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF THE HPV AND ANAL CANCER FOUNDATION LIMITED

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2023.

Responsibilities and basis of report

As the trustees of the charitable company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act'). You are satisfied that the accounts of the Company are not required by charity or company law to be audited and have chosen instead to have an independent examination.

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Company's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the Company's gross income exceeds £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a registered member of ICAEW which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Richard Billinghamurst
Knox Cropper LLP
Chartered Accountants
65-68 Leadenhall Street, London, EC3A 2AD

Date: 26/09/2024

THE HPV AND ANAL CANCER FOUNDATION LIMITED

STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	Unrestricted Funds	Restricted Funds	2023 Total Funds	2022 Total Funds
		£	£	£	£
INCOME AND ENDOWMENTS FROM					
Donations and Legacies	2	122,220	-	122,220	90,094
Other Trading Activities	3	457,311	-	457,311	64,776
Investment Income		250	-	250	22
Total		<u>579,781</u>	<u>-</u>	<u>579,781</u>	<u>154,892</u>
EXPENDITURE ON					
Raising Funds	4	95,515	-	95,515	16,407
CHARITABLE ACTIVITIES					
Care and Support	5	47,757	-	47,757	47,957
Awareness Raising & Education		192,337	-	192,337	103,849
Research for a Cure		7,364	-	7,364	4,796
TOTAL		<u>342,973</u>	<u>-</u>	<u>342,973</u>	<u>173,009</u>
NET INCOME/(EXPENDITURE)		236,808	-	236,808	(18,117)
RECONCILIATION OF FUNDS					
Total Funds Brought Forward		44,847	13,100	57,947	76,064
TOTAL FUNDS CARRIED FORWARD		<u>£281,655</u>	<u>£13,100</u>	<u>£294,755</u>	<u>£57,947</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED
(REGISTERED COMPANY NUMBER: 07955451)

BALANCE SHEET

AS AT 31st DECEMBER 2023

	Notes	2023 £	2022 £
FIXED ASSETS	12	-	-
CURRENT ASSETS	13		
Debtors		1,791	831
Cash at Bank and in hand		301,944	67,779
		303,735	68,610
CREDITORS: Amounts falling due within one year	14	(8,980)	(10,663)
NET CURRENT ASSETS		294,755	57,947
TOTAL ASSETS LESS CURRENT LIABILITIES			57,947
NET ASSETS		£294,755	£57,947
FUNDS	16		
Unrestricted Funds		281,655	44,847
Restricted Funds		13,100	13,100
TOTAL FUNDS		£294,755	£57,947

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 26 September 2024 and were signed on its behalf by:



 T Almada – Trustee

THE HPV AND ANAL CANCER FOUNDATION LIMITED

STATEMENT OF CASH FLOW
FOR THE YEAR ENDED 31 DECEMBER 2023

	2023	2022
	£	£
OPERATING ACTIVITIES		
Net income/(expenditure) for the reporting period	236,808	(18,117)
Depreciation charge	-	-
Interest payable	-	-
Investment income	(250)	(22)
(Increase)/decrease in debtors	(960)	(504)
Increase/(decrease) in creditors	(1,683)	2,594
	<hr/>	<hr/>
Net cash provided by/(used in) operating activities	233,915	16,049
INVESTING ACTIVITIES		
Investment income	250	22
Purchase of equipment	-	-
	<hr/>	<hr/>
Net cash provided by/(used in) investing activities	250	22
FINANCING ACTIVITIES		
Repayment of borrowing	-	-
Cash inflows from new borrowing	-	-
	<hr/>	<hr/>
Cash flows from financing activities	-	-
	<hr/>	<hr/>
Change in cash and cash equivalents in the reporting period	234,165	(16,027)
Cash and cash equivalents at the beginning of the reporting period	67,779	83,806
	<hr/>	<hr/>
Cash and cash equivalents at the end of the reporting period	301,944	67,779
	<hr/>	<hr/>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31st DECEMBER 2023

1. ACCOUNTING POLICIES

Basis of Preparation of Accounts

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

Financial Reporting Standard 102 – reduced disclosure exemptions

The Charitable company has taken advantage of the following disclosure exemptions in preparing these Financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

- The requirements of Section 7 Statement of Cash Flows.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible Fixed Assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Ocean rowing boat and accessories – over 3 years.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund Accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purpose within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

1. ACCOUNTING POLICIES - continued

Fund Accounting

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension Costs and Other Post-Retirement Benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Judgements and Key Sources of Estimation Uncertainty.

No judgement (apart from those involving estimates) have been made in the process of applying the above accounting policies that have significant effect on amounts recognised in the financial statements.

2. GRANTS AND DONATIONS

	2023	2022
	£	£
Grants	10,000	85,158
Donations and gift aid	112,220	4,936
	<u>122,220</u>	<u>90,094</u>

3. OTHER TRADING ACTIVITIES

	2023	2022
	£	£
Fundraising Events	<u>457,311</u>	<u>64,776</u>

4. RAISING FUNDS

Raising Donations and Legacies

	2023	2022
	£	£
Staff Costs	6,990	6,585
Development Expenses	32	42
Donor Software Subscription	3,246	2,167
Event Expenses	83,139	4,626
Support Costs	2,108	2,987
	<u>95,515</u>	<u>16,407</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

5. CHARITABLE ACTIVITIES COSTS

	Direct Costs	Grant Funding of Activities (see note 6)	Support Costs (see note 7)	2023 Totals
	£	£	£	£
Care and Support	40,826	-	6,931	47,757
Awareness Raising & Education	158,820	22,934	10,583	192,337
Research for a Cure	3,828	-	3,536	7,364
	<u>203,474</u>	<u>22,934</u>	<u>21,050</u>	<u>247,458</u>

	Direct Costs	Grant Funding of Activities (see note 6)	Support Costs (see note 7)	2022 Totals
	£	£	£	£
Care and Support	31,802	-	16,155	47,957
Awareness Raising & Education	65,467	17,069	21,313	103,849
Research for a Cure	3,092	-	1,704	4,796
	<u>100,361</u>	<u>17,069</u>	<u>39,172</u>	<u>156,602</u>

6. GRANTS PAYABLE

	2023	2022
	£	£
Awareness Raising & Education	<u>£22,934</u>	<u>£17,069</u>

The total grants paid to institutions during the year was as follows

	2023	2022
	£	£
European Cancer Organisation	17,934	17,069
Global Action on Men's Health	5,000	-
	<u>22,934</u>	<u>17,069</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

7. SUPPORT COSTS

	2023	2022
	£	£
Bank charges	301	410
Pensions	-	4,984
Rent and rates	7,212	5,724
Insurance	306	276
Fees and subscriptions	828	606
Office costs	741	333
Sundries	400	-
Travel and meetings	7,658	968
Staff training	-	52
Consultancy fees	-	20,600
Conference expenses	-	2,146
Independent examination fee	4,980	5,100
Accountancy and legal fees	732	960
	<u>£23,158</u>	<u>£42,159</u>

8. NET INCOME (EXPENDITURE)

	2023	2022
	£	£
Net Income/(Expenditure) is stated after charging/(Crediting):		
Independent Examiner's Fee	<u>£4,980</u>	<u>£5,100</u>

9. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2023 nor for the year ended 31 December 2022.

Trustees' Expenses

There were no trustees' expenses paid for the year ended 31 December 2023 nor for the year ended 31 December 2022.

10. STAFF COSTS

	2023	2022
	£	£
Wages and Salaries	40,295	42,567
Social Security Costs	4,955	4,956
Other Pension Costs	1,350	1,356
	<u>£46,600</u>	<u>£48,879</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

10. STAFF COSTS – continued

The average monthly number of employees during the year was as follows:

	2023	2022
Average monthly employees	1	1

No employees received emoluments in excess of £60,000.

The key management personnel of the charity are those persons having authority and responsibility for planning, directing and controlling the activities of the charity, directly or indirectly, including any trustee of the charity and, in the case of the charity, includes the Director of UK Operations. Total employee benefits paid to key management personnel in the period amounted to £45,250 (2022: £47,523).

11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted Funds	Restricted Funds	Total Funds
	£	£	£
INCOME AND ENDOWMENTS FROM			
Donations and Legacies	90,094	-	90,094
Other Trading Activities	64,776	-	64,776
Investment Income	22	-	22
Total	154,892	-	154,892
EXPENDITURE ON			
Raising Funds	16,407	-	16,407
Charitable Activities			
Care and Support	47,957	-	47,957
Awareness Raising & Education	103,849	-	103,849
Research for a Cure	4,796	-	4,796
Total	173,009	-	173,009
NET INCOME/(EXPENDITURE)	(18,117)	-	(18,117)
RECONCILIATION OF FUNDS			
Total Funds Brought Forward	62,964	13,100	76,064
TOTAL FUNDS CARRIED FORWARD	£44,847	£13,100	£57,947

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

12. TANGIBLE FIXED ASSETS

	Plant and Machinery
	£
COST	
At 1 January 2023 and 31 December 2023	<u>47,250</u>
DEPRECIATION	
At 1 January 2023 and 31 December 2023	<u>47,250</u>
NET BOOK VALUE	
At 31 December 2023	<u>-</u>
At 31 December 2022	<u>-</u>

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023	2022
	£	£
Gift Aid Recoverable	<u>1,791</u>	<u>831</u>

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023	2022
	£	£
Deferred Income	4,000	5,922
Accrued Expenses	4,980	4,741
	<u>£8,980</u>	<u>£10,663</u>

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

15. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted Funds	Restricted Funds	2023	2022
	£	£	£	£
Current Assets	272,675	13,100	303,735	68,610
Current Liabilities	(8,980)	-	(8,980)	(10,663)
	<u>£281,655</u>	<u>£13,100</u>	<u>£294,755</u>	<u>£57,947</u>

COMPARATIVE

	Unrestricted Funds	Restricted Funds	2022	2021
	£	£	£	£
Current Assets	55,510	13,100	68,610	84,133
Current Liabilities	(10,663)	-	(10,663)	(8,069)
	<u>£44,847</u>	<u>£13,100</u>	<u>£57,947</u>	<u>£76,064</u>

16. MOVEMENT IN FUNDS

	Brought forward	Income	Expenditure	At 31.12.23
	£	£	£	£
Unrestricted Funds				
General Fund	44,847	579,781	(342,973)	281,655
Restricted Funds				
Research for a Cure	13,100	-	-	13,100
TOTAL FUNDS	<u>£57,947</u>	<u>£579,781</u>	<u>£(342,973)</u>	<u>£294,755</u>

Net Movement in Funds, included in the above are as follows:

COMPARATIVE	Brought forward	Income	Expenditure	At 31.12.22
	£	£	£	£
Unrestricted Funds				
General Fund	62,964	154,892	(173,009)	44,847
Restricted Funds				
Research for a Cure	13,100	-	-	13,100
TOTAL FUNDS	<u>76,064</u>	<u>£154,892</u>	<u>£(173,009)</u>	<u>£57,947</u>

Capital Fund

The HPV and Anal Cancer Foundation Limited has shareholder capital equal to £1 and is owned by HPV and Anal Cancer Foundation, a registered charity in the United States of America, EIN 27-3217520.

Research for a Cure Fund

The Fund was set up to award grants to research which will advance development of effective treatments for anal and all HPV-related cancers.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31st DECEMBER 2023

17. RELATED PARTY DISCLOSURES

No remuneration was paid to the trustees in the year (2022: £NIL).

A number of trustees gave donations to the Charity during the year. There were no conditions attached to those donations. The aggregate donations given to the Charity by related parties was £35,400.

18. GOING CONCERN

The Trustees have considered the effect of the current economic climate on the Charity's activities. The Charity currently holds a comfortable level of reserves, and its fixed costs are not significant. It has the ability to align its activities to the level of reserves available. The Trustees are optimistic about the fundraising outlook for the next twelve months.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

England & Wales - Charity number 1147457

Accounts

REGISTERED COMPANY NUMBER: 07955451 (England and Wales)
REGISTERED CHARITY NUMBER: 1147457

Report of the Trustees and
Financial Statements for the Year Ended 31 December 2022
for
THE HPV AND ANAL CANCER FOUNDATION
LIMITED

Knox Cropper LLP
Chartered Accountants
65 Leadenhall Street
London
EC3A 2AD

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Contents of the Financial Statements
for the Year Ended 31 December 2022**

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 14
Independent Examiner's Report	15
Statement of Financial Activities	16
Balance Sheet	17
Notes to the Financial Statements	18 to 26
Detailed Statement of Financial Activities	27 to 28

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Reference and Administrative Details
for the Year Ended 31 December 2022**

TRUSTEES	C Almada J Almada T Almada C Levett
REGISTERED OFFICE	128 City Road London EC1V 2NX
REGISTERED COMPANY NUMBER	07955451 (England and Wales)
REGISTERED CHARITY NUMBER	1147457
INDEPENDENT EXAMINER	Knox Cropper LLP Chartered Accountants 65 Leadenhall Street London EC3A 2AD
SOLICITORS	Stone King 16 St. John's Lane London EC1M 4BS
BANKERS	HSBC 455 Strand London WC2R 0RH

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20th February 2012 and registered as a charity on the 25th May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The directors are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 26. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given an overview of the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws, and policies.

Risk Management

The trustees of the Foundation hold the responsibility of safeguarding the charity's assets and are satisfied that systems are in place to mitigate those risks which the charity may face.

FINANCIAL REVIEW

It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organisation. The revenue for the charity is dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundation in 2022 was £154,892 and expenditure was £173,009.

Reserves Policy

The reserves policy is to maintain a minimum that enables the organisation to meet its financial commitments for the year, including grants, contracts, and staff salaries.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

OBJECTIVES AND ACTIVITIES

Objectives and aims

Public Benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

History

The Foundation was first established in the USA in 2010 by three siblings who lost their mother, aged 53, to stage IV HPV-related anal cancer. Frustrated by the limited therapeutic and community support available to her, they created the organisation to fill the void caused by scant public, scientific and medical focus on this disease and its cause, the human papillomavirus (HPV). HPV causes anal cancer and at least five other cancers, amounting to 5% of cancers worldwide. These cancers are preventable. In 2012, the organization expanded to the UK with 2013 as its first full operational year.

Mission

The HPV and Anal Cancer Foundation empowers anal cancer patients and accelerates prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Objectives

- Highlight the relevance of human papillomavirus (HPV) in contracting cancer;
- Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender-neutral vaccination;
- Accelerate a cure for the 5% of all cancers that are caused by HPV, with a focus on anal cancer; and
- Provide support for survivors, caregivers, scientists and providers connected to anal cancer.

The Need

A fundamental objective of the Foundation's work is to reduce the incidence of anal cancer and other HPV-related cancers. HPV is a very common skin virus that nearly every sexually active person will get at some point in their lives. HPV affects both men and women and is responsible for 5% of the world's cancer burden. HPV causes cancers of the anus, cervix, head and neck, penis, vagina, and vulva.

Protection against HPV through universal HPV vaccination is a critical public health goal. With HPV identified as a cause of six different types of cancer, and 5% of cancer cases worldwide, it is imperative that we protect the entire population against it. The most effective method to reduce cancers related to HPV is to prevent initial infection of the virus through immunisation. The Foundation achieves this important aim through its efforts to advance equal access to HPV protection for both boys and girls through gender-neutral vaccination against the virus. At the introduction of the vaccine in most countries, only girls were able to receive this life-saving intervention while boys were generally excluded. The Foundation created and led the coalitions in the US and UK to ensure all children have equal access to protection against these cancers. The US achieved the milestone of recommending HPV protection to all children in 2011. Following the Foundation's five-year advocacy campaign in the UK, school-based HPV vaccination for boys began in September 2019. Our focus is on securing the same protection for boys as well as girls across Europe, and beyond.

While we work to prevent future cases, it is also fundamental that scientific and medical disparities are addressed for the population that will continue to be diagnosed with HPV-related cancers like anal cancer. Treatment options have barely progressed since the 1970s and minimal research has been undertaken in new therapies. The medical and scientific communities need better research tools and investment in novel ideas to develop a cure.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

The stigma surrounding anal cancer remains one of the central challenges to improving outcomes for anal cancer patients. Unfortunately, many medical centres provide only limited information specific to the experience of anal cancer. Many patients feel isolated and lack the support and educational resources that significantly improve quality of life during and after treatment.

Strategies to Achieve Our Goals

We achieve our mission in the UK and US through collaboration with scientists, clinicians, survivors, organisations, and government agencies; education of stakeholders and the general public; survivor support; and investment in the medical and scientific community to end HPV and the cancers it causes. Specifically, we take action to destigmatize and raise awareness about HPV, HPV-related cancers, and anal cancer; increase access to the HPV vaccine; improve screening protocols and preventative care; empower anal cancer survivors; and accelerate a cure for anal cancer and other HPV-related illnesses.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

OBJECTIVES AND ACTIVITIES

KEY ACHIEVEMENTS IN 2021

NOMAN is an Island

The NOMAN is an Island Campaign raises awareness about the HPV-related cancer epidemic in men and women and educates about the importance of universal HPV vaccination, while challenging participants to extreme endurance races across the world. It is through such extreme feats of athleticism that NOMEN honour the struggle and isolation that many cancer patients feel.

NOMAN has been an incredibly successful campaign. Since its inaugural event in 2013 with the Barcelona - Ibiza: Row to End HPV, over 150 individuals - and their hundreds of supporters – have embraced the cause and our values. These NOMEN have raised awareness about HPV-cancers on a local, national, and international scale as well as funds to support our programmes.

The passion of our participants never ceases to amaze us, especially in the context of the COVID-19 pandemic. The NOMAN Campaign implemented the necessary parameters and covid regulations to enable our scheduled endurance and awareness events to take place.

2022 saw NOMAN riders take on Haute Route events at Alpe D'Huez and Davos. The Haute Route is the world's most prestigious cycling event for amateur cyclists. The races provide unparalleled experiences with 3- or 7-day professional road cycling events in the most iconic cycling destinations worldwide. During the 3-day events, riders take on some 300km and 8000m+ of vertical ascent, testing themselves against the most infamous climbs in the world, all in the name of raising awareness of HPV-related cancers. Additionally, at each event all participants were given our END HPV socks to light up the climbs and generate conversation about our work to eliminate HPV cancers. NOMAN co-founder Tristan Almada also spoke about our mission to eliminate HPV cancers at the pre-stage briefing event.

Back in the United Kingdom, NOMAN riders also took on Ride London Essex's new route, racing through the streets of the capital and the surrounding countryside. We thank all our athletes for their sacrifice and energy as NOMEN.

We look forward to 2023 and building upon our Haute Route partnership and the 10th anniversary edition of our Barcelona - Ibiza: Row to End HPV.

HPV ACTION EUROPE NETWORK

In 2018 and 2019, the Foundation was involved in discussions to establish an advocacy campaign in Europe to introduce gender-neutral vaccination across the region and completely eliminate HPV-related diseases.

NOMAN has partnered with the European Cancer Organisation (ECO) to achieve this mission. ECO works to reduce the burden of cancer and improve outcomes and the quality of care for cancer patients through multidisciplinary initiatives. As the European not-for-profit federation of member organisations working in cancer, they convene oncology professionals and patients to agree on policy, advocate for positive change, and be the united voice of the European cancer community. Together with ECO, the Foundation looks forward to working with European policy makers to end the suffering caused by HPV cancers. In 2021, we achieved a milestone by securing for the first time a commitment to eliminate HPV cancers in Europe's Beating Cancer Plan. The HPV Action Network built on this major success with the following achievements in 2022:

Published research mapping the current state of HPV vaccination and cervical screening programmes across the European region

OBJECTIVES AND ACTIVITIES

Through this mapping exercise, we have been able to identify nations that are actively addressing HPV-induced cancers and, more crucially, those that are lagging behind. In various countries across the European Region, initiatives such as HPV vaccination and cervical cancer screening programs are notably absent. Even among those with vaccination efforts, a gender-neutral approach is not universally adopted. Notably, numerous countries with established vaccination and screening initiatives are encountering challenges in achieving optimal service utilisation.

There remains a substantial amount of work to be done to eliminate HPV cancers as a public health concern. Examining the state of HPV prevention across the WHO European region (WHO EURO), this data collection and analysis will inform the HPV Action Europe Network's strategy to implement change. Armed with the invaluable insights provided in this report, we are committed to expediting actions at the regional level. Additionally, we aim to lend our support to the advocacy endeavours of HPV organisations within individual countries. This collaborative approach is aimed at ensuring that all healthcare systems take the necessary steps to effectively safeguard their populations, which could lead to the prevention of nearly 100,000 cancer cases annually.

Published an 'umbrella review' of interventions used to improve HPV vaccine uptake in children, adolescents and young adults. The results were also published in the journal STI.

The HPV Action Network conducted an important review of published evidence, identifying various policies and programmes that have improved intention and uptake rates for HPV vaccination including printed materials, SMS based health information, face-to-face presentations and Q&A sessions. HPV vaccination is easy to deliver, has immediate positive health impacts, and is highly efficacious, making it one of the most effective cancer prevention strategies available. The findings of this review will be disseminated widely, with the aim of encouraging the best possible use of this evidence in HPV vaccination programmes across Europe and beyond.

HPV vaccination rates for girls in Europe and other parts of the world are highly variable, with only two European countries achieving a 90% uptake of all vaccine doses for girls. While some countries have managed to achieve over 70% uptake, others have rates below 50%, with at least two countries vaccinating fewer than 10% of girls.

The main reason for these sub-optimal vaccination rates is low vaccine confidence among parents, carers, and young people themselves. This may be due to inadequate information, distrust in health authorities and vaccine manufacturers, and concerns regarding vaccine safety. However, interventions can improve vaccine confidence and increase uptake rates.

Successfully applied for EU4Health funding for the two year PROTECT-EUROPE project which will focus on increasing HPV vaccination uptake in EU member states.

The EU4Health programme was adopted as a response to the COVID-19 pandemic and to reinforce crisis preparedness in the EU. The pandemic highlighted the fragility of national health systems. The EU4Health programme will bring a contribution to the long-term health challenges by building stronger, more resilient and more accessible health systems, through financial support from the European Union.

Through this funding, the PROTECT-EUROPE project will champion gender-neutral HPV vaccination in the EU to protect everyone against HPV cancers, by providing information and guidance to EU Member States on:

- How healthcare professionals can better communicate directly with young people and their parents or caregivers.
- How public health messaging on HPV can be tailored to better resonate with young people and their parents or caregivers.
- How other innovative approaches, such as bundling various adolescent vaccines, could improve HPV vaccine uptake.

This project will commence in January 2023.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

OBJECTIVES AND ACTIVITIES

Other achievements for the HPV Action Network in 2022 include:

- Commissioned 'HPV Changemakers' to highlight the personal stories of individuals who have successfully made the case for change in the field of HPV cancer elimination in their own countries.
- Started work on pilot projects in Romania and Bulgaria to develop multi-organisation advocacy campaigns as part of the Action Now on HPV project.
- Responded to the WHO Europe consultation on its Roadmap for the Elimination of cervical cancer and made the case for wider action in a presentation to the WHO Europe Regional Committee meeting in September.

Future plans

In 2023 and beyond, the HPV Action Network will:

- Encourage and support the EC and EU Member States to implement Europe's Beating Cancer Plan.
- Start work on PROTECT-EUROPE.
- Make the case for action to address the impact of the pandemic on vaccination and screening programmes.
- Launch 'HPV Changemakers.'
- Launch the pilot advocacy projects in Romania and Bulgaria. The next step will be to identify other countries in the European region where a similar approach can be developed.
- Continue to support the HPV Coalition in the UK.
- " Advocate for the inclusion of gender-neutral HPV vaccination in the European Code Against Cancer.

HPV Coalition

In October, the NOMAN Campaign was proud to join forces with Jo's Cervical Cancer Trust to launch and co-chair the new HPV Coalition in the United Kingdom.

The HPV Coalition is an expert advisory group of leading patient groups, professional groups, clinicians, and expert individuals who have come together to inform and advance the UK's journey towards elimination of HPV-related cancers - cancers which account for 5% of all cancers globally, and which we now, for the first time in history, have the opportunity to eliminate as a public health threat.

Despite the scale of the opportunity, the UK has yet to take the step of other countries, such as Australia and Canada, in developing an action plan for cervical cancer elimination. The UK also lags behind the European Union which, through the Beating Cancer Plan, has gone one step further, in committing to eliminate all HPV cancers. The HPV Coalition is therefore eager to see the UK put in place a concrete plan for elimination as a matter of priority, targeted at the whole range of HPV-related cancers and supporting access to preventative interventions for all parts of the population.

The Coalition will stand at the forefront of UK policymaking and will bring together a membership of patient organisations, professional groups, clinicians, and expert individuals to build and demonstrate broad stakeholder consensus around the significant - and as yet unharnessed - opportunity to pursue elimination in the UK. The membership will advocate for commitment and action from all UK governments to pursue elimination of the whole range of HPV-related cancers, in both men and women.

On October 24th 2022, the Coalition was officially launched in the Palace of Westminster in an event hosted by long standing HPV advocate, Jess Phillips MP, and supported by politicians from both sides of the aisle, as well as community stakeholders such as HPV cancer thrivers.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

OBJECTIVES AND ACTIVITIES

The next step for the Coalition will be the publication of a roadmap in Spring 2023 which will provide a blueprint of how the elimination of HPV cancers can be delivered in the UK. This will set out ambitious, yet realistic goals, mapping out key areas of action, including milestones, markers of success, and research recommendations for areas which require further understanding. Once published, this will be utilised to engage with policy and parliamentary stakeholders to facilitate wider consensus around the roadmap and the ultimate goal of elimination.

Anal Cancer Foundation

Anal cancer is one of the fastest growing cancers in the United States, and steadily increasing in the United Kingdom. We continue to work tirelessly to make life better for families facing anal cancer through our programs to raise awareness, accelerate early detection, improve quality of life, and advance a cure. This year, we made incredible progress raising awareness about the need to reform how anal cancer thrivers are diagnosed and treated.

Peer to Peer Support Programme and Thriver Education

In the UK, about 1,500 people, and in the US, about 9,700 are diagnosed with anal cancer annually. Anal cancer incidence is increasing and affects more people across the world every year. The social stigma that anal cancer carries prevents fair and equitable conversation, awareness, and funding to support research and care for people with the disease.

Support and information is limited for anal cancer thrivers (our word for survivors) and many thrivers never meet another anal cancer patient. The Foundation provides educational forums and a peer mentoring program to support thrivers to close this gap. The Peer to Peer Support Program is a free service provided by the Foundation in the UK and USA to connect patients and caregivers facing the challenges brought on by anal cancer with a peer who has undertaken the same journey.

Connections are available for anyone at any cancer stage from newly diagnosed to years after treatment. Volunteers listen and help thrivers through their cancer journey by sharing their own experiences on treatment, stigma and social experiences relating to an anal cancer diagnosis. The programme's goals are to improve the lives of those affected by anal cancer and give survivors a voice and a community. The program also matches caregivers together. At the end of 2022, the HPVACF's Peer to Peer Support Program included 1014 thrivers, caregivers, and peer mentors.

Our online educational events continue to provide hope and resources for thrivers. Our 'Taking Care of You: Managing Side Effects From Treatment For Anal Cancer' event, featuring expert clinicians who treat people living with anal cancer as well as a panel of thrivers has been viewed by over 5,000 people by the end of 2022. 'Living and Thriving After Treatment for Anal Cancer: Addressing Long Term Side Effects', was viewed 10,700 times by the end of the year.

Anal Cancer Patient Conference

On October 1st, 2022, the Anal Cancer Foundation held the second Anal Cancer Patient Summit.

Medical professionals spoke about anal cancer causes, treatments, and how to mitigate the various side effects of chemoradiation. We also heard from advocates who taught us, through sharing their own stories, how to use our personal experiences to advance the fight against anal cancer. Finally, thrivers were able to network both in groups and within one-on-one sessions which, for many people, was the first time they were meeting a fellow thriver.

The conference was created to provide an annual opportunity for anal cancer patients and caregivers to learn from medical professionals, connect with experts and each other, and take action to empower themselves and this community.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

OBJECTIVES AND ACTIVITIES

Over 400 people registered for the conference from 20 countries around the world. Feedback from participants included: "This was beyond outstanding" and "Great Summit. Learned so much more than I thought I needed to know - Terrific!"

Anal Cancer Foundation Co-Founder Justine Almada facilitated the day's events. Experts including Drs. Joel Palefsky, Cathy Eng, and Paul Romesser spoke about anal cancer causes, treatments, emerging therapies, and quality of life after treatment. Thrivers were given the opportunity to ask questions live, as well as to connect with one another. Anal Cancer Thriver and Activist Marcia Cross shared her own story alongside several other thrivers, guiding the audience in how to use their personal experiences to advance the fight against anal cancer.

We would like to make sure every family facing anal cancer has access to the same information as their doctors. Recordings of the day's events are now available on YouTube. We will hold another Anal Cancer Patient Summit on October 21st, 2023.

NCCN Treatment Guidelines

In 2021, we were thrilled to partner with NCCN to create the first anal cancer treatment guide for patients, enabling patients and their caregivers to take charge of their own care and recovery. This year, NCCN updated the guidelines for 2022, again with input from the Anal Cancer Foundation.

The National Comprehensive Cancer Network is an alliance of 31 cancer centers in the USA, recognized for dealing with complex and/or rare cancers. NCCN Clinical Guidelines are the recognized standard for clinical direction and policy in cancer care and are among the most thorough and frequently updated clinical practice guidelines available in any area of medicine. The intent of the NCCN Guidelines is to assist in the decision-making process of individuals involved in cancer care-including physicians, nurses, pharmacists, payers, patients, and their families-with the ultimate goal of improving patient care and outcomes. This companion guide for patients is the next step forward in empowering patients with accessible information.

We hope this anal cancer treatment guide presents clinical information in an easy-to-read format for people with cancer and those who support them. The patient guideline is intended to:

- Equip patients and providers with the same information as that of their medical team
- Ensure that patients, no matter where they are treated, know what the experts agree upon as the standard of treatment and care
- Empower patients with knowledge about all of their treatment and care choices
- Allow patients to self-advocate for their own best care

ANCHOR Study

A ground-breaking randomised controlled national trial of 4,500+ people has shown that anal cancer can be prevented by routine screening and removal of precancerous cells. The ANCHOR Study hoped to improve patient outcomes for people with anal precancer and cancer by finding the best way to stop anal precancer from progressing to cancer. The Anal Cancer Foundation built and led the coalition of organizations that supported and pushed for the study.

ANCHOR stands for Anal Cancer HSIL Outcomes Research and the study investigated treating anal cancer precursor lesions to see if this reduced the cancer risk for people living with HIV. Conceived and led by Anal Cancer Foundation Scientific Advisory Board Member Dr. Joel Palefsky, ANCHOR aimed to recruit 5,000 people living with HIV and was randomized into two groups: treatment of anal precancer and a control group.

What was ANCHOR researching?

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

OBJECTIVES AND ACTIVITIES

Prevention and early detection are essential to ending anal cancer. Yet, despite its growing incidence and mortality, there are no national screening guidelines for anal cancer or precancer. The rates of cervical cancer reduced by 80% once doctors starting screening for and treating cervical precancer.

The hope was that the ANCHOR study would illustrate that treating anal precancer will reduce the risk of anal cancer. The ANCHOR study had two main objectives: to determine the effectiveness of screening for and treating anal precancer, to reduce the incidence of anal cancer in HIV-positive men and women, and to create a bank of blood, anal swab, and tissue specimens to support critical scientific studies on how anal cancer progresses. There were two arms in the study: one arm that received treatment for anal precancer and a control arm that did not.

Ninety percent of anal cancer is caused by the human papillomavirus (HPV), which can cause changes to the skin around and inside the anus. These changes are called "high-grade squamous intraepithelial lesions" or HSIL. Not all anal HSIL will develop into cancer. Most HSIL will go away on their own, but some become cancer over time and can eventually spread to other parts of the body. The incidence of anal cancer is highest in people living with HIV.

What were the outcomes?

Results were published in The New England Journal of Medicine in June of 2022. They demonstrated that this reduction was as high as 57%, achieved through routine screening and removal of precancerous cells.

Additional findings include:

- A higher prevalence of HSIL than anticipated. This was most surprising in women. They were expecting 10% prevalence but found 47.2%.
- The study diagnosed 17 people with cancer, which was higher than expected.
- There was a younger median age at diagnosis than expected.
- There was no real difference in age, race, or gender in those who progressed to cancer, but a large difference in cancer progression in smokers as compared to non-smokers.

Expert Hour Webinar Series

When you know what your providers know, you are empowered to have more in-depth and productive conversations toward our #1 priority: getting you the best care possible.

We bring the experts right to our community and held our inaugural Expert Hour webinar series: Clinical Trials 101 and Immunotherapy 101, featuring world-renowned experts and a live Q&A with Dr. Lee Rosen of the University of California, Los Angeles, and Dr. Julius Strauss of the National Institutes of Health holding informative and insightful sessions. We were thrilled at the quality and depth of information about anal cancer they each brought directly to the community.

Clinical Trials 101

March 18: Clinical Trials 101: Dr. Rosen guided us through myths and facts about clinical trials, provided questions to ask when considering a trial, and outlined how to frame clinical trials during the treatment journey.

Immunotherapy 101

April 21: Immunotherapy 101: Dr. Strauss presented on the types of immunotherapies and how they work, what factors affect response to immunotherapy, potential side effects, and how to access immunotherapy clinical trials.

Thank you to our experts and to our participants!

International Anal Neoplasia Society (IANS)

IANS, the International Anal Neoplasia Medical Society, creates medical guidelines and supports research essential to preventing and treating anal cancer. IANS was created with a seed grant from the Foundation.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

OBJECTIVES AND ACTIVITIES

IANS mission is to provide a forum for individuals with a broad spectrum of background, viewpoints and geographic origin, an exchange of ideas and dissemination of knowledge regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

In support of this mission IANS:

- Develops position papers regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Represents the consensus opinion of IANS regarding the above topics to other professional societies, public organizations, regulatory authorities and governmental bodies.
- Encourages the development of a robust research agenda on the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Develops educational materials and conduct training courses that encourage the entry of a broad spectrum of clinicians into the field of anal neoplasia, and that furthers the development and depth of skills of clinicians needed to optimally diagnose, treat and prevent anal neoplasia.
- Develop educational materials for patients with anal neoplasia.

On June 5th, the third day of the 2022 IANS Scientific Meeting in New York, a panel of brave and outspoken thrivers and advocates shared their experiences with the assembled medical experts, in a session entitled, "Rare and Misunderstood: Ten Years Later - Narratives and Perspective on the Anal Cancer Experience." The session was led and facilitated by Patient Advocate at IANS, Mary-Jo Murphy.

Invited speaker Justine Almada put forward the Foundation's vision for ending the disease and called on everyone gathered to join together and RAISE their game.

Her call for RAISE means that we, collectively:

- Refer to comprehensive care, both during and after treatment
- Advocate for screening
- Invest in research for new treatments
- Stop the Stigma with connection and community
- Ensure early and accurate diagnosis

Daun, Steven, Stephen and John gave testimony of their journeys. These were raw and honest first-person stories from people who have been through the isolating, confusing, and painful experience of anal cancer and precancer. They gave no-holds-barred details on what had happened to them and how their lives had been changed by anal cancer and precancer.

The road ahead in anal cancer prevention and treatment improvement is long, but the scientific meeting and patient panel made it clear that no one is in this alone.

Information and Connection

The Foundation's anal cancer program website features a wealth of resources and is a source of information, support, and inspiration for patients and families affected by anal cancer.

Our focus is ensuring patients get the information and support they need during their anal cancer journey. Our Living with Anal Cancer section features information for patients at all stages of the anal cancer journey from newly diagnosed to post-treatment resources, such as how physical therapy can help with anal cancer treatment recovery. The site is the most comprehensive source of information on side effects and side effect mitigation during and after anal cancer treatment. This digital hub is populated with personal thriver stories (patients' stories of their experiences), information about helpful medical resources, and professional medical bodies, as well as connections to other patients and caregivers through our Peer to Peer Support Program.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

OBJECTIVES AND ACTIVITIES

Our goal in 2022 continued to be ensuring that more anal cancer thrivers have access to the information they need to face their cancer journey through targeted outreach based on our existing supporter base and a newsletter series for patients and caregivers, focused on our expert and popular resources.

With the pandemic reducing the in-person resources available to the anal cancer community, the need for communication was more important than ever. Our communications strategy focused on consistency and "useful" information, with content covering treatment and research updates, stories from community members, and explainers of our services and how we support the anal cancer community.

ACF's 2022 direct impact includes:

- 130+ new anal cancer thrivers and caregivers signing up to be matched through the Peer to Peer Support Program.
- 250+ anal cancer thrivers and caregivers helped by the 1:1 Patient Navigation Service. Peer to Peer Support signups are up 28% on 2020 figures.
- 25 thrivers sharing their story publicly with our community through our Share Your Story Initiative.
- 650+ people participating in our informational forums.

Overall, in 2022, ACF directly served over 1,100 anal cancer patients through our best-in-class patient programs, at no cost to them, interest in our resources increased with web session duration up 17% over 2021, and countless people will benefit from our advocacy, this year and for several years to come.

Going forward, we will continue working to provide all the support the anal cancer community needs.

LOOKING AHEAD: 2023

As we look ahead, the HPV and Anal Cancer Foundation continues to seek the most effective methods to prevent HPV and cure the cancers it causes.

The Foundation will continue to work tirelessly to eliminate all HPV-related cancers by furthering public policy and scientific debate, eliciting further professional and expert support, encouraging the development of regional initiatives on vaccinating boys, and demonstrating why it is important to protect all children against HPV at the recommended age.

The UK began vaccinating boys against HPV in September 2019 and we will continue to work with stakeholders in the HPV-related disease space to ensure that uptake for this cancer-preventing intervention among 12-13-year-old boys is as high as possible. The work of the HPV Coalition will be important in ensuring the unprecedented opportunity to eliminate HPV cancers in the United Kingdom is not missed on the back of the interruption caused by the pandemic.

Our advocacy efforts in Europe with the European Cancer Organisation and HPV Action Network to attain gender neutral HPV vaccination across the continent, continue apace. With the EU Beating Cancer Plan specifically including actions on HPV cancers within its remit, we have a mandate to gain support and empower stakeholders within member states to eliminate HPV cancers. With over 40% of cancers in the region preventable, the extension of HPV vaccination programmes to protect boys as well as girls provides a recognised and effective means to tackle cancer. By continuing to build our evidence base, seek and identify barriers to uptake in EC member countries, and launch advocacy groups in member states, we are confident that more countries will sign up to gender neutral protection initiatives.

Through the NOMAN is an Island Campaign, collaborations with advocates and legislators, media attention and athletic event participation, a broader audience is understanding the importance of protecting all children against HPV. Our flagship Barcelona - Ibiza: Row to End HPV event will hold its 10-year anniversary, serving as an opportunity to galvanise both long-standing and new supporters and furthering the reach of our message to prevent 5% of cancer. With the NOMAN side of the organisation leading on HPV-related activities, we will continue to partner with the Haute Route on further cycling events as their European Charity Partner, and continue to educate about our ability to end HPV cancers.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**

OBJECTIVES AND ACTIVITIES

We will continue to push for legislative, research and policy changes to end anal cancer and improve the lives of those affected by it. We are excited by the response to our Patient Summit and "Ask the Expert" sessions and look forward to providing more touchpoints for our community with these and the patient conference in 2023. Our Peer to Peer support program retains its importance in supporting and empowering anal cancer survivors and caregivers. Utilizing digital and live platforms, we will reach a wider proportion of the anal cancer community, enabling patients to gain answers to the concerns they have and to connect to other anal cancer patient experiences.

We thank all of our donors and look forward to continuing the mission to empower anal cancer patients and accelerate prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Public benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

FINANCIAL REVIEW

Reserves policy

The reserves policy is to maintain a minimum that enables the organisation to meet its financial commitments for the year, including grants, contracts, and staff salaries.

Going concern

As stated in note 19, the Trustees have considered the effect of the current economic climate. The Trustees consider that the current economic climate is likely to cause disruption to the Charity's activities but are confident that current reserves and future income will be sufficient to ensure that the Charity remains a going concern for a period of at least twelve months from the date of approval of these financial statements as well as for the foreseeable future.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document, structure and management

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20 February 2012 and registered as a charity on the 25 May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The Trustees are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 18. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public as well as contacts of the charity. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given a full introduction to the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws and policies.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2022**


STRUCTURE, GOVERNANCE AND MANAGEMENT

Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The trustees of the Foundation hold the responsibility of safeguarding the charity's assets and systems are in place to mitigate those risks which the charity may face.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on27.09.2023..... and signed on its behalf by:



.....
T Almada - Trustee

**Independent Examiner's Report to the Trustees of
The HPV and Anal Cancer Foundation
Limited**

Independent examiner's report to the trustees of The HPV and Anal Cancer Foundation Limited ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2022.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Richard Billinghamurst

Knox Cropper LLP
Chartered Accountants
65 Leadenhall Street
London
EC3A 2AD

Date: 28/09/2023

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Statement of Financial Activities
(Incorporating an Income and Expenditure Account)
for the Year Ended 31 December 2022**

	Notes	Unrestricted funds £	Restricted funds £	2022 Total funds £	2021 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		90,094	-	90,094	2,083
Other trading activities	2	64,776	-	64,776	202,664
Investment income	3	22	-	22	2
Total		154,892	-	154,892	204,749
EXPENDITURE ON					
Raising funds	4	16,407	-	16,407	56,981
Charitable activities	5				
Care and Support		47,957	-	47,957	47,743
Awareness Raising & Education		103,849	-	103,849	146,825
Research for a Cure		4,796	-	4,796	4,325
Total		173,009	-	173,009	255,874
NET INCOME/(EXPENDITURE)		(18,117)	-	(18,117)	(51,125)
RECONCILIATION OF FUNDS					
Total funds brought forward		62,964	13,100	76,064	127,189
TOTAL FUNDS CARRIED FORWARD		44,847	13,100	57,947	76,064

The notes form part of these financial statements

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED (REGISTERED NUMBER: 07955451)**

**Balance Sheet
31 December 2022**

	Notes	2022 £	2021 £
CURRENT ASSETS			
Debtors	14	831	327
Cash at bank		67,779	83,806
		68,610	84,133
CREDITORS			
Amounts falling due within one year	15	(10,663)	(8,069)
NET CURRENT ASSETS		57,947	76,064
TOTAL ASSETS LESS CURRENT LIABILITIES		57,947	76,064
NET ASSETS		57,947	76,064
FUNDS	17		
Unrestricted funds		44,847	62,964
Restricted funds		13,100	13,100
TOTAL FUNDS		57,947	76,064

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2022 in accordance with Section 476 of the Companies Act 2006.


The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on**27.09.2023**..... and were signed on its behalf by:

Type text here


.....
T Almada - Trustee

The notes form part of these financial statements

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements
for the Year Ended 31 December 2022**

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

Financial reporting standard 102 - reduced disclosure exemptions

The charitable company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland':

- the requirements of Section 7 Statement of Cash Flows.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Ocean rowing boat and accessories - over 3 years

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

1. ACCOUNTING POLICIES - continued

Fund accounting

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Judgments and key sources of estimation uncertainty

No judgement (apart from those involving estimates) have been made in the process of applying the above accounting policies that have a significant effect on amounts recognised in the financial statements.

2. OTHER TRADING ACTIVITIES

	2022	2021
	£	£
Fundraising events	64,776	202,664

3. INVESTMENT INCOME

	2022	2021
	£	£
Deposit account interest	22	2

4. RAISING FUNDS

Raising donations and legacies

	2022	2021
	£	£
Staff costs	6,585	5,900
Development expenses	42	118
Donor software subscription	2,167	2,002
Event Expenses	4,626	46,842
Support costs (Operating)	2,987	2,119
	16,407	56,981

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

5. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 6) £	Grant funding of activities (see note 7) £	Support costs (see note 8) £	Totals £
Care and Support	31,802	-	16,155	47,957
Awareness Raising & Education	65,467	17,069	21,313	103,849
Research for a Cure	3,092	-	1,704	4,796
	<u>100,361</u>	<u>17,069</u>	<u>39,172</u>	<u>156,602</u>

6. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2022 £	2021 £
Staff costs	37,310	33,429
Development Expenses	3,032	5,035
Marketing	34,297	43,064
Miscellaneous Expense	2,104	1,682
Event Expenses	4,626	46,843
Media	17,552	20,778
Internet and Website	1,440	-
	<u>100,361</u>	<u>150,831</u>

7. GRANTS PAYABLE

	2022 £	2021 £
Awareness Raising & Education	17,069	17,365
The total grants paid to institutions during the year was as follows:		
	2022 £	2021 £
European Cancer Organisation	17,069	17,365

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

8. SUPPORT COSTS

	Finance £	Other £	Governance costs £	Totals £
Raising donations and legacies	62	2,016	909	2,987
Care and Support	107	14,472	1,576	16,155
Awareness Raising & Education	213	17,949	3,151	21,313
Research for a Cure	28	1,252	424	1,704
	<u>410</u>	<u>35,689</u>	<u>6,060</u>	<u>42,159</u>

Support costs, included in the above, are as follows:

	Raising donations and legacies £	Care and Support £	Awareness Raising & Education £
Bank charges	62	107	213
Pensions	747	1,296	2,592
Rent and Rates	859	1,488	2,976
Insurance	41	72	144
Fees and subscriptions	-	303	303
Telephone, printing, postage and stationery	21	133	169
Sundries	-	-	-
Travel and Meetings	-	322	323
Staff Training	26	-	26
Consultancy fees	-	10,300	10,300
Conference expenses	322	558	1,116
Independent Examiner's fee	765	1,326	2,652
Accountancy and legal fees	144	250	499
	<u>2,987</u>	<u>16,155</u>	<u>21,313</u>
		2022	2021
	Research for a Cure £	Total activities £	Total activities £
Bank charges	28	410	274
Pensions	349	4,984	4,884
Rent and Rates	401	5,724	3,680
Insurance	19	276	480
Fees and subscriptions	-	606	714
Telephone, printing, postage and stationery	10	333	563
Sundries	-	-	519
Travel and Meetings	323	968	1,620
Staff Training	-	52	67
Consultancy fees	-	20,600	16,229
Carried forward	<u>1,130</u>	<u>33,953</u>	<u>29,030</u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

8. SUPPORT COSTS - continued

	Research for a Cure £	2022 Total activities £	2021 Total activities £
Brought forward	1,130	33,953	29,030
Conference expenses	150	2,146	606
Independent Examiner's fee	357	5,100	3,180
Accountancy and legal fees	67	960	-
	<u>1,704</u>	<u>42,159</u>	<u>32,816</u>

9. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2022 £	2021 £
Independent Examiner's fee	<u>5,100</u>	<u>3,180</u>

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2022 nor for the year ended 31 December 2021.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2022 nor for the year ended 31 December 2021.

11. STAFF COSTS

	2022 £	2021 £
Wages and salaries	34,140	39,329
Social security costs	9,755	-
Other pension costs	4,984	4,884
	<u>48,879</u>	<u>44,213</u>

The average monthly number of employees during the year was as follows:

	2022	2021
Average monthly employees	<u>1</u>	<u>1</u>

No employees received emoluments in excess of £60,000.

The key management personnel of the charity are those persons having authority and responsibility for planning, directing and controlling the activities of the charity, directly or indirectly, including any trustee of the charity and, in the case of the charity, includes the Director of UK Operations. Total employee benefits paid to key management personnel in the period amounted to £49,194 (2021: £44,213).

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	2,083	-	2,083
Other trading activities	202,664	-	202,664
Investment income	2	-	2
Total	<u>204,749</u>	<u>-</u>	<u>204,749</u>
EXPENDITURE ON			
Raising funds	56,981	-	56,981
Charitable activities			
Care and Support	47,743	-	47,743
Awareness Raising & Education	146,825	-	146,825
Research for a Cure	4,325	-	4,325
Total	<u>255,874</u>	<u>-</u>	<u>255,874</u>
NET INCOME/(EXPENDITURE)	(51,125)	-	(51,125)
RECONCILIATION OF FUNDS			
Total funds brought forward	114,089	13,100	127,189
TOTAL FUNDS CARRIED FORWARD	<u>62,964</u>	<u>13,100</u>	<u>76,064</u>

13. TANGIBLE FIXED ASSETS

	Plant and machinery £
COST	
At 1 January 2022 and 31 December 2022	<u>47,250</u>
DEPRECIATION	
At 1 January 2022 and 31 December 2022	<u>47,250</u>
NET BOOK VALUE	
At 31 December 2022	<u>-</u>
At 31 December 2021	<u>-</u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022	2021
	£	£
Gift aid recoverable	831	327
	<u>831</u>	<u>327</u>

15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022	2021
	£	£
Social security and other taxes	-	4,889
Deferred income	5,922	-
Accrued expenses	4,741	3,180
	<u>10,663</u>	<u>8,069</u>

16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted funds £	Restricted funds £	2022 Total funds £	2021 Total funds £
Current assets	55,510	13,100	68,610	84,133
Current liabilities	(10,663)	-	(10,663)	(8,069)
	<u>44,847</u>	<u>13,100</u>	<u>57,947</u>	<u>76,064</u>

17. MOVEMENT IN FUNDS

	At 1.1.22 £	Net movement in funds £	At 31.12.22 £
Unrestricted funds			
General fund	62,964	(18,117)	44,847
Restricted funds			
Research for a Cure	13,100	-	13,100
TOTAL FUNDS	<u>76,064</u>	<u>(18,117)</u>	<u>57,947</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	154,892	(173,009)	(18,117)
TOTAL FUNDS	<u>154,892</u>	<u>(173,009)</u>	<u>(18,117)</u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

17. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.21 £	Net movement in funds £	At 31.12.21 £
Unrestricted funds			
General fund	114,089	(51,125)	62,964
Restricted funds			
Research for a Cure	13,100	-	13,100
TOTAL FUNDS	<u>127,189</u>	<u>(51,125)</u>	<u>76,064</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	204,749	(255,874)	(51,125)
TOTAL FUNDS	<u>204,749</u>	<u>(255,874)</u>	<u>(51,125)</u>

Capital fund

The HPV and Anal Cancer Foundation Limited has shareholder capital equal to £1 and is owned by HPV and Anal Cancer Foundation, a registered charity in the United States of America, EIN 27-3217520.

Research for a Cure Fund

The fund was set up to award grants to research which will advance development of effective treatments for anal and all HPV-related cancers.

18. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2022.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2022**

19. GOING CONCERN

The Trustees have considered the effect of the current economic climate on the Charity's activities. The Charity currently holds a comfortable level of reserves and its fixed costs are not significant. It has the ability to align its activities to the level of reserves available. The Trustees are optimistic about the fundraising outlook for the next twelve months.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Detailed Statement of Financial Activities
for the Year Ended 31 December 2022**

	2022 £	2021 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	4,936	2,083
Grants	85,158	-
	<u>90,094</u>	<u>2,083</u>
Other trading activities		
Fundraising events	64,776	202,664
Investment income		
Deposit account interest	22	2
	<u>154,892</u>	<u>204,749</u>
Total incoming resources		
EXPENDITURE		
Raising donations and legacies		
Wages	6,585	5,900
Development expenses	42	118
Donor software subscription	2,167	2,002
Event Expenses	4,626	46,842
	<u>13,420</u>	<u>54,862</u>
Charitable activities		
Wages	27,555	33,429
Social security	9,755	-
Development Expenses	3,032	5,035
Marketing	34,297	43,064
Miscellaneous Expense	2,104	1,682
Event Expenses	4,626	46,843
Media	17,552	20,778
Internet and Website	1,440	-
Grants to institutions	17,069	17,365
	<u>117,430</u>	<u>168,196</u>
Support costs (Operating)		
Finance		
Bank charges	410	274
Other		
Pensions	4,984	4,884
Carried forward	4,984	4,884

This page does not form part of the statutory financial statements

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Detailed Statement of Financial Activities
for the Year Ended 31 December 2022**

	2022 £	2021 £
Other		
Brought forward	4,984	4,884
Rent and Rates	5,724	3,680
Insurance	276	480
Fees and subscriptions	606	714
Telephone, printing, postage and stationery	333	563
Sundries	-	519
Travel and Meetings	968	1,620
Staff Training	52	67
Consultancy fees	20,600	16,229
Conference expenses	2,146	606
	<u>35,689</u>	<u>29,362</u>
Governance costs		
Independent Examiner's fee	5,100	3,180
Accountancy and legal fees	960	-
	<u>6,060</u>	<u>3,180</u>
Total resources expended	<u>173,009</u>	<u>255,874</u>
Net expenditure	<u>(18,117)</u>	<u>(51,125)</u>

This page does not form part of the statutory financial statements

THE HPV AND ANAL CANCER FOUNDATION LIMITED

England & Wales - Charity number 1147457

Accounts

REGISTERED COMPANY NUMBER: 07955451 (England and Wales)
REGISTERED CHARITY NUMBER: 1147457

Report of the Trustees and
Financial Statements for the Year Ended 31 December 2021
for
THE HPV AND ANAL CANCER FOUNDATION
LIMITED

Knox Cropper LLP
Chartered Accountants
65 Leadenhall Street
London
EC3A 2AD

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Contents of the Financial Statements
for the Year Ended 31 December 2021**

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 14
Independent Examiner's Report	15
Statement of Financial Activities	16
Balance Sheet	17
Notes to the Financial Statements	18 to 26
Detailed Statement of Financial Activities	27 to 28

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Reference and Administrative Details
for the Year Ended 31 December 2021**

TRUSTEES	C Almada J Almada T Almada C Levett
REGISTERED OFFICE	128 City Road London EC1V 2NX
REGISTERED COMPANY NUMBER	07955451 (England and Wales)
REGISTERED CHARITY NUMBER	1147457
INDEPENDENT EXAMINER	Knox Cropper LLP Chartered Accountants 65 Leadenhall Street London EC3A 2AD
SOLICITORS	Stone King 16 St. John's Lane London EC1M 4BS
BANKERS	HSBC 455 Strand London WC2R 0RH

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20th February 2012 and registered as a charity on the 25th May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The directors are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 18. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public as well as contacts of the charity. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given a full introduction to the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws, and policies.

Risk Policy

The reserves policy is to maintain a minimum that enables the organisation to meet its financial commitments for the year, including grants, contracts, and staff salaries.

FINANCIAL REVIEW

It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organization. The revenue for the charity is dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundation in 2021 was £204,749 and expenditure was £255,874..

Reserves Policy

The reserves policy is to maintain a minimum that enables the organisation to meet its financial commitments for the year, including grants, contracts, and staff salaries.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES

Objectives and aims

Public Benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

History

The Foundation was first established in the USA in 2010 by three siblings who lost their mother, aged 53, to stage IV HPV-related anal cancer. Frustrated by the limited therapeutic and community support available to her, they created the organisation to fill the void caused by scant public, scientific and medical focus on this disease and its cause, the human papillomavirus (HPV). HPV causes anal cancer and at least five other cancers, amounting to 5% of cancers worldwide. These cancers are preventable. In 2012, the organization expanded to the UK with 2013 as its first full operational year.

Mission

The HPV and Anal Cancer Foundation empowers anal cancer patients and accelerates prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Objectives

- Highlight the relevance of human papillomavirus (HPV) in contracting cancer;
- Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender-neutral vaccination;
- Accelerate a cure for the 5% of all cancers that are caused by HPV, with a focus on anal cancer; and
- Provide support for survivors, caregivers, scientists and providers connected to anal cancer.

The Need

A fundamental objective of the Foundation's work is to reduce the incidence of anal cancer and other HPV-related cancers. HPV is a very common skin virus that nearly every sexually active person will get at some point in their lives. HPV affects both men and women and is responsible for 5% of the world's cancer burden. HPV causes cancers of the anus, cervix, head and neck, penis, vagina, and vulva.

Protection against HPV through universal HPV vaccination is a critical public health goal. With HPV identified as a cause of six different types of cancer, and 5% of cancer cases worldwide, it is imperative that we protect the entire population against it. The most effective method to reduce cancers related to HPV is to prevent initial infection of the virus through immunisation. The Foundation achieves this important aim through its efforts to advance equal access to HPV protection for both boys and girls through gender-neutral vaccination against the virus. At the introduction of the vaccine in most countries, only girls were able to receive this life-saving intervention while boys were generally excluded. The Foundation created and led the coalitions in the US and UK to ensure all children have equal access to protection against these cancers. The US achieved the milestone of recommending HPV protection to all children in 2011. Following the Foundation's five-year advocacy campaign in the UK, school-based HPV vaccination for boys began in September 2019. Our focus is on securing the same protection for boys as well as girls across Europe, and beyond.

While we work to prevent future cases, it is also fundamental that scientific and medical disparities are addressed for the population that will continue to be diagnosed with HPV-related cancers like anal cancer. Treatment options have barely progressed since the 1970s and minimal research has been undertaken in new therapies. The medical and scientific communities need better research tools and investment in novel ideas to develop a cure.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2021**

The stigma surrounding anal cancer remains one of the central challenges to improving outcomes for anal cancer patients. Unfortunately, many medical centres provide only limited information specific to the experience of anal cancer. Many patients feel isolated and lack the support and educational resources that significantly improve quality of life during and after treatment.

Strategies to Achieve Our Goals

We achieve our mission in the UK and US through collaboration with scientists, clinicians, survivors, organisations, and government agencies; education of stakeholders and the general public; survivor support; and investment in the medical and scientific community to end HPV and the cancers it causes. Specifically, we take action to destigmatize and raise awareness about HPV, HPV-related cancers, and anal cancer; increase access to the HPV vaccine; improve screening protocols and preventative care; empower anal cancer thrivers; and accelerate a cure for anal cancer and other HPV-related illnesses.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES

KEY ACHIEVEMENTS IN 2021

NOMAN is an Island

The NOMAN is an Island Campaign raises awareness about the HPV-related cancer epidemic in men and women and educates about the importance of universal HPV vaccination while challenging participants to extreme endurance races across the world. It is through such extreme feats of athleticism that NOMEN honour the struggle and isolation that many cancer patients feel.

NOMAN has been an incredibly successful campaign. Since its inaugural event in 2013 with the Barcelona - Ibiza: Row to End HPV, 141 individuals - and their hundreds of supporters - have embraced the cause and our values. These NOMEN have raised awareness about HPV-cancers on a local, national, and international scale as well as funds to support our programmes.

The passion of our participants never ceases to amaze us, especially in the context of the COVID-19 pandemic. The NOMAN Campaign implemented the necessary parameters and covid regulations to enable our scheduled endurance and awareness events to take place.

2021 saw the return of the NOMAN is an Island: Race to End HPV campaign's flagship Barcelona - Ibiza ocean rowing events. NOMAN's ocean rowing race pits teams of amateur rowers against each other in a three-day sprint across the Mediterranean. Rowing across an ocean is like no other sport: it is as much about the crews' ability to cope mentally as it is about technique and physical strength. Such is the enthusiasm for the event, that in 2015 we introduced a return leg from Ibiza to Barcelona. The race has seen great interest amongst adventure seekers looking to benefit a cause. Rowers range from people with no prior experience to more seasoned rowers looking to attempt an ocean row before committing to a larger challenge such as the Pacific or Atlantic Oceans.

Undoubtedly the pandemic impacted sign ups for the 2021 edition. The uncertainty around travel restrictions lifted around 3 weeks before the races themselves, restricting the races to 2 crews for both legs of the race. Enquiries around participation for future editions remains aligned with pre pandemic numbers which indicates a return to pre pandemic levels of participation in 2023, for the 10th anniversary edition.

2021 also saw NOMAN riders take on Haute Route events at Crans-Montana and Ventoux. The Haute Route is the world's most prestigious cycling event for amateur cyclists. The races provide unparalleled experiences with 3- or 7-day professional road cycling events in the most iconic cycling destinations worldwide. During the 3-day events, riders take on some 300km and 8000m+ of vertical ascent, testing themselves against the most infamous climbs in the world, all in the name of raising awareness of HPV-related cancers. Additionally, the Ventoux event saw a first with NOMAN lighting up the climbs in our ochre gold 'END HPV' socks. 300 attendees of the event wore the socks with pride and heard from NOMAN co-founder Tristan Almada on our mission to eliminate HPV cancers at the pre-stage briefing event.

Proving that lack of boats or bikes is no impediment to those passionate about ending cancer, our first cohort of runners took on the iconic London Marathon, racing the streets of the capital. We thank all our athletes for their sacrifice and energy as NOMEN.

We look forward to 2022 and building upon our Haute Route partnership and beginning to take the steps in preparation for the 10th anniversary Row to End HPV.

HPV ACTION EUROPE NETWORK

In 2018 and 2019, the Foundation was involved in discussions to establish an advocacy campaign in Europe to introduce gender-neutral vaccination across the region and completely eliminate HPV-related diseases.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES

NOMAN has partnered with the European Cancer Organisation (ECO) to achieve this mission. ECO works to reduce the burden of cancer and improve outcomes and the quality of care for cancer patients through multidisciplinary initiatives. As the European not-for-profit federation of member organisations working in cancer, they convene oncology professionals and patients to agree on policy, advocate for positive change, and be the united voice of the European cancer community. Together with the ECO, the Foundation looks forward to working with European policy makers to end the suffering caused by HPV cancers.

The main achievements of the HPV Action Network in 2021 were as follows:

Securing commitment to eliminating HPV cancers in Europe's Beating Cancer Plan

Just 14 months after the establishment of the European HPV Action Network, we achieved a European Commission 'flagship' commitment to gender-neutral HPV vaccination. **As a result, for the first time, the EU will dedicate resources to eliminate all HPV-caused cancers.**

Europe's Beating Cancer Plan is the EU's roadmap to act against cancer, mobilising the collective power of EU members to deliver change to benefit its citizens. It entails four areas; prevention, early detection, diagnosis and treatment, and improving the quality of life of cancer patients and survivors. The section pertinent to our work is:

3.7 Saving Lives through Cancer Prevention: Preventing cancers caused by infections

"With dedicated funds under the EU4Health programme and other funding instruments, Europe's Beating Cancer Plan will support Member States' efforts to extend routine vaccination against human papillomaviruses of girls and boys - in order to eliminate cervical cancer and other cancers caused by human papillomaviruses. The objective is to vaccinate at least 90% of the EU target population of girls and to significantly increase the vaccination of boys by 2030".

The above is outlined as a 'flagship initiative on prevention'. Needless to say, this is a massive victory for our campaign and is indicative that our advocacy and case for action set out in 'Viral Protection: Achieving the Possible' has momentum.

You can read the full report [here](#).

Call for the establishment of an HPV Vaccine Tracker

In European Immunisation Week 2021 (26 April - 2 May), the European Cancer Organisation's HPV Action Network called for the establishment of an HPV Vaccine Tracker to be hosted by the European Centre for Disease Prevention and Control (ECDC). This monitoring system would provide invaluable information about EU Member States' progress towards meeting the Beating Cancer Plan's goal of eliminating the cancers caused by HPV.

10 out of 27 EU countries have gender-neutral national HPV vaccination programmes, and eight others have made a commitment to introduce HPV vaccination for boys. Uptake of the vaccine in many countries is well below 90% with second dose completion rates ranging from 14% in Luxembourg to 24% in France to 31% in Germany. No EU country has a vaccination rate of 90% or more for the second dose. In addition, uptake rates in boys by comparison to girls are also lower, in Italy the vaccination rate of boys is 40% of that of girls. It is clear however that the COVID19 pandemic has disrupted vaccination programmes and led to a significant fall in uptake rates.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2021**

OBJECTIVES AND ACTIVITIES

A HPV Vaccine Tracker would help monitor progress towards Europe's Beating Cancer Plan goals, indicate slow progress and countries where additional support may be required, in addition to helping encourage Member States to adopt best practice. It will be a key indicator to the world how the EU is contributing towards a global effort to eliminate HPV cancers. The optimal platform for the HPV Vaccine Tracker would be provided by the European Centre for Disease Prevention and Control (ECDC), an EU organisation that works to improve Europe's defences against infectious illnesses and has a strong track record of work on HPV-related issues. ECDC's COVID-19 vaccine tracker provides an ideal template for such a model.

Self-sampling and HPV screening in Europe

To eliminate cervical cancer, there must be a large rise in the use of HPV testing for cervical cancer screening.

Providing women and people with a cervix the chance to self-sample for HPV, often known as self-sampling is an important component of any national screening program. Self-sampling is especially useful for those who have trouble accessing normal screening facilities.

In a position paper published by the Network, the key points of recommendation were:

- Self-sampling should form a central component of national cervical cancer screening programmes.
- Self-sampling should be utilised to return screening rates to pre-pandemic levels.
- HPV self-sampling should be endorsed by the European Commission's guidelines on cervical cancer. There should also be guidance on effective delivery.
- Research should continue into the best methods of delivering effective self-sampling with high levels of uptake as part of cervical cancer screening programmes.

Numerous studies have shown that self-sampling may be as accurate as traditional testing and is well received by consumers. In one case study, it is being provided as an alternative to a clinician assessment in the Netherlands to positive response from participants.

The paper can be read in full here.

HPV TESTIMONIES

The human papillomavirus (HPV) and the cancers it causes can devastate people's lives. We worked with survivors of HPV cancers to become advocates, empowered to tell their story. They explained how they were diagnosed with cancer and their emotions and experiences as they dealt with that, and then started treatment. They talk about the impact on their lives and on those around them, and whether they have been able to get back to a 'normal' life.

They also talk to us about their thoughts on HPV itself and the availability of vaccination, and whether they would like to see universal vaccination for men and women. Finally, they give us their message to patients and policymakers so that others can learn from their stories.

Future plans

The Network now has 47 members/stakeholders, shown here:

<https://www.europeancancer.org/topic-networks/1:hpv-action.html>. In 2022 and beyond, the HPV Action Network will:

- Encourage and support the EC and EU Member States to implement Europe's Beating Cancer Plan.
- Make the case for action to address the impact of the pandemic on vaccination and screening programmes.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES

- Identify countries in the region that are falling behind on vaccination and screening and encourage and support advocacy in countries where progress seems possible.
- Continue to develop HPV Testimonies.
- Build on the momentum created by the WHO's global strategy for cervical cancer elimination, Europe's Beating Cancer Plan, and recent research showing that vaccination can prevent up to 90% of cervical cancer cases.
- Publish research commissioned into an 'umbrella review of interventions used to improve HPV vaccine uptake in children, adolescents and young adults (to be completed Spring 2022)'
- Publish research commissioned into the current state of HPV vaccination and cervical cancer screening programmes across the European region

Getting stakeholders round the table

Director David Winterflood presented at several roundtables in 2021 on the opportunity provided by gender neutral vaccination programmes to end preventable cancer. In October, a study published in the Lancet reported that vaccinating girls against HPV in England had cut rates of cervical cancer by 87%. This is incredibly exciting news, and as the causal agent of 5% of all cancers, we can expect to see rates of all HPV cancers reduce significantly over the coming years with increased vaccination. To that effect, we renewed calls in the UK for a catch-up programme for boys who have missed out on this life-saving intervention following the expansion of the HPV vaccine programme in 2019.

Anal Cancer Foundation

Anal cancer is one of the fastest growing cancers in the United States, and steadily increasing in the United Kingdom. We continue to work tirelessly to make life better for families facing anal cancer through our programs to raise awareness, accelerate early detection, improve quality of life, and advance a cure. This year, we made incredible progress raising awareness about the need to reform how anal cancer thrivers are diagnosed and treated.

Peer to Peer Support Programme and Thriver Education

In the UK, about 1,500 people, and in the US, about 8,600 are diagnosed with anal cancer annually. Anal cancer incidence is increasing and affects more people across the world every year. The social stigma that anal cancer carries prevents fair and equitable conversation, awareness, and funding to support research and care for people with the disease.

Support and information is limited for anal cancer thrivers (our word for survivors) and many thrivers never meet another anal cancer patient. The Foundation provides educational forums and a peer mentoring program to support thrivers to close this gap. The Peer to Peer support program is a free service provided by the Foundation in the UK and USA to connect patients and caregivers facing the challenges brought on by anal cancer with a peer who has undertaken the same journey.

Connections are available for anyone at any cancer stage from newly diagnosed to years after treatment. Volunteers listen and help thrivers through their cancer journey by sharing their own experiences on treatment, stigma and social experiences relating to an anal cancer diagnosis. The programme's goals are to improve the lives of those affected by anal cancer and give survivors a voice and a community. The program also matches caregivers together. At the end of 2021, the HPVACF's Peer-to-Peer programme included 705 participants.

Our online educational events continue to provide hope and resources for thrivers. Our 'Taking Care of You: Managing Side Effects From Treatment For Anal Cancer' event, featuring expert clinicians who treat people living with anal cancer as well as a panel of thrivers has been viewed by over 4,600 people by the end of 2021. 'Living and Thriving After Treatment for Anal Cancer: Addressing Long Term Side Effects', was viewed 10,000 times by the end of the year.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2021**

OBJECTIVES AND ACTIVITIES

Anal Cancer Patient Conference

On September 25th, 2021, the Anal Cancer Foundation held the first virtual Anal Cancer Patient Conference.

Medical professionals spoke about anal cancer causes, treatments, and how to mitigate the various side effects of chemoradiation. We also heard from advocates who taught us, through sharing their own stories, how to use our personal experiences to advance the fight against anal cancer. Finally, thrivers were able to network both in groups and one-on-one which, for many people, was the first time they were meeting a fellow thriver.

We created this event as an opportunity for anal cancer patients and caregivers to learn from medical professionals, connect with experts and each other, and take action to empower themselves and this community.

Over 440 people registered for the conference from 20 countries around the world. Feedback from participants included that, "this is, without doubt, one of the finest virtual conferences I've ever attended, personal and professional -- and I've attended a lot!," "thank you for this conference. It provided me with a lot of information and more confidence to share my own story and help others become more aware of this disease," and "superb conference - so informative and deeply touching! Really, thank you!"

Anal Cancer Foundation Co-Founder Justine Almada facilitated the day's events. Experts including Drs. Joel Palefsky, Cathy Eng, Karyn Goodman, and Paul Romesser spoke about anal cancer causes, treatments, emerging therapies, and how to mitigate the various side effects of chemoradiation. Thrivers were given the opportunity to ask questions live, as well as to connect with one another. Anal Cancer Thriver and Activist Marcia Cross and Cervivor's Tamika Felder shared their own stories, guiding the audience in how to use their personal experiences to advance the fight against anal cancer.

We would like to make sure every family facing anal cancer has access to the same information as their doctors. Recordings of the day's events are now available on YouTube. We will hold another Anal Cancer Patient Summit in 2022.

NCCN treatment guidelines

In 2021, we were thrilled to partner with NCCN to create the first anal cancer treatment guide for patients, enabling patients and their caregivers to take charge of their own care and recovery!

The National Comprehensive Cancer Network is an alliance of 31 cancer centers in the USA, recognized for dealing with complex and/or rare cancers. NCCN Clinical Guidelines are the recognized standard for clinical direction and policy in cancer care and are among the most thorough and frequently updated clinical practice guidelines available in any area of medicine. The intent of the NCCN Guidelines is to assist in the decision-making process of individuals involved in cancer care-including physicians, nurses, pharmacists, payers, patients, and their families-with the ultimate goal of improving patient care and outcomes. The creation of a companion guide for patients is the next step forward in empowering patients with accessible information.

This new anal cancer treatment guide presents clinical information in an easy-to-read format for people with cancer and those who support them. The patient guideline is intended to:

- Equip patients and providers with the same information as that of their medical team
- Ensure that patients, no matter where they are treated, know what the experts agree upon as the standard of treatment and care
- Empower patients with knowledge about all of their treatment and care choices
- Allow patients to self-advocate for their own best care

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2021**

OBJECTIVES AND ACTIVITIES

ANCHOR Study

A ground-breaking randomised controlled national trial of 4,500+ people has shown that anal cancer can be prevented by routine screening and removal of precancerous cells. The ANCHOR Study hoped to improve patient outcomes for people with anal precancer and cancer by finding the best way to stop anal precancer from progressing to cancer. The Anal Cancer Foundation built and led the coalition of organizations that supported and pushed for the study.

ANCHOR stands for Anal Cancer HSIL Outcomes Research and the study investigated treating anal cancer precursor lesions to see if this reduced the cancer risk for people living with HIV. Conceived and led by Anal Cancer Foundation Scientific Advisory Board Member Dr. Joel Palefsky, ANCHOR aimed to recruit 5,000 people living with HIV and was randomized into two groups: treatment of anal precancer and a control group. The incidence of anal cancer is highest in people living with HIV.

What was ANCHOR researching?

Prevention and early detection are essential to ending anal cancer. Yet, despite its growing incidence and mortality, there are no national screening guidelines for anal cancer or precancer. The rates of cervical cancer reduced by 80% once doctors starting screening for and treating cervical precancer.

The hope was that the ANCHOR study would illustrate that treating anal precancer will reduce the risk of anal cancer. The Anchor study had two main objectives: to determine the effectiveness of screening for and treating anal precancer to reduce the incidence of anal cancer in HIV-positive men and women, and to create a bank of blood, anal swab, and tissue specimens to support critical scientific studies on how anal cancer progresses. There were two arms in the study: one arm that received treatment for anal precancer and a control arm that did not.

Ninety percent of anal cancer is caused by the human papillomavirus (HPV), which can cause changes to the skin around and inside the anus. These changes are called "high-grade squamous intraepithelial lesions" or HSIL. Not all anal HSIL will develop into cancer. Most HSIL will go away on their own, but some become cancer over time and can eventually spread to other parts of the body.

What were the outcomes?

For now, we know that NIH halted the study in fall 2021 due to the therapy's success in reducing the incidence of anal cancer. Researchers will compile the data and submit for publication after peer review. It is expected that the data will provide guidance on recommendations to make anal cancer prevention programs the standard of care for people at high risk of anal cancer.

What does this mean for the anal cancer community?

Anal cancer is currently rapidly increasing at 3% a year. More people are being diagnosed with late stage anal cancer than ever before.

We need standard methods to find it early. The study proved that treating anal precancer in people living with HIV, the group at most high-risk for developing anal cancer, reduces their cancer risk. The next step is ensuring this becomes the standard of care so that we can end anal cancer by finding it and treating it before it ever becomes cancer.

Taking Care of You: Tips and Exercises to Restore Your Pelvic Health After Anal Cancer Chemoradiation

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES

On Anal Cancer Awareness Day, Sunday March 21st 2021, Anal Cancer Foundation co-founder Justine Almada and board-certified physical therapist Dr. Allison Romero, PT, DPT of Reclaim Pelvic Therapy hosted a webinar to discuss Taking Care of You: Tips and Exercises to Restore Your Pelvic Health after Anal Cancer Chemoradiation.

This hour-long webinar included an overview of the impacts of anal cancer treatment as well as a plan to care for the nerves, muscles, and fascia that are affected by chemoradiation. It ended with an audience-led Q & A.

The resources we discussed and the physical therapy exercises Dr. Romero demonstrated and recommended for daily practice can be accessed [here](#).

International Anal Neoplasia Society (IANS)

IANS, the International Anal Neoplasia Medical Society, creates medical guidelines and supports research essential to preventing and treating anal cancer. IANS was created with a seed grant from the Foundation.

IANS mission is to provide a forum for individuals with a broad spectrum of background, viewpoints and geographic origin, an exchange of ideas and dissemination of knowledge regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

In support of this mission IANS:

- Develops position papers regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Represents the consensus opinion of IANS regarding the above topics to other professional societies, public organizations, regulatory authorities and governmental bodies.
- Encourages the development of a robust research agenda on the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Develops educational materials and conduct training courses that encourage the entry of a broad spectrum of clinicians into the field of anal neoplasia, and that furthers the development and depth of skills of clinicians needed to optimally diagnose, treat and prevent anal neoplasia.
- Develop educational materials for patients with anal neoplasia.

We look forward to being part of the next IANS conference which in 2022 will be held in New York City.

Information and Connection

The Foundation's anal cancer program website features a wealth of resources and is a source of information, support, and inspiration for patients and families affected by anal cancer.

Our focus is ensuring patients get the information and support they need during their anal cancer journey. Our Living with Anal Cancer section features information for patients at all stages of the anal cancer journey from newly diagnosed to post-treatment resources, such as how physical therapy can help with anal cancer treatment recovery. The site is the most comprehensive source of information on side effects and side effect mitigation during and after anal cancer treatment. This digital hub is populated with personal thriver stories (patients stories of their experiences), information about helpful medical resources, and professional medical bodies, as well as connections to other patients and caregivers through our Peer to Peer support programme.

Our goal in 2021 continues to be ensuring more anal cancer thrivers have access to the information they need to face their cancer journey through targeted outreach based on our existing supporter base and a newsletter series for patients and caregivers, focused on our expert and popular resources.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

OBJECTIVES AND ACTIVITIES

With the pandemic reducing the in-person resources available to the anal cancer community, the need for communication with our community was more important than ever. Our communications strategy focused on consistency and 'being useful', with content covering treatment and research updates, stories from community members, and explainers of our services and how we support the anal cancer community.

- Returning users now make up 20.68% of visitors vs 16.14% in 2014
 - Peer to Peer support signups are up 28% on 2020 figures, and 241% vs 2014 figures
- Going forward, we aim to continue providing all the support the anal cancer community needs.

LOOKING AHEAD: 2022

As we look ahead, the HPV and Anal Cancer Foundation continues to seek the most effective methods to prevent HPV and cure the cancers it causes.

The Foundation will continue to work tirelessly to eradicate all HPV-related cancers by furthering public policy and scientific debate, eliciting further professional and expert support, encouraging the development of regional initiatives on vaccinating boys, and demonstrating why it is important to protect all children against HPV at the recommended age.

The UK began vaccinating boys against HPV as pupils returned to schools in September 2019 and we will continue to work with stakeholders in the HPV-related disease space to ensure that uptake for this cancer-preventing intervention among 12-13 year old boys is as high as possible. The interruption caused by the pandemic will undoubtedly affect vaccination rates in the UK and beyond. In the wake of a growing vaccine hesitancy sentiment, our work is more important than ever.

Our advocacy efforts in Europe with the European Cancer Organisation and HPV Action Network to attain gender neutral HPV vaccination across the continent continue apace. With the EU Beating Cancer Plan specifically including actions on HPV cancers within its remit, we have a mandate to gain support and empower stakeholders within member states to eliminate HPV cancers. With over 40% of cancers in the region preventable, the extension of HPV vaccination programmes to protect boys as well as girls provides a recognised and effective means to tackle cancer.

Through the NOMAN is an Island Campaign, collaborations with advocates and legislators, media attention and athletic event participation, a broader audience is understanding the importance of protecting all children against HPV. With the NOMAN side of the organisation leading on HPV-related activities, our platform is growing from which to broadcast our message. In 2022, we will continue to partner with the Haute Route on further cycling events as their European Charity Partner, furthering the reach of our message to prevent 5% of cancer, and providing the opportunity to reconnect with the cyclists within our community.

We will continue to provide anal cancer survivors with information and support they need on their journey. In addition, our Peer to Peer support programme retains its importance in supporting and empowering anal cancer survivors and caregivers. Utilizing digital and live platforms, we will reach a wider proportion of the anal cancer community, enabling patients to gain answers to the concerns they have and to connect to other anal cancer patient experiences. We are excited by the response to our "Ask the Expert" sessions and look forward to providing more touchpoints for our community with these and the patient conference in 2022.

We thank all of our donors and look forward to continuing the mission to empower anal cancer patients and accelerate prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Public benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2021

FINANCIAL REVIEW

Financial position

It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organization. The revenue for the charity is dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundation in 2021 was £204,749 and expenditure was £255,874.

Reserves policy

The reserves policy is to maintain a minimum that enables the organisation to meet its financial commitments for the year, including grants, contracts, and staff salaries.

Going concern

As stated in note 20, the Trustees have considered the effect of the COVID-19 pandemic. The Trustees consider that the pandemic is likely to cause disruption to the Charity's activities but are confident that current reserves and future income will be sufficient to ensure that the Charity remains a going concern for a period of at least twelve months from the date of approval of these financial statements as well as for the foreseeable future.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document, structure and management

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20 February 2012 and registered as a charity on the 25 May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The Trustees are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 18. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public as well as contacts of the charity. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given a full introduction to the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws and policies.

Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The trustees of the Foundation hold the responsibility of safeguarding the charity's assets and systems are in place to mitigate those risks which the charity may face.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2021**

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on28.09.2022..... and signed on its behalf by:


.....
T Almada - Trustee

**Independent Examiner's Report to the Trustees of
The HPV and Anal Cancer Foundation
Limited**

Independent examiner's report to the trustees of The HPV and Anal Cancer Foundation Limited ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2021.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Richard Billinghamurst
FCA
Knox Cropper LLP
Chartered Accountants
65 Leadenhall Street
London
EC3A 2AD

Date:30/09/2022.....

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Statement of Financial Activities
(Incorporating an Income and Expenditure Account)
for the Year Ended 31 December 2021**

	Notes	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		2,083	-	2,083	17,061
Other trading activities	2	202,664	-	202,664	73,105
Investment income	3	2	-	2	20
Total		204,749	-	204,749	90,186
EXPENDITURE ON					
Raising funds	4	56,981	-	56,981	20,478
Charitable activities					
Care and Support	5	47,743	-	47,743	27,417
Awareness Raising		146,825	-	146,825	76,467
Research for a Cure		4,325	-	4,325	4,906
Total		255,874	-	255,874	129,268
NET INCOME/(EXPENDITURE)		(51,125)	-	(51,125)	(39,082)
RECONCILIATION OF FUNDS					
Total funds brought forward		114,089	13,100	127,189	166,271
TOTAL FUNDS CARRIED FORWARD		62,964	13,100	76,064	127,189

The notes form part of these financial statements

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED (REGISTERED NUMBER: 07955451)**

**Balance Sheet
31 December 2021**

	Notes	2021 £	2020 £
CURRENT ASSETS			
Debtors	14	327	218
Cash at bank		83,806	135,806
		<u>84,133</u>	<u>136,024</u>
CREDITORS			
Amounts falling due within one year	15	(8,069)	(8,835)
		<u>76,064</u>	<u>127,189</u>
NET CURRENT ASSETS			
		<u>76,064</u>	<u>127,189</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>76,064</u>	<u>127,189</u>
NET ASSETS		<u>76,064</u>	<u>127,189</u>
FUNDS	17		
Unrestricted funds		62,964	114,089
Restricted funds		13,100	13,100
TOTAL FUNDS		<u>76,064</u>	<u>127,189</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2021 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on28.09.2022..... and were signed on its behalf by:

.....
T Almada - Trustee

The notes form part of these financial statements

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

Financial reporting standard 102 - reduced disclosure exemptions

The charitable company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland':

- the requirements of Section 7 Statement of Cash Flows.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Ocean rowing boat and accessories - over 3 years

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

1. ACCOUNTING POLICIES - continued

Fund accounting

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Judgments and key sources of estimation uncertainty

No judgement (apart from those involving estimates) have been made in the process of applying the above accounting policies that have a significant effect on amounts recognised in the financial statements.

2. OTHER TRADING ACTIVITIES

	2021	2020
	£	£
Fundraising events	<u>202,664</u>	<u>73,105</u>

3. INVESTMENT INCOME

	2021	2020
	£	£
Deposit account interest	<u>2</u>	<u>20</u>

4. RAISING FUNDS

Raising donations and legacies

	2021	2020
	£	£
Staff costs	5,900	5,611
Development expenses	118	152
Donor software subscription	2,002	1,174
Event Expenses	46,842	4,226
Media	-	3,300
Support costs (Operating)	2,119	6,015
	<u>56,981</u>	<u>20,478</u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

5. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 6) £	Grant funding of activities (see note 7) £	Support costs (see note 8) £	Totals £
Care and Support	34,986	-	12,757	47,743
Awareness Raising	113,037	17,365	16,423	146,825
Research for a Cure	2,808	-	1,517	4,325
	<u>150,831</u>	<u>17,365</u>	<u>30,697</u>	<u>198,893</u>

6. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2021 £	2020 £
Staff costs	33,429	15,713
Development Expenses	5,035	6,642
Marketing	43,064	12,939
Miscellaneous Expense	1,682	806
Event Expenses	46,843	4,226
Media	20,778	13,200
Internet and Website	-	6,545
	<u>150,831</u>	<u>60,071</u>

7. GRANTS PAYABLE

	2021 £	2020 £
Awareness Raising	17,365	13,235

The total grants paid to institutions during the year was as follows:

	2021 £	2020 £
European Cancer Organisation	17,365	13,235

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

8. SUPPORT COSTS

	Finance £	Other £	Governance costs £	Totals £
Raising donations and legacies	41	1,602	476	2,119
Care and Support	71	11,859	827	12,757
Awareness Raising	143	14,626	1,654	16,423
Research for a Cure	19	1,275	223	1,517
	<u>274</u>	<u>29,362</u>	<u>3,180</u>	<u>32,816</u>

Support costs, included in the above, are as follows:

	Raising donations and legacies £	Care and Support £	Awareness Raising £
Bank charges	41	71	143
Wages	-	-	-
Pensions	732	1,270	2,540
Rent and Rates	551	957	1,914
Insurance	71	125	250
Fees and subscriptions	-	357	357
Telephone, printing, postage and stationery	46	208	288
Sundries	77	135	270
Travel and Meetings	38	514	568
Staff Training	16	11	35
Consultancy fees	-	8,115	8,114
Conference expenses	71	167	290
Independent Examiner's fee	476	827	1,654
Accountancy and legal fees	-	-	-
	<u>2,119</u>	<u>12,757</u>	<u>16,423</u>
		2021	2020
	Research for a Cure £	Total activities £	Total activities £
Bank charges	19	274	177
Wages	-	-	16,082
Pensions	342	4,884	4,847
Rent and Rates	258	3,680	8,587
Insurance	34	480	244
Fees and subscriptions	-	714	413
Telephone, printing, postage and stationery	21	563	404
Sundries	37	519	831
Travel and Meetings	500	1,620	159
Carried forward	<u>1,211</u>	<u>12,734</u>	<u>31,744</u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

8. SUPPORT COSTS - continued

	Research for a Cure £	2021 Total activities £	2020 Total activities £
Brought forward	1,211	12,734	31,744
Staff Training	5	67	-
Consultancy fees	-	16,229	5,439
Conference expenses	78	606	1,196
Independent Examiner's fee	223	3,180	2,640
Accountancy and legal fees	-	-	480
	<u>1,517</u>	<u>32,816</u>	<u>41,499</u>

9. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2021 £	2020 £
Independent Examiner's fee	<u>3,180</u>	<u>3,000</u>

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2021 nor for the year ended 31 December 2020.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2021 nor for the year ended 31 December 2020.

11. STAFF COSTS

	2021 £	2020 £
Wages and salaries	39,329	37,406
Other pension costs	4,884	4,847
	<u>44,213</u>	<u>42,253</u>

The average monthly number of employees during the year was as follows:

	2021	2020
Average monthly employees	<u>1</u>	<u>1</u>

No employees received emoluments in excess of £60,000.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

11. STAFF COSTS - continued

The key management personnel of the charity are those persons having authority and responsibility for planning, directing and controlling the activities of the charity, directly or indirectly, including any trustee of the charity and, in the case of the charity, includes the Director of UK Operations. Total employee benefits paid to key management personnel in the period amounted to £39,329 (2020: £37,406).

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	17,061	-	17,061
Other trading activities	73,105	-	73,105
Investment income	20	-	20
Total	<u>90,186</u>	<u>-</u>	<u>90,186</u>
EXPENDITURE ON			
Raising funds	20,478	-	20,478
Charitable activities			
Care and Support	27,417	-	27,417
Awareness Raising	76,467	-	76,467
Research for a Cure	4,906	-	4,906
Total	<u>129,268</u>	<u>-</u>	<u>129,268</u>
NET INCOME/(EXPENDITURE)	(39,082)	-	(39,082)
RECONCILIATION OF FUNDS			
Total funds brought forward	153,171	13,100	166,271
TOTAL FUNDS CARRIED FORWARD	<u><u>114,089</u></u>	<u><u>13,100</u></u>	<u><u>127,189</u></u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

13. TANGIBLE FIXED ASSETS

	Plant and machinery £
COST	
At 1 January 2021 and 31 December 2021	<u>47,250</u>
DEPRECIATION	
At 1 January 2021 and 31 December 2021	<u>47,250</u>
NET BOOK VALUE	
At 31 December 2021	<u><u>-</u></u>
At 31 December 2020	<u><u>-</u></u>

14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021 £	2020 £
Gift aid recoverable	327	-
Prepayments	-	218
	<u>327</u>	<u>218</u>

15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021 £	2020 £
Social security and other taxes	4,889	5,835
Accrued expenses	3,180	3,000
	<u>8,069</u>	<u>8,835</u>

16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
Current assets	71,033	13,100	84,133	136,024
Current liabilities	(8,069)	-	(8,069)	(8,835)
	<u>62,964</u>	<u>13,100</u>	<u>76,064</u>	<u>127,189</u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

17. MOVEMENT IN FUNDS

	At 1.1.21 £	Net movement in funds £	At 31.12.21 £
Unrestricted funds			
General fund	114,089	(51,125)	62,964
Restricted funds			
Research for a Cure	13,100	-	13,100
TOTAL FUNDS	<u>127,189</u>	<u>(51,125)</u>	<u>76,064</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	204,749	(255,874)	(51,125)
TOTAL FUNDS	<u>204,749</u>	<u>(255,874)</u>	<u>(51,125)</u>

Comparatives for movement in funds

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	153,171	(39,082)	114,089
Restricted funds			
Research for a Cure	13,100	-	13,100
TOTAL FUNDS	<u>166,271</u>	<u>(39,082)</u>	<u>127,189</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	90,186	(129,268)	(39,082)
TOTAL FUNDS	<u>90,186</u>	<u>(129,268)</u>	<u>(39,082)</u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2021**

17. MOVEMENT IN FUNDS - continued

Capital fund

The HPV and Anal Cancer Foundation Limited has shareholder capital equal to £1 and is owned by HPV and Anal Cancer Foundation, a registered charity in the United States of America, EIN 27-3217520.

Research for a Cure Fund

The fund was set up to award grants to research which will advance development of effective treatments for anal and all HPV-related cancers.

18. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2021.

19. GOING CONCERN

The Trustees have considered the effect of the COVID-19 pandemic in 2020 and into 2021 on the Charity's activities. While the outbreak is likely to cause some changes to the charity's business, the Charity currently holds a comfortable level of reserves and its fixed costs are not significant. It has the ability to align its activities to the level of reserves available. The Trustees are optimistic about the fundraising outlook for the next twelve months.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Detailed Statement of Financial Activities
for the Year Ended 31 December 2021**

	2021 £	2020 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	2,083	17,061
Other trading activities		
Fundraising events	202,664	73,105
Investment income		
Deposit account interest	2	20
Total incoming resources	204,749	90,186
EXPENDITURE		
Raising donations and legacies		
Wages	5,900	5,611
Development expenses	118	152
Donor software subscription	2,002	1,174
Event Expenses	46,842	4,226
Media	-	3,300
	54,862	14,463
Charitable activities		
Wages	33,429	15,713
Development Expenses	5,035	6,642
Marketing	43,064	12,939
Miscellaneous Expense	1,682	806
Event Expenses	46,843	4,226
Media	20,778	13,200
Internet and Website	-	6,545
Grants to institutions	17,365	13,235
	168,196	73,306
Support costs (Operating)		
Finance		
Bank charges	274	177
Other		
Wages	-	16,082
Pensions	4,884	4,847
Rent and Rates	3,680	8,587
Carried forward	8,564	29,516

This page does not form part of the statutory financial statements

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Detailed Statement of Financial Activities
for the Year Ended 31 December 2021**

	2021 £	2020 £
Other		
Brought forward	8,564	29,516
Insurance	480	244
Fees and subscriptions	714	413
Telephone, printing, postage and stationery	563	404
Sundries	519	831
Travel and Meetings	1,620	159
Staff Training	67	-
Consultancy fees	16,229	5,439
Conference expenses	606	1,196
	<hr/>	<hr/>
	29,362	38,202
Governance costs		
Independent Examiner's fee	3,180	2,640
Accountancy and legal fees	-	480
	<hr/>	<hr/>
	3,180	3,120
Total resources expended	<hr/>	<hr/>
	255,874	129,268
Net expenditure	<hr/>	<hr/>
	(51,125)	(39,082)

This page does not form part of the statutory financial statements

THE HPV AND ANAL CANCER FOUNDATION LIMITED

England & Wales - Charity number 1147457

Accounts

REGISTERED COMPANY NUMBER: 07955451 (England and Wales)
REGISTERED CHARITY NUMBER: 1147457

Report of the Trustees and
Financial Statements for the Year Ended 31 December 2020
for
THE HPV AND ANAL CANCER FOUNDATION
LIMITED

Knox Cropper LLP
Chartered Accountants
65 Leadenhall Street
London
EC3A 2AD

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Contents of the Financial Statements
for the Year Ended 31 December 2020**

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 14
Independent Examiner's Report	15
Statement of Financial Activities	16
Balance Sheet	17
Notes to the Financial Statements	18 to 26
Detailed Statement of Financial Activities	27 to 28

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Reference and Administrative Details
for the Year Ended 31 December 2020**

TRUSTEES	C Almada J Almada T Almada C Levett
REGISTERED OFFICE	Kemp House 160 City Road London London EC1V 2NX
REGISTERED COMPANY NUMBER	07955451 (England and Wales)
REGISTERED CHARITY NUMBER	1147457
INDEPENDENT EXAMINER	Knox Cropper LLP Chartered Accountants 65 Leadenhall Street London EC3A 2AD
SOLICITORS	Stone King 16 St. John's Lane London EC1M 4BS
BANKERS	HSBC 455 Strand London WC2R 0RH

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2020**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20th February 2012 and registered as a charity on the 25th May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The directors are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 27. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public as well as contacts of the charity. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given a full introduction to the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws, and policies.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2020

OBJECTIVES AND ACTIVITIES

Objectives and aims

History

The Foundation was first established in the USA in 2010 by three siblings who lost their mother, aged 53, to stage IV HPV-related anal cancer. Frustrated by the limited therapeutic and community support available to her, they created the organisation to fill the void caused by scant public, scientific and medical focus on this disease and its cause, the human papillomavirus (HPV). HPV causes anal cancer and at least five other cancers, amounting to 5% of cancers worldwide. These cancers are preventable. In 2012, the organization expanded to the UK with 2013 as its first full operational year.

Mission

The HPV and Anal Cancer Foundation empowers anal cancer patients and accelerates prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Objectives

- Highlight the relevance of human papillomavirus (HPV) in contracting cancer;
- Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender-neutral vaccination;
- Accelerate a cure for the 5% of all cancers that are caused by HPV, with a focus on anal cancer; and
- Provide support for survivors, caregivers, scientists and providers connected to anal cancer.

The Need

A fundamental objective of the Foundation's work is to reduce the incidence of anal cancer and other HPV-related cancers. HPV is a very common skin virus that nearly every sexually active person will get at some point in their lives. HPV affects both men and women and is responsible for 5% of the world's cancer burden. HPV causes cancers of the anus, cervix, head and neck, penis, vagina, and vulva.

Protection against HPV through universal HPV vaccination is a critical public health goal. With HPV identified as a cause of six different types of cancer, and 5% of cancer cases worldwide, it is imperative that we protect the entire population against it. The most effective method to reduce cancers related to HPV is to prevent initial infection of the virus through immunisation. The Foundation achieves this important aim through its efforts to advance equal access to HPV protection for both boys and girls through gender-neutral vaccination against the virus. At the introduction of the vaccine in most countries, only girls were able to receive this life-saving intervention while boys were generally excluded. The Foundation created and led the coalitions in the US and UK to ensure all children have equal access to protection against these cancers. The US achieved the milestone of recommending HPV protection to all children in 2011. Following the Foundation's five-year advocacy campaign in the UK, school-based HPV vaccination for boys began in September 2019. Our focus now turns to securing the same protection for boys as well as girls across Europe.

While we work to prevent future cases, it is also fundamental that scientific and medical disparities are addressed for the population that will continue to be diagnosed with HPV-related cancers like anal cancer. Treatment options have barely progressed since the 1970s and minimal research has been undertaken in new therapies. The medical and scientific communities need better research tools and investment in novel ideas to develop a cure.

The stigma surrounding anal cancer remains one of the central challenges to improving outcomes for anal cancer patients. Unfortunately, many medical centres provide only limited information specific to the experience of anal cancer. Many patients feel isolated and lack the support and educational resources that significantly improve quality of life during and after treatment.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2020**

Strategies to Achieve Our Goals

We achieve our mission in the UK and US through collaboration with scientists, clinicians, survivors, organisations, and government agencies; education of stakeholders and the general public; survivor support; and investment in the medical and scientific community to end HPV and the cancers it causes. Specifically, we take action to destigmatize and raise awareness about HPV, HPV-related cancers, and anal cancer; increase access to the HPV vaccine; improve screening protocols and preventative care; empower anal cancer thrivers; and accelerate a cure for anal cancer and other HPV-related illnesses.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2020**

**OBJECTIVES AND ACTIVITIES
KEY ACHIEVEMENTS IN 2020**

Foundation Restructure

In 2020 we continue our two-pronged programmatic approach, operating under the umbrella of The Anal Cancer Foundation (registered as The HPV and Anal Cancer Foundation Limited in the UK).

The Anal Cancer Foundation: Improve the lives of anal cancer patients through prevention, treatment, and support.

The NOMAN Campaign: End 5% of the world's cancer through global coverage of HPV immunisation for all children.

NOMAN is an Island

The NOMAN is an Island Campaign raises awareness about the HPV-related cancer epidemic in men and women and educates about the importance of universal HPV vaccination while challenging participants to extreme endurance races across the world. It is through such extreme feats of athleticism that NOMEN honour the struggle and isolation that many cancer patients feel.

NOMAN has been an incredibly successful campaign. Since its inaugural event in 2013 with the Barcelona - Ibiza: Row to End HPV, 141 individuals - and their hundreds of supporters - have embraced the cause and our values. These NOMEN have raised awareness about HPV-related cancers on a local, national, and international scale as well as funds to support our programmes.

In 2020, NOMAN riders took on the Haute Route Ventoux event. The Haute Route is the world's most prestigious cycling event for amateur cyclists providing unparalleled experiences with the key ingredients of 3 or 7 day professional road racing events in the most iconic cycling destinations worldwide. In October, a team of NOMAN riders took on the Haute Route Ventoux, a 3-day event comprising nearly 300km of riding and 8000 metres of height gain, raising funds to prevent 5% of cancer in the process. We are grateful for their extraordinary efforts to raise awareness around HPV-related cancers.

Additionally a group of supporters in Geneva undertook the inaugural 'Anieres Man for NOMAN' event - tackling 1.5km of swimming, 49km of cycling including 500m elevation gain, and a 13km run - all in the name of NOMAN's mission to prevent 5% of cancers.

We now look forward to the 2021 edition of our Barcelona - Ibiza: Row to End HPV races, and the Haute Route events of that summer.

HPV Action

HPV Action (HPVA) is a collaborative partnership of patient and professional organisations that are working to reduce the health burden of HPV. The HPV and Anal Cancer Foundation was a founding member of HPVA in 2013 and has since provided financial support and leadership for the coalition.

Following a five-year campaign, the Foundation and its partners in HPV Action achieved a monumental milestone to end all HPV-related cancers with the adoption of school-based vaccinations for boys.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2020

OBJECTIVES AND ACTIVITIES

HPV causes 5% of cancers worldwide in men and women. At the end of 2019, around 40 countries vaccinate boys as well as girls.

HPVA advocates equal access to HPV protection for both boys and girls to prevent a range of HPV-related conditions including cancers, precancers, and genital warts. HPVA's efforts illustrated that boys should be included in the UK HPV immunisation program to protect: (1) men and women from HPV-related anal, cervical, penile, oropharyngeal, vaginal and vulval cancers and precancers; (2) men and women from genital warts; and (3) children and adults from recurrent, respiratory papillomatosis (RRP), a rare but disabling HPV-related condition. HPVA estimates that over 2,000 men a year in the UK develop a cancer (penile, anal or oropharyngeal) caused by HPV and 5,000 women a year develop a cancer (anal, cervical, oropharyngeal, vaginal or vulval) caused by HPV. HPV additionally causes 48,000 new cases in men and 39,000 cases in women of genital warts annually. Approximately 600 adults and children in the UK have RRP.

A national HPV vaccination programme that includes all children in the UK will improve public health and health inequalities, prove cost-effective and, above all, reduce the suffering caused by cancers and diseases that are easily preventable. As part of the HPVA group, we educate MPs, ministers, governments and NHS officials on the importance of protecting all children against the carcinogenic HPV virus; inform the public; build scientific support; and engage patient, professional and other organisations in support of ending HPV and the cancers it causes.

Prior to 2019, HPV immunisation programmes in the UK were exclusively for females, with girls aged 12 and 13 routinely vaccinated predominantly via a school-based programme since 2007. Consequently, men were not protected against HPV. HPV infects both men and women, and causes cancer in both sexes, including cancers of the anus, cervix, head and neck, penis, vagina, and vulva. Many of these cancer cases are preventable if the person is immunised before they are exposed to the virus.

HPV Action Impact 2020

Gender-neutral HPV vaccination began in September 2019, however no announcement was made as to whether a catch-up programme would be instigated for boys aged 13-18.

In its meeting in early February 2020, the JCVI decided not to recommend a catch-up vaccination programme for older boys. HPV Action did as much as we could to advocate for a catch-up programme despite our limited capacity including meeting with JCVI/PHE in January 2020, correspondence with JCVI, the engagement of several MPs who wrote letters to ministers and tabled PQs, and a social media campaign through twitter and Facebook. Whilst this was a disappointing outcome it was felt that it was not worth continuing with this effort because it was extremely unlikely that JCVI would change its mind, especially in the context of the global vaccine shortage (predicted to last until 2023).

In March 2020 the future of HPV Action was discussed which took account of the achievement of the universal programme, the recent JCVI decision on a catch-up programme for boys, and the new ECCO HPV initiative. It was agreed that HPVA would be wound up in September, with the Jabs for the Boys website to continue as a legacy project. Numerous HPV Action members agreed to stay on a database so that they can if necessary be contacted if an issue with vaccination arises in the future, such as a fall in uptake due to anti-vaccination campaigning. A broad-based campaign in this vein played a key role in reversing a fall in vaccination uptake in Ireland in recent years.

Several members are involved in the European HPV Action Network which aims to eliminate HPV cancers in the 53 member states of the WHO European region.

Coalition Building

The 51 organisations in the membership of HPV Action, included:

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2020

OBJECTIVES AND ACTIVITIES

British Association for Sexual Health and HIV, British Association of Dental Nurses, British Association of Dental Therapists, British Dental Association, British Society for Immunology, British Society of Dental Hygiene and Therapy, Brook, Cancer Focus Northern Ireland, Children's HIV Association of the UK & Ireland (CHIVA), ENT UK, European Men's Health Forum, Faculty of General Dental Practice (UK), Faculty of Public Health, Faculty of Sexual and Reproductive Healthcare, Family Planning Association, GMFA (Gay Men's Health Charity), Herpes Viruses Association, HPV and Anal Cancer Foundation, Let's Talk About Mouth Cancer, London Cancer Alliance, London Friend, Men's Health Forum (GB), Men's Health Forum Ireland, Mouth Cancer Foundation, National Aids Manual, National Association of Laryngectomee Clubs (NALC), National Education Union, National Oral Health Promotion Group, National Union of Students, Northern Head and Neck Cancer Fund, Oral Cancer Foundation (USA), Oral Health Foundation, Primary Care Urology Society, Rainbow Project, Reproductive Health Matters, Royal College of Obstetricians and Gynaecologists, Royal Society for Public Health, The School and Public Health Nurses Association, Sexpression:UK, Society of British Dental Nurses, Society of Sexual Health Advisers, Stonewall, The Swallows Head and Neck Cancer Support Group, Tenovus, Terrence Higgins Trust, Throat Cancer Foundation, The Urology Foundation, and Wellbeing of Women.

HPV Action Europe Network

In 2018 and 2019, the Foundation was involved in discussions to establish an advocacy campaign in Europe to introduce gender-neutral vaccination across the region and completely eliminate HPV-related diseases.

NOMAN has partnered with the European Cancer Organisation to achieve this mission. The European Cancer Organisation works to reduce the burden of cancer and improve outcomes and the quality of care for cancer patients through multidisciplinary and multi-professionalism. As the not-for-profit federation of member organisations working in cancer at a European level, they convene oncology professionals and patients to agree on policy, advocate for positive change, and be the united voice of the European cancer community. Together with the European Cancer Organisation, the Foundation looks forward to working with European policy makers to end the suffering caused by HPV cancers.

The main achievements of the HPV Action Network in 2020 were as follows:

Launch of new HPV report: **Viral Protection: Achieving the Possible**

In October we launched a major new report 'Viral Protection: Achieving the Possible. A Four Step Plan for Eliminating HPV Cancers in Europe' calling for a series of goals in order to prevent 67,500 cancer cases per year across the 27 EU member states, rising to 90,000 across the wider World Health Organisation (WHO) European region.

The central recommendation of our plan to eliminate HPV Cancers in Europe is as follows:

'The European Union and the wider WHO European region should commit to the core goal of matching and exceeding the WHO Global Strategy for Cervical Cancer Elimination and implement policies and strategies for the elimination of all the cancers and diseases caused by HPV.'

Action areas to achieve this goal are:

1. Universal (or 'gender-neutral') HPV vaccination for adolescents and optimal levels of uptake.
2. National organised population-based cervical cancer screening programmes using HPV testing systems and with higher levels of uptake.
3. Cancer treatments consistently and equitably offered in line with best practice guidelines and care and support that maximises patients' quality of life.

OBJECTIVES AND ACTIVITIES

4. Action to improve public and professional awareness and education about HPV in order to improve vaccination and screening uptake.

We believe that the WHO's strategy for the global elimination of cervical cancer as a public health problem, is not ambitious enough. The forthcoming Europe Beating Cancer Plan, EU Cancer Mission and EU4Health Programme must include actions to eliminate all HPV Cancers. The world has used vaccines to eliminate the suffering caused by many diseases such as smallpox and polio - it is time we add HPV and the suffering it causes to this list.

The HPV Action Network urges Europe to make HPV cancer elimination a formal European shared goal. Europe's Beating Cancer Plan and other Regional/EU/National initiatives present significant opportunities for progress to be made.

Viral Protection highlights that:

- A quarter (14 out of 54, 26%) of European region countries still do not vaccinate girls against HPV.
- Under a half (26 countries, 48%) vaccinate, or are planning to start vaccinating, boys as well as girls.
- Few countries meet the widely-accepted target of 80% HPV vaccination coverage.
- 16 countries have 'opportunistic' cervical cancer screening which means their success depends on the initiative of individual women and their doctors, resulting in lower uptake.
- Treatment outcomes for cancers caused by HPV vary widely across the region; for women diagnosed with cervical cancer, five-year survival rates range from 80% in Iceland to 55% in Poland and Bulgaria.
- 'Fake news' about HPV vaccination safety, widely shared via social media, has resulted in falls in uptake; in Denmark, it fell from 90% to 54%.

You can read the plan below, and find out more about the campaign here. The report was distributed to key DG Sante officials, MEPs and other health stakeholders.

European Cancer Summit

NOMAN co-founder Tristan Almada was invited to address the European Cancer Summit on the role of civil society organisations in the fight to eliminate HPV Cancers in Europe, reflecting on the success of our campaign in the USA and UK to extend HPV vaccination programmes to include boys as well as girls.

Speaking alongside Professor Margaret Stanley, Emilié Karafakilis and Cobi Reisman, topics included public health needs, the possibility of an HPV Cancer free Europe by 2030, and tackling vaccine hesitancy.

The following resolutions were passed at the summit by attendees, following the session:

Resolution 1 - Screening

"Immediate and urgent action should be taken to ensure that cervical cancer screening programmes are not interrupted by COVID-19, especially in countries with the lowest screening rates. The adoption of HPV self-sampling must be accelerated in order to improve uptake."

Resolution 2 - Vaccination

"HPV-associated cancers are preventable by universal vaccination. Anti-vaccination misinformation is putting programmes at serious risk and all European health authorities must act now to improve public confidence in HPV vaccination."

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2020

OBJECTIVES AND ACTIVITIES

Other milestones included

- Presentation on HPV to ENVI Health Working Group (18 February 2020)
- Presentation to IPVS Conference (24 July 2020)
- Meeting on HPV and Europe's Beating Cancer Plan with Matthias Schuppe, DG Sante (29 July 2020)
- Presentation to the BECA Committee, EU Parliament (2 December)
- Increased stakeholder engagement in Network

The Network now has 21 members/stakeholders, shown here:
<https://www.europeancancer.org/topic-networks/1:hpv-action.html>.

We now await the publication of the Beating Cancer Plan to see if actions on HPV have been included.

Anal Cancer Foundation

Anal cancer is one of the fastest growing cancers in the United States, and steadily increasing in the United Kingdom. We continue to work tirelessly to make life better for families facing anal cancer through our programs to raise awareness, accelerate early detection, improve quality of life, and advance a cure. This year, we made incredible progress raising awareness about the need to reform how anal cancer thrivers are diagnosed and treated.

Peer to Peer Support Programme and Thriver Education

In the UK, about 1,500 people, and in the US, about 8,600 are diagnosed with anal cancer annually. Anal cancer incidence is increasing and affects more people across the world every year. The social stigma that anal cancer carries with it prevents fair and equitable conversation, awareness, and funding to support research and care for people with the disease.

Support and information is limited for anal cancer thrivers (our word for survivors) and many thrivers never meet another anal cancer patient. The Foundation provides educational forums and a peer mentoring program to support thrivers to close this gap. The Peer to Peer support program is a free service provided by the Foundation in the UK and USA to connect patients and caregivers facing the challenges brought on by anal cancer with a peer who has undertaken the same journey.

Connections are available for anyone at any cancer stage from newly diagnosed to years after treatment. Volunteers listen and help thrivers through their cancer journey by sharing their own experiences on treatment, stigma and social experiences relating to an anal cancer diagnosis. The programme's goals are to improve the lives of those affected by anal cancer and give survivors a voice and a community. The program also matches caregivers together. At the end of 2020, the HPVACF's Peer-to-Peer programme included 558 participants.

Our online educational events continue to provide hope and resources for thrivers. Our 'Taking Care of You: Managing Side Effects From Treatment For Anal Cancer' event, featuring expert clinicians who treat people living with anal cancer as well as a panel of thrivers has been viewed by over 4000 people by the end of 2020. 'Living and Thriving After Treatment for Anal Cancer: Addressing Long Term Side Effects', was viewed 8000 times by the end of the year.

International Anal Neoplasia Society (IANS)

IANS, the International Anal Neoplasia Medical Society, creates medical guidelines and supports research essential to preventing and treating anal cancer. IANS was created with a seed grant from the Foundation.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2020**

OBJECTIVES AND ACTIVITIES

IANS mission is to provide a forum for individuals with a broad spectrum of background, viewpoints and geographic origin, an exchange of ideas and dissemination of knowledge regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

In support of this mission IANS:

- Develop position papers regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.
- Represent the consensus opinion of IANS regarding the above topics to other professional societies, public organizations, regulatory authorities and governmental bodies.

" Encourage the development of a robust research agenda on the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

- Develop educational materials and conduct training courses that encourage the entry of a broad spectrum of clinicians into the field of anal neoplasia, and that furthers the development and depth of skills of clinicians needed to optimally diagnose, treat and prevent anal neoplasia.
- Develop educational materials for patients with anal neoplasia.

In 2020, IANS:

- Developed IANS COVID-19 guidelines, published in Colorectal Diseases
- Held the first IANS Virtual Standard HRA Course in November with 133 participants
- Held 11 WebRounds - nine in English, one in Portuguese, and one in Spanish
- Created European and Spanish/Portuguese Task Forces to strengthen and diversify its membership base
- Constituted Screening Task Forces that are currently working to develop international guidelines

Information and Connection

The Foundation's anal cancer program website features a wealth of resources and is a source of information, support, and inspiration for patients and families affected by anal cancer.

Our focus is ensuring patients get the information and support they need during their anal cancer journey. Our Living with Anal Cancer section features information for patients at all stages of the anal cancer journey from newly diagnosed to post-treatment resources, such as how physical therapy can help with anal cancer treatment recovery. The site is the most comprehensive source of information on side effects and side effect mitigation during and after anal cancer treatment. This digital hub is populated with personal thriver stories (patients stories of their experiences), information about helpful medical resources, and professional medical bodies, as well as connections to other patients and caregivers through our Peer to Peer support programme.

Our goal in 2020 continues to be ensuring more anal cancer thrivers have access to the information they need to face their cancer journey through targeted outreach based on our existing supporter base and a newsletter series for patients and caregivers, focused on our expert and popular resources.

With the pandemic reducing the in person resources available to the anal cancer community, the need for communication with our community was more important than ever. Our communications strategy focused on consistency and 'being useful', with content covering treatment and research updates, stories from community members, and explainers of our services and how we support the anal cancer community.

The results spoke for themselves.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2020**

OBJECTIVES AND ACTIVITIES

- A 17% increase in visitor sessions online
- A 15% increase in the number of pages per session
- An 8% decrease in single page sessions
- A 2.5% increase in sessions per user

Going forward, we aim to continue providing all the support the anal cancer community needs.

Investing in cures: financing ground-breaking research

As a non-profit funder of medical research motivated by personal loss, our mission is to offer new treatments to patients as quickly as possible. Our research philosophy is to invest in high-risk, high-reward projects that we believe hold tremendous promise for advancing the treatment field for anal cancer patients and other patients living with HPV-related cancers.

We accomplish this by aligning incentives across all of the relevant stakeholders, fostering collaboration wherever possible, receiving input from a board of key opinion leaders and expert advisors, and using funding to address resource gaps in preclinical and clinical settings. We collaborate with other foundations and government agencies to ensure funding for the research that we seek to advance. These partnerships have allowed us to leverage our funds to produce faster and more robust research outcomes to urgently find a cure.

The Foundation's mission is focused on improving the lives of two cancer populations specifically: people facing HPV-related cancers and people facing anal cancer (one type of HPV-related cancer). Six years ago, people who were diagnosed with these cancers in a late stage had few therapeutic options available to them. For anal cancer, no significant update to advanced cancer treatment had occurred in four decades. For HPV-related cancers, there were no clinically recognized trials seeking one therapy to treat the different-but-connected cancers simultaneously. With a few focused grants, the Foundation sought to raise the profile of these cancers, increase interest among the scientific community, spur innovative research, and deliver new drugs into the hands of patients.

The Foundation chose to invest in an emerging approach to the fight against cancer: immunotherapy. Cancer, in essence, is a failure of the immune system to "see" and dismantle abnormal cells. This breakdown allows one or multiple errant cells to multiply until they affect the functioning of the body. Immunotherapies seek to address this malfunction by modulating specific aspects of the immune system to target cancer cells.

Supporting Research to Find A Cure for Multiple HPV-Related Cancers

HPV-related cancers represent 5% of the world's cancers and treatment to cure these malignancies has barely advanced in decades. To address this vast and unmet need, the Foundation partnered with Stand Up To Cancer and the Farrah Fawcett Foundation in a \$1.2 million grant to support researchers at Dana-Farber Cancer Institute in Boston, Massachusetts, who are investigating the treatment of HPV-related cancer by harnessing the immune system against it. The study was a first of its kind as we sought a therapy to help multiple HPV-related cancers, instead of addressing each cancer individually.

The study focuses on the preclinical and clinical development of an immunotherapy treatment for patients with recurrent HPV-related anal, cervical, and head and neck cancers who have relapsed after their initial therapy as such patients have few therapeutic options available to them. A successful vaccine would be used to augment chemotherapeutic outcomes and improve survival. Specifically, this Phase 1b/2 trial tests tumor response and safety/efficacy of vaccination with E711-19 nanomer for the treatment of incurable HPV-16 related head & neck, cervical, and anal cancer in HLA-A2 positive patients. It investigates the theory of therapeutic CD8 vaccines against HPV epitopes. This project is led by Ellis L. Reinherz, M.D., Chief of the Laboratory of Immunobiology and Co-Director of the Cancer Vaccine Center at Dana-Farber and Robert I. Haddad, M.D., Disease Center Leader for Head and Neck Oncology at Dana-Farber.

THE HPV AND ANAL CANCER FOUNDATION LIMITED

Report of the Trustees for the Year Ended 31 December 2020

OBJECTIVES AND ACTIVITIES

The trial was completed in 2019 and resulted in three publications. Whilst the trial agent produced no durable response in study participants, researchers studying the results were able to gain a better understanding of the diversity of cancer cells in HPV cancers as well as why certain HPV therapeutic vaccines might fail. Additionally, the trial improved care in the HPV cancer space by creating connections among HPV laboratory and clinical investigators across the Boston research community, and more broadly, across the national HPV advocacy community. As the first trial to investigate a therapeutic vaccine for multiple HPV cancers, it was a critical first step towards unifying a once-siloed research community to find a cure for all HPV cancers. As a result, where once each HPV cancer was researched solely in individual trials, there are now multiple clinical trials specifically researching agents to treat and cure all HPV cancers.

Encouraging the scientific field to view these cancers comprehensively resulted in a new approach for generating promising treatments on behalf of the hundreds of thousands of people living with HPV-related cancers. In light of this significant shift led by the Foundation, there are now several phase I and II trials underway that seek to find a treatment for multiple HPV-related cancers at the same time.

LOOKING AHEAD: 2021

As we look ahead, the HPV and Anal Cancer Foundation continues to seek the most effective methods to prevent HPV and cure the cancers it causes.

The Foundation will continue to work tirelessly to eradicate all HPV-related cancers by furthering public policy and scientific debate, eliciting further professional and expert support, encouraging the development of regional initiatives on vaccinating boys, and demonstrating why it is important to protect all children against HPV at the recommended age.

Although the UK began vaccinating boys against HPV as pupils return to schools in September 2019, we will continue to work with Public Health England and other stakeholders in the HPV-related disease space to ensure that uptake for this cancer-preventing intervention among 12-13 year old boys is as high as possible. The interruption caused by the pandemic will undoubtedly affect vaccination rates in the UK and beyond. In the wake of a growing vaccine hesitancy sentiment, our work is more important than ever.

Our advocacy focus now turns towards building our nascent partnership with the European Cancer Organisation and the HPV Action Network in order to achieve change across the European continent. The EU Beating Cancer Plan set to be announced in 2021 will address cancer-related inequalities between and within Member States with actions to support, coordinate, and complement Member States' efforts. With over 40% of cancers in the region preventable, the extension of HPV vaccination programmes to protect boys as well as girls provides a recognised and effective means to tackle cancer.

Through the NOMAN is an Island Campaign, collaborations with advocates and legislators, media attention and athletic event participation, a broader audience is understanding the importance of protecting all children against HPV. With the NOMAN side of the organisation leading on HPV-related activities, our platform is growing from which to broadcast our message. In 2021, we will continue to partner with the Haute Route on further cycling events as their European Charity Partner, furthering the reach of our message to prevent 5% of cancer, and providing the opportunity to reconnect with the cyclists within our community. Additionally, the return of our flagship Barcelona - Ibiza: Row to End HPV races will as ever, capture the imagination of, and spread the message of how we can prevent HPV cancers, to a broader audience.

We remain committed to finding better cures for patients and creating the essential research building blocks that currently do not exist. For four decades, treatment for all stages of anal cancer had remained essentially the same with no FDA-approved drugs targeted and the same toxic side effects as in the 1970's. Our breakthrough with MD Anderson Cancer Center is offering new hope to anal cancer patients and we look forward to further progress in the search for a cure.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2020**

OBJECTIVES AND ACTIVITIES

We will continue to provide anal cancer thrivers with information and support they need on their journey. In addition, our Peer to Peer support programme retains its importance in supporting and empowering anal cancer survivors and caregivers. Utilizing digital and live platforms, we will reach a wider proportion of the anal cancer community, enabling patients to gain answers to the concerns they have and to connect to other anal cancer patient experiences.

We thank all of our donors and look forward to continuing the mission to empower anal cancer patients and accelerate prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Public benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

FINANCIAL REVIEW

Financial position

It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organization. The revenue for the charity is dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundation in 2020 was £90,186 and expenditure was £129,268.

Reserves policy

The reserves policy is to maintain a minimum that enables the organisation to meet its financial commitments for the year, including grants, contracts, and staff salaries.

Going concern

As stated in note 20, the Trustees have considered the effect of the COVID-19 pandemic. The Trustees consider that the pandemic is likely to cause disruption to the Charity's activities but are confident that current reserves and future income will be sufficient to ensure that the Charity remains a going concern for a period of at least twelve months from the date of approval of these financial statements as well as for the foreseeable future.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document, structure and management

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Report of the Trustees
for the Year Ended 31 December 2020**

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20 February 2012 and registered as a charity on the 25 May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The Trustees are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 21. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the Director of UK Operations is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public as well as contacts of the charity. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given a full introduction to the work of The HPV and Anal Cancer Foundation in addition to copies of the organization's financial documents, bylaws and policies.

Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The trustees of the Foundation hold the responsibility of safeguarding the charity's assets and systems are in place to mitigate those risks which the charity may face.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on27.09.2021..... and signed on its behalf by:



.....

T Almada - Trustee

**Independent Examiner's Report to the Trustees of
The HPV and Anal Cancer Foundation
Limited**

Independent examiner's report to the trustees of The HPV and Anal Cancer Foundation Limited ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2020.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Richard Billinghamurst
FCA
Knox Cropper LLP
Chartered Accountants
65 Leadenhall Street
London
EC3A 2AD

28/09/2021

Date:

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Statement of Financial Activities
(Incorporating an Income and Expenditure Account)
for the Year Ended 31 December 2020**

	Notes	Unrestricted funds £	Restricted funds £	2020 Total funds £	2019 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		17,061	-	17,061	11,790
Other trading activities	2	73,105	-	73,105	428,398
Investment income	3	20	-	20	55
Total		90,186	-	90,186	440,243
EXPENDITURE ON					
Raising funds	4	20,478	-	20,478	147,779
Charitable activities					
Care and Support	5	27,417	-	27,417	8,664
Awareness Raising		76,467	-	76,467	187,219
Research for a Cure		4,906	-	4,906	3,828
Total		129,268	-	129,268	347,490
NET INCOME/(EXPENDITURE)		(39,082)	-	(39,082)	92,753
RECONCILIATION OF FUNDS					
Total funds brought forward		153,171	13,100	166,271	73,518
TOTAL FUNDS CARRIED FORWARD		114,089	13,100	127,189	166,271

The notes form part of these financial statements

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED (REGISTERED NUMBER: 07955451)**

**Balance Sheet
31 December 2020**

	Notes	2020 £	2019 £
CURRENT ASSETS			
Debtors	14	218	11,999
Cash at bank		135,806	160,983
		<u>136,024</u>	<u>172,982</u>
CREDITORS			
Amounts falling due within one year	15	(8,835)	(6,711)
		<u>127,189</u>	<u>166,271</u>
NET CURRENT ASSETS			
		<u>127,189</u>	<u>166,271</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			
		<u>127,189</u>	<u>166,271</u>
NET ASSETS			
		<u>127,189</u>	<u>166,271</u>
FUNDS	18		
Unrestricted funds		114,089	153,171
Restricted funds		13,100	13,100
		<u>127,189</u>	<u>166,271</u>
TOTAL FUNDS		<u>127,189</u>	<u>166,271</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2020 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on27.09.2021..... and were signed on its behalf by:



.....
T Almada - Trustee

The notes form part of these financial statements

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

Financial reporting standard 102 - reduced disclosure exemptions

The charitable company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland':

- the requirements of Section 7 Statement of Cash Flows.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Ocean rowing boat and accessories - over 3 years

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2020**

1. ACCOUNTING POLICIES - continued

Fund accounting

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Judgments and key sources of estimation uncertainty

No judgement (apart from those involving estimates) have been made in the process of applying the above accounting policies that have a significant effect on amounts recognised in the financial statements.

2. OTHER TRADING ACTIVITIES

	2020	2019
	£	£
Fundraising events	73,105	428,398

3. INVESTMENT INCOME

	2020	2019
	£	£
Deposit account interest	20	55

4. RAISING FUNDS

Raising donations and legacies

	2020	2019
	£	£
Staff costs	5,611	-
Development expenses	152	638
Marketing	-	9,318
Miscellaneous expenses	-	49
Donor software subscription	1,174	1,896
Event Expenses	4,226	117,494
Media	3,300	4,149
Support costs (Operating)	6,015	14,235
	20,478	147,779

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2020**

5. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 6) £	Grant funding of activities (see note 7) £	Support costs (see note 8) £	Totals £
Care and Support	23,114	-	4,303	27,417
Awareness Raising	36,094	13,235	27,138	76,467
Research for a Cure	863	-	4,043	4,906
	<u>60,071</u>	<u>13,235</u>	<u>35,484</u>	<u>108,790</u>

6. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2020 £	2019 £
Staff costs	15,713	-
Development Expenses	6,642	640
Marketing	12,939	9,318
Miscellaneous Expense	806	49
Event Expenses	4,226	117,496
Media	13,200	16,597
Internet and Website	6,545	-
	<u>60,071</u>	<u>144,100</u>

7. GRANTS PAYABLE

	2020 £	2019 £
Awareness Raising	13,235	7,963

The total grants paid to institutions during the year was as follows:

	2020 £	2019 £
ECCO	13,235	6,963
Oral Health Foundation	-	1,000
	<u>13,235</u>	<u>7,963</u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2020**

8. SUPPORT COSTS

	Finance £	Other £	Governance costs £	Totals £
Raising donations and legacies	45	5,191	779	6,015
Care and Support	28	3,776	499	4,303
Awareness Raising	92	25,423	1,623	27,138
Research for a Cure	12	3,812	219	4,043
	<u>177</u>	<u>38,202</u>	<u>3,120</u>	<u>41,499</u>

Support costs, included in the above, are as follows:

	Raising donations and legacies £	Care and Support £	Awareness Raising £
Bank charges	45	28	92
Wages	-	-	14,174
Pensions	1,212	776	2,520
Rent and Rates	2,147	1,374	4,465
Insurance	61	39	127
Fees and subscriptions	103	66	215
Telephone, printing, postage and stationery	101	65	210
Sundries	207	133	433
Travel and Meetings	-	53	53
Consultancy fees	1,360	870	2,828
Conference expenses	-	400	398
Independent Examiner's fee	660	422	1,373
Accountancy and legal fees	119	77	250
	<u>6,015</u>	<u>4,303</u>	<u>27,138</u>
		2020	2019
	Research for a Cure £	Total activities £	Total activities £
Bank charges	12	177	422
Wages	1,908	16,082	35,763
Pensions	339	4,847	4,478
Rent and Rates	601	8,587	8,192
Insurance	17	244	40
Fees and subscriptions	29	413	449
Telephone, printing, postage and stationery	28	404	870
Sundries	58	831	418
Travel and Meetings	53	159	3,512
Consultancy fees	381	5,439	4,420
Carried forward	<u>3,426</u>	<u>37,183</u>	<u>58,564</u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2020**

8. SUPPORT COSTS - continued

	Research for a Cure £	2020 Total activities £	2019 Total activities £
Brought forward	3,426	37,183	58,564
Conference expenses	398	1,196	193
Independent Examiner's fee	185	2,640	2,645
Accountancy and legal fees	34	480	481
	<u>4,043</u>	<u>41,499</u>	<u>61,883</u>

9. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2020 £	2019 £
Independent Examiner's fee	<u>3,000</u>	<u>2,640</u>

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2020 nor for the year ended 31 December 2019.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2020 nor for the year ended 31 December 2019.

11. STAFF COSTS

	2020 £	2019 £
Wages and salaries	37,406	35,763
Other pension costs	4,847	4,478
	<u>42,253</u>	<u>40,241</u>

The average monthly number of employees during the year was as follows:

	2020	2019
Average monthly employees	<u>1</u>	<u>1</u>

No employees received emoluments in excess of £60,000.

The key management personnel of the charity are those persons having authority and responsibility for planning, directing and controlling the activities of the charity, directly or indirectly, including any trustee of the charity and, in the case of the charity, includes the Director of UK Operations. Total employee benefits paid to key management personnel in the period amounted to £37,406 (2019: £35,763).

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2020**

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	11,790	-	11,790
Other trading activities	428,398	-	428,398
Investment income	55	-	55
Total	440,243	-	440,243
EXPENDITURE ON			
Raising funds	147,779	-	147,779
Charitable activities			
Care and Support	8,664	-	8,664
Awareness Raising	187,219	-	187,219
Research for a Cure	3,828	-	3,828
Total	347,490	-	347,490
NET INCOME	92,753	-	92,753
RECONCILIATION OF FUNDS			
Total funds brought forward	60,418	13,100	73,518
TOTAL FUNDS CARRIED FORWARD	153,171	13,100	166,271

13. TANGIBLE FIXED ASSETS

	Plant and machinery £
COST	
At 1 January 2020 and 31 December 2020	47,250
DEPRECIATION	
At 1 January 2020 and 31 December 2020	47,250
NET BOOK VALUE	
At 31 December 2020	-
At 31 December 2019	-

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2020**

14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Gift aid recoverable	-	11,528
Prepayments	218	471
	<u>218</u>	<u>11,999</u>

15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Social security and other taxes	5,835	4,071
Accrued expenses	3,000	2,640
	<u>8,835</u>	<u>6,711</u>

16. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:

	2020	2019
	£	£
Within one year	-	1,925
	<u>-</u>	<u>1,925</u>

17. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted funds	Restricted funds	2020 Total funds	2019 Total funds
	£	£	£	£
Current assets	122,924	13,100	136,024	172,982
Current liabilities	(8,835)	-	(8,835)	(6,711)
	<u>114,089</u>	<u>13,100</u>	<u>127,189</u>	<u>166,271</u>

18. MOVEMENT IN FUNDS

	At 1.1.20 £	Net movement in funds £	At 31.12.20 £
Unrestricted funds			
General fund	153,171	(39,082)	114,089
Restricted funds			
Research for a Cure	13,100	-	13,100
TOTAL FUNDS	<u>166,271</u>	<u>(39,082)</u>	<u>127,189</u>

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2020**

18. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	90,186	(129,268)	(39,082)
TOTAL FUNDS	<u>90,186</u>	<u>(129,268)</u>	<u>(39,082)</u>

Comparatives for movement in funds

	At 1.1.19 £	Net movement in funds £	At 31.12.19 £
Unrestricted funds			
General fund	60,418	92,753	153,171
Restricted funds			
Research for a Cure	13,100	-	13,100
TOTAL FUNDS	<u>73,518</u>	<u>92,753</u>	<u>166,271</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	440,243	(347,490)	92,753
TOTAL FUNDS	<u>440,243</u>	<u>(347,490)</u>	<u>92,753</u>

Capital fund

The HPV and Anal Cancer Foundation Limited has shareholder capital equal to £1 and is owned by HPV and Anal Cancer Foundation, a registered charity in the United States of America, EIN 27-3217520.

Research for a Cure Fund

The fund was set up to award grants to research which will advance development of effective treatments for anal and all HPV-related cancers.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Notes to the Financial Statements - continued
for the Year Ended 31 December 2020**

19. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2020.

20. GOING CONCERN

The Trustees have considered the effect of the COVID-19 pandemic in 2020 and into 2021 on the Charity's activities. While the outbreak is likely to cause some changes to the charity's business, the Charity currently holds a comfortable level of reserves and its fixed costs are not significant. It has the ability to align its activities to the level of reserves available. The Trustees are optimistic about the fundraising outlook for the next twelve months.

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Detailed Statement of Financial Activities
for the Year Ended 31 December 2020**

	2020 £	2019 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	17,061	11,790
Other trading activities		
Fundraising events	73,105	428,398
Investment income		
Deposit account interest	20	55
Total incoming resources	90,186	440,243
EXPENDITURE		
Raising donations and legacies		
Wages	5,611	-
Development expenses	152	638
Marketing	-	9,318
Miscellaneous expenses	-	49
Donor software subscription	1,174	1,896
Event Expenses	4,226	117,494
Media	3,300	4,149
	14,463	133,544
Charitable activities		
Wages	15,713	-
Development Expenses	6,642	640
Marketing	12,939	9,318
Miscellaneous Expense	806	49
Event Expenses	4,226	117,496
Media	13,200	16,597
Internet and Website	6,545	-
Grants to institutions	13,235	7,963
	73,306	152,063
Support costs (Operating)		
Finance		
Bank charges	177	422
Other		
Wages	16,082	35,763
Carried forward	16,082	35,763

This page does not form part of the statutory financial statements

**THE HPV AND ANAL CANCER FOUNDATION
LIMITED**

**Detailed Statement of Financial Activities
for the Year Ended 31 December 2020**

	2020 £	2019 £
Other		
Brought forward	16,082	35,763
Pensions	4,847	4,478
Rent and Rates	8,587	8,192
Insurance	244	40
Fees and subscriptions	413	449
Telephone, printing, postage and stationery	404	870
Sundries	831	418
Travel and Meetings	159	3,512
Consultancy fees	5,439	4,420
Conference expenses	1,196	193
	38,202	58,335
Governance costs		
Independent Examiner's fee	2,640	2,645
Accountancy and legal fees	480	481
	3,120	3,126
Total resources expended	129,268	347,490
Net (expenditure)/income	(39,082)	92,753

This page does not form part of the statutory financial statements